<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication Issue 1, 2012" DOI="10.1002/14651858.CD001955.pub3" GROUP_ID="ARI" ID="527599090815131477" MERGED_FROM="" MODIFIED="2011-11-30 22:12:14 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A035" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.6">
<COVER_SHEET MODIFIED="2011-11-30 22:11:40 +0100" MODIFIED_BY="Liz Dooley">
<TITLE>Glucocorticoids for croup</TITLE>
<CONTACT MODIFIED="2011-11-30 22:11:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="5344" ROLE="AUTHOR"><FIRST_NAME>Terry</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Klassen</LAST_NAME><SUFFIX>MD, MSc, FRCPC</SUFFIX><POSITION>Director</POSITION><EMAIL_1>tklassen@mich.ca</EMAIL_1><URL>http://www.mich.ca</URL><MOBILE_PHONE>+1 780 970 3615</MOBILE_PHONE><ADDRESS><ORGANISATION>Manitoba Institute of Child Health</ORGANISATION><ADDRESS_1>513-715 McDermot Avenue</ADDRESS_1><CITY>Winnipeg</CITY><ZIP>MB R3E 3P4</ZIP><REGION>Manitoba</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 204 789 3754</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-11-30 22:11:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="12327" ROLE="AUTHOR"><FIRST_NAME>Kelly</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Russell</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Research Assistant</POSITION><EMAIL_1>krussell@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Aberhart Centre One</ADDRESS_1><ADDRESS_2>11402 University Ave</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 1078</PHONE_1><FAX_1>+1 780 492 6435</FAX_1></ADDRESS></PERSON><PERSON ID="07FA479882E26AA200831C193CD1D1E5" ROLE="AUTHOR"><FIRST_NAME>Yuanyuan</FIRST_NAME><LAST_NAME>Liang</LAST_NAME><POSITION>Assistant Professor</POSITION><ADDRESS><DEPARTMENT>Department of Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>University of Texas Health Science Center at San Antonio</ORGANISATION><ADDRESS_1>7703 Floyd Curl Drive</ADDRESS_1><CITY>San Antonio</CITY><ZIP>78229</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 210 567 0854</PHONE_1><FAX_1>+1 210 567 0921</FAX_1></ADDRESS></PERSON><PERSON ID="92A0DF3D82E26AA20020E746F617151D" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Kathleen</FIRST_NAME><LAST_NAME>O'Gorman</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>kogorman@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Aberhart Centre One</ADDRESS_1><ADDRESS_2>11402 University Ave</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 0310</PHONE_1><FAX_1>+1 780 407 6435</FAX_1></ADDRESS></PERSON><PERSON ID="12282" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Johnson</LAST_NAME><POSITION>Pediatric Emergency Physician and Medical Toxicologist</POSITION><EMAIL_1>david.johnson@albertahealthservices.ca</EMAIL_1><MOBILE_PHONE>+1 403 473 6442</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Calgary, Alberta Children's Hospital</ORGANISATION><ADDRESS_1>2888 Shaganappi Trail NW</ADDRESS_1><CITY>Calgary</CITY><ZIP>T3B 6A8</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 403 955 7507</PHONE_1><FAX_1>+1 403 955 7552</FAX_1></ADDRESS></PERSON><PERSON ID="5344" ROLE="AUTHOR"><FIRST_NAME>Terry</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Klassen</LAST_NAME><SUFFIX>MD, MSc, FRCPC</SUFFIX><POSITION>Director</POSITION><EMAIL_1>tklassen@mich.ca</EMAIL_1><URL>http://www.mich.ca</URL><MOBILE_PHONE>+1 780 970 3615</MOBILE_PHONE><ADDRESS><ORGANISATION>Manitoba Institute of Child Health</ORGANISATION><ADDRESS_1>513-715 McDermot Avenue</ADDRESS_1><CITY>Winnipeg</CITY><ZIP>MB R3E 3P4</ZIP><REGION>Manitoba</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 204 789 3754</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-07-18 02:48:41 +1000" MODIFIED_BY="Kelly Russell">
<UP_TO_DATE>
<DATE DAY="23" MONTH="7" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="7" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="7" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2011-12-01 07:10:34 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-01 07:01:16 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="1" MONTH="12" YEAR="2011"/>
<DESCRIPTION>
<P>Grammatical correction made to the Plain language summary.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-01 07:00:39 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-12-01 07:00:39 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="18" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>
<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK> contained an error, as the negative signs for the change in croup scores at 6 hours were not included. The mean difference remains non-significant.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-07-18 10:23:04 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>Searches conducted. We have added seven new trials (<LINK REF="STD-Alshehri--2005" TYPE="STUDY">Alshehri 2005</LINK>; <LINK REF="STD-Amir--2006" TYPE="STUDY">Amir 2006</LINK>; <LINK REF="STD-Cetinkaya-2004" TYPE="STUDY">Cetinkaya 2004</LINK>; <LINK REF="STD-Duman-2005" TYPE="STUDY">Duman 2005</LINK>; <LINK REF="STD-Fifoot--2007" TYPE="STUDY">Fifoot 2007</LINK>; <LINK REF="STD-Geelhoed-2005" TYPE="STUDY">Geelhoed 2005</LINK>; <LINK REF="STD-Sparrow--2006" TYPE="STUDY">Sparrow 2006</LINK>) since the 2004 publication. We have excluded three new trials (<LINK REF="STD-Chub_x002d_Uppakarn-2007" TYPE="STUDY">Chub-Uppakarn 2007</LINK>; <LINK REF="STD-Cluster--2005" TYPE="STUDY">Cluster 2005</LINK>; <LINK REF="STD-Schoooff--2005" TYPE="STUDY">Schoooff 2005</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-07-18 10:23:08 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>New authors joined the team to update the review. The conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-09 13:42:47 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-08-25 08:09:47 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="3" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Feedback incorporated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-25 08:10:25 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="7" MONTH="4" YEAR="2003"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-25 08:10:55 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="17" MONTH="8" YEAR="1997"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Thomas C. Chalmers Center for Systematic Reviews, Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>INSALUD, Madrid</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Alberta Research Centre for Child Health Evidence</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Alberta Heritage Foundation for Medical Research</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-12-01 06:59:00 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-11-21 08:31:44 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-05-25 12:58:18 +1000" MODIFIED_BY="[Empty name]">Glucocorticoids for croup</TITLE>
<SUMMARY_BODY MODIFIED="2011-11-21 08:31:44 +1000" MODIFIED_BY="[Empty name]">
<P>Croup is common in children and is thought to be triggered after a viral infection. Croup causes swelling in the throat and windpipe (trachea) and causes hoarseness, a barking cough and noisy breathing. Croup usually gets better by itself but sometimes drugs are used to try and improve this condition. The review looked at trials of one type of steroid drug, glucocorticoids. Glucocorticoids can reduce the swelling and make it easier for the child to breathe. We found that glucocorticoids can start improving croup in children within six hours (14 studies, 1031 children). The effect lasts about 12 hours (eight studies, 532 children), lessens the need for other drugs, and shortens hospital stays by 12 hours (eight studies, 795 children). There were no adverse events associated with glucocorticoids. Additional studies are needed to determine the best dose of glucocorticoids.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-12-01 06:55:26 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-11-29 09:07:08 +1000" MODIFIED_BY="[Empty name]">
<P>Since the initial publication of this systematic review in 1997, several randomized trials examining the benefit of glucocorticoids have been published. The objective of this review is to provide evidence to guide clinicians in their treatment of patients with croup by determining the effectiveness of glucocorticoids and to identify areas requiring future research.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effect of glucocorticoids for children with croup.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-12-01 06:55:26 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2010, Issue 3), which contains the Cochrane Acute Respiratory Infections Group's Specialized Register, MEDLINE (1966 to July week 2, 2010) and EMBASE.com (1974 to July 2010). We also contacted authors of identified croup trials published in the last 10 years to inquire about additional published or unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-12-01 06:55:18 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) that examine children with croup and objectively measure the effectiveness of glucocorticoids.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-11-07 23:00:17 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors identified studies for potential relevance based on the review of the title and abstract (when available). Two review authors independently reviewed studies for relevance using a priori inclusion criteria and assessed trial quality. Differences were resolved by consensus. One review author extracted data using a structured form and another review author checked the results for accuracy. We performed standard statistical analyses.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-11-25 02:53:24 +1000" MODIFIED_BY="[Empty name]">
<P>Thirty-eight studies were included (n = 4299). Glucocorticoids were associated with an improved Westley score (maximum 17 points) at six hours with a mean difference of -1.2 (95% confidence interval (CI) -1.6 to -0.8) and at 12 hours -1.9 (95% CI -2.4 to -1.3); at 24 hours this improvement was no longer significant (-1.3, 95% CI -2.7 to 0.2). Fewer return visits and/or (re)admissions occurred in participants treated with glucocorticoids (risk ratio (RR) 0.5; 95% CI 0.3 to 0.7). Length of time spent in accident and emergency or hospital (mean difference 12 hours, five to 19 hours) was significantly decreased for participants treated with glucocorticoids. Use of epinephrine decreased for children treated with a glucocorticoid (risk difference 10%; 95% CI 1 to 20).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-25 02:53:41 +1000" MODIFIED_BY="[Empty name]">
<P>Dexamethasone and budesonide are effective in relieving the symptoms of croup as early as six hours after treatment. Fewer return visits and/or (re)admissions are required and the length of time spent in hospital is decreased. Research is required to examine the most beneficial method for disseminating croup practice guidelines and to increase the uptake of evidence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-12-01 06:59:00 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-12-01 06:53:46 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-11-29 09:11:46 +1000" MODIFIED_BY="[Empty name]">
<P>Croup (laryngotracheobronchitis) is a common cause of upper airway obstruction in children and is characterized by hoarseness, a barking cough and inspiratory stridor. These symptoms are thought to occur as a result of oedema of the larynx and trachea, which has been triggered by a recent viral infection. Para influenza virus type 1 is the agent most commonly identified in cases of croup (<LINK REF="REF-Henrickson-1994" TYPE="REFERENCE">Henrickson 1994</LINK>).</P>
<P>Although croup is a self-limiting illness, it is a large burden on health care systems because of frequent visits to doctors and accident and emergency departments and, when necessary, hospitalizations. The annual incidence of croup in children younger than six years ranges from 1.5% to 6% (<LINK REF="REF-Denny-1983" TYPE="REFERENCE">Denny 1983</LINK>). During a six-year period in Alberta, Canada, 20,019 infants less than two years of age visited the emergency department for 27,355 episodes of croup and 8.0% of infants were admitted (<LINK REF="REF-Rosychuk-2010" TYPE="REFERENCE">Rosychuk 2010</LINK>). Admission rates for croup in children seen in outpatient settings range from 1.5% to 31% of cases seen; these figures vary widely, depending on hospital admission practices and the severity of the disease in the population being assessed (<LINK REF="REF-Marx-1997" TYPE="REFERENCE">Marx 1997</LINK>; <LINK REF="REF-To-1994" TYPE="REFERENCE">To 1994</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-12-01 06:53:46 +1000" MODIFIED_BY="[Empty name]">
<P>Since the late 1980s it has been recognized that glucocorticoids provide some clinical benefit for children with croup. In 1989 <LINK REF="REF-Kairys-1989" TYPE="REFERENCE">Kairys 1989</LINK> published a meta-analysis of clinical trials examining the benefit of glucocorticoids. Previous research has shown that a greater proportion of children are receiving glucocorticoids in the emergency department. An Australian hospital introduced a mandatory glucocorticoid policy for children with croup and this resulted in decreased admissions and intubation (<LINK REF="REF-Geelhoed-1996b" TYPE="REFERENCE">Geelhoed 1996b</LINK>). A second Australian study found that by 1992, 87% of children received corticosteroids upon admission and ICU admissions and intubation rates decreased (<LINK REF="REF-McDonogh--1994" TYPE="REFERENCE">McDonogh 1994</LINK>). Racaemic adrenaline (epinephrine), or L-adrenaline, has been shown to provide temporary relief to patients with croup but is not thought to have long-term benefits (<LINK REF="REF-Johnson-2009" TYPE="REFERENCE">Johnson 2009</LINK>; <LINK REF="REF-Waisman-1992" TYPE="REFERENCE">Waisman 1992</LINK>). In the past, the standard management of croup included mist treatment (that is, treatment with humidified air), although there is little evidence of its effectiveness (<LINK REF="REF-Lavine-2001" TYPE="REFERENCE">Lavine 2001</LINK>; <LINK REF="REF-Moore-2007" TYPE="REFERENCE">Moore 2007</LINK>; <LINK REF="REF-Neto-2002" TYPE="REFERENCE">Neto 2002</LINK>; <LINK REF="REF-Scolnick-2006" TYPE="REFERENCE">Scolnick 2006</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-11-07 21:40:12 +1000" MODIFIED_BY="[Empty name]">
<P>Localised inflammation of the upper airway caused by a virus is believed to cause croup symptoms. The narrowest part of the airway is the subglottic region. Even small amounts of oedema in this region can significantly increase the work of breathing in young children because airway resistance increases dramatically. Poiseuille's law states that airway resistance is related to the radius of the airway to the power of four. Glucocorticoids are believed to reduce the degree of inflammation and swelling through their anti-inflammatory properties leading to decreased effort in breathing for the child.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-11-07 21:40:35 +1000" MODIFIED_BY="[Empty name]">
<P>In 1999 this review was first published in <I>The Cochrane Library</I> and included 24 RCTs that examined the effectiveness of glucocorticoids for children with croup (<LINK REF="REF-Ausejo-2000" TYPE="REFERENCE">Ausejo 2000</LINK>). However, since then a number of RCTs have been published and there has been continued interest in the use of glucocorticoids to treat patients with croup. This is an update of the original review. There are areas of uncertainty regarding the use of glucocorticoids in children with croup, such as direct comparisons within a study examining the various routes of administration of glucocorticoids and the role of glucocorticoids in the treatment of mild croup. Also, in the previous version of this review, publication bias was a threat to the validity of results and incorporation of additional trials may influence the presence of publication bias.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-11-29 09:07:44 +1000" MODIFIED_BY="[Empty name]">
<P>The objective of this systematic review was to provide evidence to guide clinicians in their treatment of children with croup, to examine the effectiveness of glucocorticoids (oral, spray, nebulized or injected) compared to placebo or active treatment(s) in croup patients and to identify areas of uncertainty for future research.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-12-01 06:59:00 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-12-01 06:56:10 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-11-07 21:40:29 +1000" MODIFIED_BY="[Empty name]">
<P>Participants had to have been randomly assigned to treatment groups. We included studies regardless of language of publication or publication status.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-11-07 21:41:43 +1000" MODIFIED_BY="[Empty name]">
<P>We included children with croup, pseudo croup or laryngotracheitis. We excluded bronchiolitis. We defined croup as a syndrome consisting of hoarseness, barking cough and stridor, in which alternative diagnosis of acute stridor was excluded. We included both inpatients and outpatients; we classified patients treated in an emergency department as outpatients.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-12-01 06:56:10 +1000" MODIFIED_BY="[Empty name]">
<P>We included studies where the effectiveness of glucocorticoids (administered orally, parenterally or by nebulization) was compared to a placebo or any active treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-07 21:42:07 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-05-25 13:15:51 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Change in clinical croup score from baseline to six hours, 12 hours or 24 hours.</LI>
<LI>Return visits and/or (re)admissions.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-11-07 21:42:07 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Length of stay in hospital or accident and emergency department.</LI>
<LI>Patient improvement (yes or no).</LI>
<LI>The use of additional treatments such as epinephrine, supplemental glucocorticoids, mist treatment, intubation, or antibiotics.</LI>
</OL>
<P>Studies that failed to meet all four of the inclusion criteria were excluded.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-12-01 06:59:00 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-12-01 06:59:00 +1000" MODIFIED_BY="[Empty name]">
<P>For the original review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2006, Issue 1), which contains the Cochrane Acute Respiratory Infections Group's Specialized Register. In addition, we searched MEDLINE (January 1966 to January 2006), exploding glucocorticoid treatment (and each of the terms for corticosteroids) and croup; we restricted the search to randomized controlled trials using a previously validated strategy. We also searched Excerpta Medica and EMBASE (January 1974 to April 2006) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategies).</P>
<P>For this update, we searched Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, Issue 3), which contains the Cochrane Acute Respiratory Infections Group's Specialized Register, MEDLINE (1966 to July week 2, 2010) and EMBASE.com (1974 to July 2010). We also contacted authors of identified croup trials published in the last 10 years to inquire about additional published or unpublished trials.</P>
<P>We used the following search strategy to search MEDLINE and CENTRAL. We combined the MEDLINE search strategy with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision) Ovid format (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). The search was adapted for EMBASE (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) and MEDLINE in-process (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>
<B>MEDLINE</B>
<BR/>1 exp Laryngitis/<BR/>2 laryngit*.tw.<BR/>3 croup*.tw.<BR/>4 laryngotracheobronchit*.tw.<BR/>5 (pseudocroup* or pseudo-croup*).tw.<BR/>6 laryngotracheit*.tw.<BR/>7 or/1-6<BR/>8 exp Glucocorticoids/<BR/>9 glucocorticoid*.tw,nm.<BR/>10 Adrenal Cortex Hormones/<BR/>11 corticosteroid*.tw,nm.<BR/>12 corticoid*.tw,nm.<BR/>13 Hydrocortisone/<BR/>14 hydrocortisone.tw,nm.<BR/>15 hydroxypregnenolone.tw,nm.<BR/>16 Pregnenolone/<BR/>17 pregnenolone.tw,nm.<BR/>18 Tetrahydrocortisol/<BR/>19 tetrahydrocortisol.tw,nm.<BR/>20 Hydrocortisone/<BR/>21 hydrocortisone.tw,nm.<BR/>22 Cortodoxone/<BR/>23 cortodoxone.tw,nm.<BR/>24 Cortisone/<BR/>25 cortisone.tw,nm.<BR/>26 Corticosterone/<BR/>27 corticosterone.tw,nm.<BR/>28 Hydroxycorticosteroids/<BR/>29 hydroxycorticosteroid*.tw,nm.<BR/>30 triamcinolone.tw,nm.<BR/>31 prednisone.tw,nm.<BR/>32 prednisolone.tw,nm.<BR/>33 paramethasone.tw,nm.<BR/>34 methylprednisolone.tw,nm.<BR/>35 dexamethasone.tw,nm.<BR/>36 clobetasol.tw,nm.<BR/>37 beclomethasone.tw,nm.<BR/>38 betamethasone.tw,nm.<BR/>39 Pregnenediones/<BR/>40 pregnenedione*.tw,nm.<BR/>41 budesonide*.tw,nm.<BR/>42 or/8-41<BR/>43 7 and 42</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-11-07 21:43:43 +1000" MODIFIED_BY="[Empty name]">
<P>In addition, we sent letters to the trial authors of studies published in the past 10 years to enquire whether they knew of any other published or unpublished trials. We retrieved more than 700 unique references. There were no language or publication restrictions in our searches.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-29 09:08:02 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-07-14 08:58:48 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (original review AS, TPK; 2004 update KR, LH, NW; 2010 update KR, KO) independently selected studies from this list of references as being potentially relevant based on a review of titles and, when available, the abstracts. We retrieved the potentially relevant studies as full manuscripts. Two review authors (original review AS, TPK; 2004 update KR, LH, NW; 2010 update KR, KO) independently reviewed all potentially relevant studies. Discrepancies were resolved through discussion, or when needed, by an arbitrator.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-11-07 21:44:32 +1000" MODIFIED_BY="[Empty name]">
<P>We extracted data using a structured form that captured patients' status (inpatient or outpatient) and intervention and control characteristics, such as type of drug, route of administration and dosage. Additionally, we collected data on the primary outcome measures: change from baseline clinical croup scores; return visits and/or (re)admissions; length of stay in hospital or accident and emergency (hours); patient improvement (yes or no); and the use of additional interventions such as epinephrine, supplemental glucocorticoids, mist treatment, intubation or antibiotic treatment. One review author (original review MA; 2004 update KR; 2010 update KO) extracted data and a second review author (original review TPK; 2004 update KC, NW; 2010 update KR) checked the results for accuracy.</P>
<P>We extracted data from graphs (<LINK REF="STD-Fitzgerald-1996" TYPE="STUDY">Fitzgerald 1996</LINK>; <LINK REF="STD-Geelhoed-1995a" TYPE="STUDY">Geelhoed 1995a</LINK>; Geelhoed 1995 C&amp;D; <LINK REF="STD-Husby-1993" TYPE="STUDY">Husby 1993</LINK>; <LINK REF="STD-Kuusela-1988" TYPE="STUDY">Kuusela 1988</LINK>; <LINK REF="STD-Roberts-1999" TYPE="STUDY">Roberts 1999</LINK>) and obtained additional data from two trial authors (<LINK REF="STD-Bjornson-2004" TYPE="STUDY">Bjornson 2004</LINK>; <LINK REF="STD-Luria-2001" TYPE="STUDY">Luria 2001</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-11-07 21:44:37 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed methodological quality of the five studies that were added to this review using the 'Risk of bias' tool. This tool examines the adequacy of the following domains: allocation sequence generation, allocation concealment, blinding, management of incomplete outcome data, selective outcome reporting, and other sources of bias (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). Sponsorship of studies was recorded as pharmaceutical company, other sources, or not mentioned (<LINK REF="REF-Cho-1996" TYPE="REFERENCE">Cho 1996</LINK>). Two review authors (original review MA, JK; 2004 update KR, MA, AS, NW, LH; 2010 update KR, KO) independently assessed quality. Differences were resolved by consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-29 09:08:02 +1000" MODIFIED_BY="[Empty name]">
<P>The croup score was reported as either the Westley score, the telephone outpatient score (TOP) score or various author-created scales, hence standardized mean differences (SMDs) were used to combine the outcome for any croup score. A treatment effect (difference between treatment means) divided by its measurement variation (for example, a pooled standard deviation) gives a SMD. Mean differences in Westley scores were calculated for the primary outcome and consequently used in the subgroup and sensitivity analyses because estimates between Westley and other croup scores were found to be significantly different (see <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK>).</P>
<P>We expressed length of stay as mean differences and calculated an overall mean difference. We calculated risk ratios for binary data (i.e. return visits and/or (re)admissions and improvement in signs and symptoms). Risk differences were derived where outcomes had zero events in both groups (namely, the use of various additional treatments). We calculated the number needed to treat (NNT) or harm (NNH) for significant results. We reported the pooled baseline rates (i.e. the control group rates) using the inverse variance method. We calculated NNTs or NNHs for this complete range when the baseline rates varied extensively.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-11-07 23:09:33 +1000" MODIFIED_BY="[Empty name]">
<P>We calculated the change from baseline measures in cases where change from baseline measures were not reported directly (<LINK REF="STD-Geelhoed-1995a" TYPE="STUDY">Geelhoed 1995a</LINK>; Geelhoed 1995 C&amp;D; <LINK REF="STD-Husby-1993" TYPE="STUDY">Husby 1993</LINK>; <LINK REF="STD-Johnson-1996" TYPE="STUDY">Johnson 1996</LINK>; <LINK REF="STD-Klassen-1994" TYPE="STUDY">Klassen 1994</LINK>; <LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>; <LINK REF="STD-Koren-1983" TYPE="STUDY">Koren 1983</LINK>; <LINK REF="STD-Kuusela-1988" TYPE="STUDY">Kuusela 1988</LINK>; <LINK REF="STD-Leipzig-1979" TYPE="STUDY">Leipzig 1979</LINK>; <LINK REF="STD-Martinez-1993" TYPE="STUDY">Martinez 1993</LINK>; <LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>; <LINK REF="STD-Super-1989" TYPE="STUDY">Super 1989</LINK>; <LINK REF="STD-von-Muhlendahl-1982" TYPE="STUDY">von Muhlendahl 1982</LINK>). We pooled counts, means and variances when studies contained more than one treatment group (<LINK REF="STD-Geelhoed-1995a" TYPE="STUDY">Geelhoed 1995a</LINK>; Geelhoed 1995 C&amp;D; Johnson 1998 A&amp;B; <LINK REF="STD-Luria-2001" TYPE="STUDY">Luria 2001</LINK>) in the glucocorticoid versus placebo comparison.</P>
<P>Many variance imputations were performed according to the work of Follman (<LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>). The variance of a change from baseline measure was derived from the common variance of a single croup score assuming a correlation of 0.5 between pre- and post-treatment scores (<LINK REF="STD-Cruz-1995" TYPE="STUDY">Cruz 1995</LINK>; <LINK REF="STD-Johnson-1996" TYPE="STUDY">Johnson 1996</LINK>; <LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>; <LINK REF="STD-Martinez-1993" TYPE="STUDY">Martinez 1993</LINK>; <LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>; <LINK REF="STD-Super-1989" TYPE="STUDY">Super 1989</LINK>; <LINK REF="STD-von-Muhlendahl-1982" TYPE="STUDY">von Muhlendahl 1982</LINK>). Variances were also derived or imputed from the measurement of confidence intervals assuming a 0.5 correlation between pre- and post-treatment scores (<LINK REF="STD-Fitzgerald-1996" TYPE="STUDY">Fitzgerald 1996</LINK>; <LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>), as well as range and inter-quartile range calculations (<LINK REF="STD-Cruz-1995" TYPE="STUDY">Cruz 1995</LINK>; <LINK REF="STD-Johnson-1996" TYPE="STUDY">Johnson 1996</LINK>; <LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>; <LINK REF="STD-Super-1989" TYPE="STUDY">Super 1989</LINK>). Average variances from similar studies (same comparison, outcome and inpatient/outpatient status) were substituted where no 'imputable' information was present (<LINK REF="STD-Geelhoed-1995a" TYPE="STUDY">Geelhoed 1995a</LINK>; Geelhoed 1995 C&amp;D; <LINK REF="STD-Godden-1997" TYPE="STUDY">Godden 1997</LINK>; <LINK REF="STD-Kuusela-1988" TYPE="STUDY">Kuusela 1988</LINK>).</P>
<P>Medians were substituted for means in three studies (<LINK REF="STD-Cruz-1995" TYPE="STUDY">Cruz 1995</LINK>; <LINK REF="STD-Johnson-1996" TYPE="STUDY">Johnson 1996</LINK>; <LINK REF="STD-Super-1989" TYPE="STUDY">Super 1989</LINK>). Time points close to six, 12 or 24 hours were used when our exact time points were not provided (for six hours: <LINK REF="STD-Cruz-1995" TYPE="STUDY">Cruz 1995</LINK>; <LINK REF="STD-Fitzgerald-1996" TYPE="STUDY">Fitzgerald 1996</LINK>; <LINK REF="STD-Godden-1997" TYPE="STUDY">Godden 1997</LINK>; <LINK REF="STD-Husby-1993" TYPE="STUDY">Husby 1993</LINK>; <LINK REF="STD-Johnson-1996" TYPE="STUDY">Johnson 1996</LINK>; <LINK REF="REF-Klassen-1996c" TYPE="REFERENCE">Klassen 1996c</LINK>; <LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>; <LINK REF="STD-Massicotte-1973" TYPE="STUDY">Massicotte 1973</LINK>); for 12 hours: <LINK REF="STD-Massicotte-1973" TYPE="STUDY">Massicotte 1973</LINK>; and for 24 hours, <LINK REF="STD-Massicotte-1973" TYPE="STUDY">Massicotte 1973</LINK>; <LINK REF="STD-von-Muhlendahl-1982" TYPE="STUDY">von Muhlendahl 1982</LINK>).</P>
</UNIT_OF_ANALYSIS>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-11-07 21:45:54 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity quantitatively with the Chi<SUP>2</SUP> test for heterogeneity (significance cutoff at P = 0.10) and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). The I<SUP>2</SUP> statistic indicates the percent variability due to between study (or inter-study) variability as opposed to within study (or intra-study) variability. An I<SUP>2</SUP> statistic value greater than 50% should be considered large. For the analyses of all outcomes, we used random-effects models to combine treatment effects regardless of quantified heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<SUBGROUP_ANALYSIS MODIFIED="2010-11-07 21:46:00 +1000" MODIFIED_BY="[Empty name]">
<P>We explored heterogeneity between studies using subgroup and sensitivity analyses performed on the primary outcomes of change in Westley scores from baseline to six hours and return visits and/or (re)admissions using meta-regression. We considered the following subgroups: type and route of glucocorticoid administered, quality (i.e. allocation concealment, funding), inpatient or outpatient status.</P>
<P>In addition to funnel plots, we used the rank correlation test (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>) and weighted regression (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) for the detection of publication bias (<LINK REF="REF-Light-1984" TYPE="REFERENCE">Light 1984</LINK>). Adjustment for publication bias in the pooled estimates was performed using the trim and fill method (<LINK REF="REF-Taylor-1998" TYPE="REFERENCE">Taylor 1998</LINK>). We used more than one method since the relative merits of the methods are not well established.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-11-07 21:46:15 +1000" MODIFIED_BY="[Empty name]">
<P>We considered fixed-effect models in sensitivity analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-12-01 06:54:03 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-12-01 06:53:54 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-12-01 06:53:54 +1000" MODIFIED_BY="[Empty name]">
<P>In this update we identified 35 potentially relevant records from the searches.</P>
<P>We identified 124 studies as being potentially relevant. In this update, we added seven unique studies and there are 38 studies in this review (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; also at <A HREF="http://www.bmj.com">www.bmj.com</A> for the original review). However, three of the included studies had multiple treatment arms resulting in multiple comparisons; these comparisons are differentially referenced (Geelhoed 1995 C&amp;D; Johnson 1998 A&amp;B; Skowron 1966 A&amp;B). Thus, we analyzed 41 comparisons.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-11-29 09:08:11 +1000" MODIFIED_BY="[Empty name]">
<P>All of the included trials were of parallel design. Thirty-eight of the included studies were published in English, one in French (<LINK REF="STD-Massicotte-1973" TYPE="STUDY">Massicotte 1973</LINK>), one in Spanish (<LINK REF="STD-Martinez-1993" TYPE="STUDY">Martinez 1993</LINK>) and another in Danish (<LINK REF="STD-Vad-Pedersen-1998" TYPE="STUDY">Vad Pedersen 1998</LINK>). Twenty-nine studies were placebo-controlled and 18 trials examined more than one active treatment (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Eighteen trials were conducted on inpatients and the remaining 23 were conducted on outpatients. Dexamethasone was evaluated in 31 trials and against an active treatment in 17 of these. Dexamethasone was administered intramuscularly in 13 studies, orally in 13, sub-cutaneously in two, and two studies delivered dexamethasone via a nebulizer. There were two factorial studies examining placebo, epinephrine, dexamethasone and epinephrine/dexamethasone (<LINK REF="STD-Kuusela-1988" TYPE="STUDY">Kuusela 1988</LINK>; <LINK REF="STD-Martinez-1993" TYPE="STUDY">Martinez 1993</LINK>). Five trials examined budesonide versus placebo only and budesonide was compared to an active treatment in 13 studies; two studies had dexamethasone as a co-intervention in the budesonide and placebo arm (<LINK REF="STD-Geelhoed-2005" TYPE="STUDY">Geelhoed 2005</LINK>; <LINK REF="REF-Klassen-1996c" TYPE="REFERENCE">Klassen 1996c</LINK>). Two studies had three treatment arms: budesonide versus dexamethasone versus dexamethasone/budesonide (<LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>) and mist and dexamethasone versus epinephrine and dexamethasone versus epinephrine and budesonide (<LINK REF="STD-Duman-2005" TYPE="STUDY">Duman 2005</LINK>). One study had four treatment arms: budesonide versus oral dexamethasone versus intramuscular dexamethasone versus placebo (<LINK REF="STD-Cetinkaya-2004" TYPE="STUDY">Cetinkaya 2004</LINK>). Prednisolone was compared to placebo in three trials (<LINK REF="STD-Eden-1964" TYPE="STUDY">Eden 1964</LINK>; <LINK REF="STD-Massicotte-1973" TYPE="STUDY">Massicotte 1973</LINK>; <LINK REF="STD-Tibballs-1992" TYPE="STUDY">Tibballs 1992</LINK>) and compared to dexamethasone in two other studies (<LINK REF="STD-Fifoot--2007" TYPE="STUDY">Fifoot 2007</LINK>; <LINK REF="STD-Sparrow--2006" TYPE="STUDY">Sparrow 2006</LINK>). One study examined fluticasone versus placebo (<LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>) while another study compared dexamethasone and betamethasone (<LINK REF="STD-Amir--2006" TYPE="STUDY">Amir 2006</LINK>). One study examined three different doses of dexamethasone (<LINK REF="STD-Geelhoed-1995a" TYPE="STUDY">Geelhoed 1995a</LINK>) and four studies compared different routes of administration for dexamethasone (<LINK REF="STD-Donaldson-2003" TYPE="STUDY">Donaldson 2003</LINK>; <LINK REF="STD-Luria-2001" TYPE="STUDY">Luria 2001</LINK>; <LINK REF="STD-Rittichier-2000" TYPE="STUDY">Rittichier 2000</LINK>; <LINK REF="STD-Vad-Pedersen-1998" TYPE="STUDY">Vad Pedersen 1998</LINK>). Three studies included only children with mild croup (<LINK REF="STD-Bjornson-2004" TYPE="STUDY">Bjornson 2004</LINK>; <LINK REF="STD-Geelhoed-1996a" TYPE="STUDY">Geelhoed 1996a</LINK>; <LINK REF="STD-Luria-2001" TYPE="STUDY">Luria 2001</LINK>). Studies tended to be small with a median of 73 (inter-quartile range 53 to 99) participants.</P>
<P>Two previously validated croup scores were used. The first, Westley score (<LINK REF="REF-Westley-1978" TYPE="REFERENCE">Westley 1978</LINK>) is a 17-point scale to assess air entry (two points), stridor (two points), intercostal retractions (indrawing of the chest wall between the ribs on inspiration) (three points), cyanosis (five points) and level of consciousness (five points). The Westley score was used in 12 trials to measure baseline and post-treatment croup scores. The second validated croup score was the Telephone Out Patient (TOP) that was validated to be used over the telephone and it was used in one trial (<LINK REF="STD-Bjornson-2004" TYPE="STUDY">Bjornson 2004</LINK>). The TOP score is a three-point telephone outpatient score that assesses the presence of stridor and barky cough by asking parents about their child's symptoms in the last 24 hours.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-10-04 14:23:52 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded a total of 82 studies. The precise reasons for exclusion are described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-29 09:08:24 +1000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> describe the quality parameters of the included studies. All studies were described as randomized controlled trials.</P>
<ALLOCATION MODIFIED="2010-05-25 14:40:32 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation concealment was adequate in 19 (44%) of the studies, inadequate in one (2%), and unclear in 21 (46%).</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-05-25 14:40:37 +1000" MODIFIED_BY="[Empty name]">
<P>The majority of the studies were described as double-blind (n = 35).</P>
</BLINDING>
<OTHER_BIAS_SOURCES MODIFIED="2010-05-25 14:41:15 +1000" MODIFIED_BY="[Empty name]">
<P>Pharmaceutical sponsorship was identified in five (12%) studies, support was from other sources in six (15%), funding source was not mentioned in 27 (66%) and two studies reported that the study was conducted without funding (5%).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-12-01 06:54:03 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison: any glucocorticoid versus placebo</HEADING>
<P>Twenty-four studies involving 2878 participants compared a glucocorticoid to a placebo. These glucocorticoids were dexamethasone (n = 15), budesonide (n = six), methylprednisolone (n = three) and fluticasone (n = one).</P>
<SUBSECTION>
<HEADING LEVEL="4">Croup score</HEADING>
<P>Overall differences including any croup scores gave similar results, smaller in magnitude but the same direction. At six hours, the standardized mean difference (SMD) was -0.6, 95% confidence interval (CI) -0.8 to -0.4; I<SUP>2</SUP> statistic 67% (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). At 12 and 24 hours, the SMDs were -0.7, 95% CI -1.0 to -0.3; I<SUP>2</SUP> statistic 74% (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and -0.6, 95% CI -1.1 to 0; I<SUP>2</SUP> statistic 83% (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), respectively.</P>
<P>The most frequent outcome utilized in nine studies was the clinical croup score based on a 17-point ordinal scale developed by Westley (<LINK REF="REF-Westley-1978" TYPE="REFERENCE">Westley 1978</LINK>). Other scoring systems, only one other of which have been validated, were utilized in seven studies; in eight studies no clinical score was reported.</P>
<P>Westley scores at six hours showed significantly greater differences then the other croup scores combined (meta-regression P = 0.02). All croup scores combined at six hours attributed 67% of the total variability to between study variability; combined Westley scores attributed 23% of the total variability to between study variability. The Westley and TOP score are the only methods that have undergone validation and reliability testing and been shown to be sensitive to important changes in a patient's clinical status. The smaller treatment effect noted with non-Westley scores could be the result of insensitivity to change or perhaps a greater degree of variability caused by low reliability.</P>
<P>The mean difference in improvement in the Westley score between any glucocorticoid treatment and placebo at six hours was -1.2, 95% CI -1.6 to -0.8; I<SUP>2</SUP> statistic 41% (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). At 12 hours this difference was MD -1.9, 95% CI -2.4 to -1.3; I<SUP>2</SUP> statistic 37% (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). This change was not significant at 24 hours (MD -1.3, 95% CI -2.7 to 0.2; I<SUP>2</SUP> statistic 82%, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). However, fewer participants were evaluated at 24 hours and hence the lack of significance may be a reflection of reduced statistical power or a reflection of large between study variability (82%). The magnitude of change of one is similar to that seen at earlier evaluation points but the 95% CI crosses zero. A decrease in Westley score of one from baseline is thought to be a clinically important change. The fixed-effect estimate at 24 hours was significant.</P>
<P>Meta-regression found no differences in the Westley score between different glucocorticoid types (P = 0.107). The improvement in the Westley croup score at six hours was a mean difference of -1.3, 95% CI -1.7 to -0.9; I<SUP>2</SUP> statistic 0% (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (1.7.2)) for dexamethasone versus placebo; this was similar to budesonide versus placebo (MD -1.4; 95% CI -2.1 to -0.7; I<SUP>2</SUP> statistic 55%, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (1.7.1)). One study that compared fluticasone versus placebo had non-significant findings (MD 0.1; 95% CI -1.4 to 1.6, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (1.7.3)).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Improvement</HEADING>
<P>'Improvement' was defined in a variety of ways, such as relief of symptoms, a dichotomization of a croup score or by a minimal incremental improvement in croup score. Heterogeneity, assessed by the I<SUP>2</SUP> statistic was not large; all I<SUP>2</SUP> statistics were less than 60% for each time point. At six hours, the RR for 'improvement' was 1.4, 95% CI 1.1 to 1.8; I<SUP>2</SUP> statistic 26% (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>) with a NNT of five (three to 11). The baseline rate of clinical improvement was 45% (39% to 52%). At 12 hours the RR was 1.3, 95% CI 1.1 to 1.6; 52% (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>) with a NNT of five (three to 10). The baseline rate of clinical improvement was 62% (55% to 69%). At 24 hours, the RR was 1.2, 95% CI 1.1 to 1.5; I<SUP>2</SUP> statistic 31% (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>) and the NNT was five (three to 13). The baseline rate of clinical improvement was 86% (80% to 92%). The degree of benefit of a NNT of five patients would be sufficient to support the use of glucocorticoids over placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Return visits and/or (re)admissions</HEADING>
<P>There was a significant decrease in the rate of return visits and/or (re)admissions for patients treated with glucocorticoid versus patients treated with placebo (RR 0.5, 95% CI 0.3 to 0.7, I<SUP>2</SUP> statistic 49%, <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). The range of baseline rates was 2% to 72%. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> gives the NNT for this range of rates. The average (inverse variance method) baseline rate was 12% (10% to 14%). This corresponds to a NNT of 17 (13 to 28). Total variability attributable to between-study variation was not too large (I<SUP>2</SUP> statistic 49%). Nevertheless, the definitions for return visits and/or (re)admissions varied between studies, for example, re-admittance for inpatients versus unscheduled visits to a primary care giver or emergency room. In any case, the effect remains consistent in direction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of stay</HEADING>
<P>Overall, a significantly shorter time was spent in accident and emergency (<LINK REF="STD-Leipzig-1979" TYPE="STUDY">Leipzig 1979</LINK>) and hospital (nine studies) when children were treated with a glucocorticoid as compared with placebo (825 patients); the mean difference was -12 (-19 to -five) hours (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). Total variability attributable to between-study variation was large (I<SUP>2</SUP> statistic 64%). Two inpatient studies (<LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>; <LINK REF="STD-Super-1989" TYPE="STUDY">Super 1989</LINK>) did not favour glucocorticoids, but both were very small and had insignificant results; the remaining studies were consistent in direction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Use of additional interventions</HEADING>
<P>All but one random-effects model showed no significant differences for use of any particular additional intervention for any glucocorticoid versus placebo. Children treated with a glucocorticoid were 10% (1% to 20%; I<SUP>2</SUP> statistic 55%, Analysis 1.17.4) less often treated additionally with epinephrine. The NNT was 10 (five to 100). In the sensitivity analyses, use of mist treatment for the fixed-effect model was significant and favoured any glucocorticoid. Additional use of mist treatment was measured in two studies (<LINK REF="STD-Johnson-1996" TYPE="STUDY">Johnson 1996</LINK>; <LINK REF="STD-Super-1989" TYPE="STUDY">Super 1989</LINK>); their respective RDs were -12% (95% CI -19% to -6%) and -15% (95% CI -25% to -4%). Their baseline rates were 16% (12% to 21%) and 11% (6% to 16%). Use of mist treatment was quite heterogeneous (I<SUP>2</SUP> statistic 95%) between the two included studies and this result should be interpreted with caution. There was no difference in the need for intubation or tracheostomy between the two groups (RD 0%, 95% CI -1% to 1%; I<SUP>2</SUP> statistic 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup and sensitivity analyses</HEADING>
<P>In the subgroup analyses (between study comparisons), all quality items (funding, methodological quality, allocation concealment) were insignificant for both Westley score at six hours and return visits and/or (re)admissions. Clinical setting (inpatient versus outpatient), route of administration (oral, spray, intramuscular, subcutaneous), and type of glucocorticoid were also not significantly different for both primary outcomes. However, fluticasone was close to being significantly less beneficial than dexamethasone and budesonide (P = 0.11) for the Westley score at six hours. This study (<LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>) was small (n = 17); the meta-regression was likely underpowered to detect a difference, if one existed. This study did not record return visits or (re)admissions. Three studies included only mild croup patients (<LINK REF="STD-Bjornson-2004" TYPE="STUDY">Bjornson 2004</LINK>; <LINK REF="STD-Geelhoed-1996a" TYPE="STUDY">Geelhoed 1996a</LINK>; <LINK REF="STD-Luria-2001" TYPE="STUDY">Luria 2001</LINK>) and compared dexamethasone to placebo. One study used 0.6 mg/kg of oral dexamethasone (<LINK REF="STD-Bjornson-2004" TYPE="STUDY">Bjornson 2004</LINK>), one study administered 0.15 mg/kg of oral dexamethasone (<LINK REF="STD-Geelhoed-1996a" TYPE="STUDY">Geelhoed 1996a</LINK>) and the final study examined 0.60 mg/kg of oral dexamethasone or nebulized dexamethasone (<LINK REF="STD-Luria-2001" TYPE="STUDY">Luria 2001</LINK>). <LINK REF="STD-Bjornson-2004" TYPE="STUDY">Bjornson 2004</LINK> included children with a Westley croup score of &#8806; 2, <LINK REF="STD-Luria-2001" TYPE="STUDY">Luria 2001</LINK> included children with 'mild croup'; however some children exhibited stridor and <LINK REF="STD-Geelhoed-1996a" TYPE="STUDY">Geelhoed 1996a</LINK> also included children with 'mild croup'. Severity of croup was explored post hoc. The relative risk of return visits and/or re(admissions) was similar for the trials limited to mild croup (RR 0.5, 95% CI 0.3 to 1.0; I<SUP>2</SUP> statistic 48%, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>) and trials among children with moderate croup (RR 0.5, 95% CI 0.3 to 0.8; I<SUP>2</SUP> statistic 49%, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison: any glucocorticoid versus another glucocorticoid(s)</HEADING>
<P>Three studies (<LINK REF="STD-Duman-2005" TYPE="STUDY">Duman 2005</LINK>; <LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>; <LINK REF="STD-Vad-Pedersen-1998" TYPE="STUDY">Vad Pedersen 1998</LINK>) directly compared (within-study comparison) budesonide to dexamethasone using our primary outcomes. The SMD for the croup score at six hours was insignificant (SMD -0.4, 95% CI -1.1 to 0.3, two studies; I<SUP>2</SUP> statistic 74%, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), but at 12 hours for just one of the studies the SMD was significantly different and favoured dexamethasone (SMD -0.9, 95% CI -1.6 to -0.2, <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Return visits and/or (re)admissions were not significantly different (RD 0.01, 95% CI -0.02 to 0.05; two studies, I<SUP>2</SUP> statistic 0%, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). In one study, there were no return visits and/or (re)admissions in either treatment arm (<LINK REF="STD-Duman-2005" TYPE="STUDY">Duman 2005</LINK>). Combinations of budesonide and dexamethasone treatments versus either budesonide (<LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>) or dexamethasone (<LINK REF="STD-Geelhoed-2005" TYPE="STUDY">Geelhoed 2005</LINK>; <LINK REF="STD-Klassen-1998" TYPE="STUDY">Klassen 1998</LINK>) did not give significant differences for either primary outcomes. Also dosage comparisons of dexamethasone do not give significant differences (<LINK REF="STD-Alshehri--2005" TYPE="STUDY">Alshehri 2005</LINK>; <LINK REF="STD-Fifoot--2007" TYPE="STUDY">Fifoot 2007</LINK>; <LINK REF="STD-Geelhoed-1995a" TYPE="STUDY">Geelhoed 1995a</LINK>).</P>
<P>Two further studies (<LINK REF="STD-Donaldson-2003" TYPE="STUDY">Donaldson 2003</LINK>; <LINK REF="STD-Rittichier-2000" TYPE="STUDY">Rittichier 2000</LINK>) directly compared (within-study comparison) oral versus intramuscular routes of administration for dexamethasone. Combined results favoured the oral route. However, they were not statistically significant. One study (<LINK REF="STD-Rittichier-2000" TYPE="STUDY">Rittichier 2000</LINK>) measured the presence of croup symptoms (stridor, barky cough, expiratory sounds and normal sleeping patterns at 24 hours); the difference in Westley scores (0.04) was too small to be clinically important. Both studies recorded return visits and/or (re)admissions; this RR 0.8, 95% CI 0.6 to 1.1; I<SUP>2</SUP> statistic 0% (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>) although clinically important is underpowered (power 22% for a Chi<SUP>2</SUP> test).</P>
<P>Two studies compared dexamethasone to prednisolone. While there was no significant difference in croup score, children randomized to dexamethasone were significantly less likely to have a return visit/(re)admission than those randomized to prednisolone (RR 0.3, 95% CI 0.2 to 0.6; I<SUP>2</SUP> statistic 0%, <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>) (<LINK REF="STD-Fifoot--2007" TYPE="STUDY">Fifoot 2007</LINK>; <LINK REF="STD-Sparrow--2006" TYPE="STUDY">Sparrow 2006</LINK>).</P>
<P>The final study examined dexamethasone and betamethasone (<LINK REF="STD-Amir--2006" TYPE="STUDY">Amir 2006</LINK>). The change in croup score at six hours was not significantly different (MD -1.5; 95% CI -2.4 to -0.6), <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>), nor was the return visits/(re)admissions (RR 1.0, 95% CI 0.7 to 1.3, <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison: any glucocorticoid versus epinephrine</HEADING>
<P>Three studies compared any glucocorticoid versus epinephrine with a total of 205 participants. These glucocorticoids included dexamethasone (n = 2) and budesonide (n = 1). All croup scores comparing any glucocorticoid with epinephrine were insignificant. SMDs were 0.2 (95% CI -0.2 to 0.5; I<SUP>2</SUP> statistic 0%, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) at six hours, 0.1 (95% CI -0.3 to 0.4; I<SUP>2</SUP> statistic 0%, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) at 12 hours, and 0.2 (95% CI -0.2 to 0.5; I<SUP>2</SUP> statistic 0%, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) at 24 hours. The SMDs were too small to consider evaluating power. Only one of these studies recorded return visits and/or (re)admissions; there were none.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Publication bias</HEADING>
<P>Considering the Westley scores at six hours for any glucocorticoid versus placebo, we found no indication of publication bias; this is in contrast to the earlier version of this review. The earlier version of this review included all croup scores in this assessment. Since the meta-regression found Westley scores to be significantly different from other croup scores, we included only Westley scores to avoid unnecessary heterogeneity. This funnel plot appears symmetrical. The rank correlation test was insignificant (P = 0.18). The bias coefficient from weighted regression was insignificant (P = 0.34). The trim and fill method indicated zero missing studies. In addition, since fluticasone may have a different effect on croup score, we also assessed publication bias without the one study (<LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>) administering fluticasone. In this sensitivity analysis, two out of three publication bias tests were significant when using the less stringent cutoff of P = 0.10 (rank correlation, P = 0.06; weighted regression, P = 0.02).</P>
<P>One out of three tests using return visits and/or (re)admission indicated publication bias. The bias coefficient in weighted regression was significant using the P = 0.10 cutoff (P = 0.07). The trim and fill method indicated no missing studies and the rank correlation test was insignificant (P = 0.36). The funnel plot appears asymmetrical.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-12-01 06:54:11 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Efficacy of glucocorticoids</HEADING>
<P>This systematic review has shown that treatment with glucocorticoids is effective in improving symptoms of croup in children as early as six hours and for up to at least 12 hours after treatment. This is shown by the significant improvement in scores of croup severity, fewer return visits and/or (re)admissions, shorter lengths of stay, and the fact that epinephrine was used less often as an additional intervention. The degree of benefit identified would merit the use of glucocorticoids, since five patients would need to be treated with glucocorticoids for one patient to experience a significant improvement in symptoms.</P>
<P>The generally small numbers of patients in each study and confounding variables make it difficult to make definitive recommendations regarding the superiority of dexamethasone or budesonide, dose or route of administration. There was some evidence that fluticasone was less beneficial than dexamethasone and budesonide (P = 0.11) for the Westley score at six hours, thus we do not recommend it as the optimal treatment choice. In the absence of further evidence, a single oral dose of dexamethasone, probably 0.6 mg/kg, should be preferred because of its safety, efficacy and cost-effectiveness (<LINK REF="REF-Klassen-1996c" TYPE="REFERENCE">Klassen 1996c</LINK>; <LINK REF="REF-Klassen-1997" TYPE="REFERENCE">Klassen 1997</LINK>). In a child who is vomiting, nebulized budesonide or intramuscular dexamethasone might be preferable.</P>
<P>Our results are fairly consistent with those of the systematic review by <LINK REF="STD-Kairys-1989" TYPE="STUDY">Kairys 1989</LINK> which found that glucocorticoids are beneficial in patients with croup but there are some important differences. Because of the lower probability of bias in RCTs we excluded pseudo-RCTs. These excluded studies tended to be older and used techniques of quasi-randomization, such as alternate allocation (<LINK REF="STD-Martensson-1960" TYPE="STUDY">Martensson 1960</LINK>; <LINK REF="STD-Novik-1960" TYPE="STUDY">Novik 1960</LINK>; <LINK REF="STD-Sussman-1964" TYPE="STUDY">Sussman 1964</LINK>). Additionally, 30 RCTs on this topic have been published since 1989, many of them outpatient trials examining the effectiveness of budesonide or dexamethasone. The differences between inclusion criteria in our systematic review and that by <LINK REF="STD-Kairys-1989" TYPE="STUDY">Kairys 1989</LINK> may account for their finding that glucocorticoids significantly decrease the risk of intubation, whereas we did not observe a significantly decreased risk. Our updated results are also consistent with <LINK REF="STD-Kairys-1989" TYPE="STUDY">Kairys 1989</LINK> and improve upon the results of the original review. These results strengthen the existing evidence supporting glucocorticoids. Our updated analysis now shows that glucocorticoids significantly reduce return visits and/or (re)admissions. Dexamethasone is also effective in treating mild croup; no significant differences were found between mild and moderate croup populations. Also, as discussed below, publication bias is no longer a threat.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Publication bias</HEADING>
<P>Contrary to the first edition of this review, we found less evidence of publication bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The initial review used any croup scores at six hours to estimate publication bias, we used the Westley score exclusively and return visits and/or (re)admissions. Because the Westley score has been shown to be valid, responsive and a reliable measure (<LINK REF="REF-Klassen-1995" TYPE="REFERENCE">Klassen 1995</LINK>) and since the Westley score was found to be significantly different from the other croup scores via the meta-regression, we chose this outcome to test for the presence of publication bias. The initial review concluded that publication bias existed and had produced an exaggeration of the benefit of glucocorticoid treatment. This discrepancy is not attributable to the exclusive use of Westley scores; the original set of trials using Westley scores still indicate substantial evidence of publication bias. This updated review added one study (<LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>) to the Westley score outcome. When publication bias is tested on the Westley croup score including this additional study (<LINK REF="STD-Roorda-1998" TYPE="STUDY">Roorda 1998</LINK>), all three methods we used (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>; <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>; <LINK REF="REF-Taylor-1998" TYPE="REFERENCE">Taylor 1998</LINK>) gave no evidence of bias. Although, this is the only study that used fluticasone, thus it confounds our new findings. However, since the addition of one study erases all evidence of publication bias and since the estimates with and without this one study are both clinically important and of similar magnitude, this small indication of publication bias is clinically unimportant. In addition, return visits and/or (re)admissions gave no evidence of publication bias. This small to zero indication of publication bias strengthens our findings that glucocorticoids are an effective treatment option for treating children with croup.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Limitations</HEADING>
<P>In 50% of the trials allocation was adequately concealed whereas in most other studies about 10% to 15% of the trials being assessed have adequate concealment (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Another marker of quality, funding source, was reported in 28% of the trials and this is consistent with previous research.</P>
<P>We performed many calculations and imputations to create a usable data set. We chose change from baseline measures rather than final value measures to alleviate any possible concerns with imbalanced confounders, in spite of the fact that few studies were small. Assuming a correlation of 0.5 between baseline and final value measures equates the change from baseline standard deviation with the pooled baseline and final value standard deviations (note, our baseline and final value standard deviations were largely homogeneous). Thus, no gain in efficiency occurred. In a sensitivity analysis, we assumed a correlation of 0 between baseline and final value measures thereby multiplying the change standard deviation by the square root of two. This resulted in no visible change given the units reported here.</P>
<P>Since standard deviations within groups were largely homogeneous, our substitution for missing standard deviations with the arithmetic average of the reported standard deviations was reasonable. Only three studies provided medians rather than means. One study reported medians and means (<LINK REF="STD-Donaldson-2003" TYPE="STUDY">Donaldson 2003</LINK>) and a number of studies reported ranges or inter-quartile ranges. We chose to assume that the data were approximately normal based on the fact that the means and the medians in this one study were proximal, that the ranges were relatively entered on the median or mean, and since the vast majority of the studies reported statistics that required an assumption of normality. Hence, the medians should roughly approximate the means in these croup score outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Future research</HEADING>
<P>We believe that additional trials assessing the effectiveness of dexamethasone or budesonide compared to placebo are unwarranted. The cumulative meta graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) for return visits and/or (re)admissions shows that when new studies are being added, the pooled RR is fairly constant. The cumulative mean differences for the Westley six-hour score (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) may not have stabilized; however, the lower confidence limit, 0.5, is still of marginal clinical importance. With the relatively consistent statistical picture across our full set of measured outcomes, it is unlikely that additional trials simply comparing the effectiveness of dexamethasone or budesonide against placebo are warranted. Also, oral dexamethasone may perform better than intramuscular dexamethasone; at this point, the evidence is insufficiently powered to statistically determine the answer. Using Barrowman's new participant ratio (<LINK REF="REF-Barrowman-2003" TYPE="REFERENCE">Barrowman 2003</LINK>), if the secular trend were to continue we would require an additional 513 patients to achieve statistically significance. This is over twice the number of patients presently acquired for this comparison. In addition, the optimal dose of oral dexamethasone (0.15 to 0.6 mg) may yet need to be defined.</P>
<P>The results from this review demonstrate that glucocorticoids can substantially reduce hospitalization rates and return to care in children with croup. Nonetheless there is evidence that significant proportions of children with croup do not receive glucocorticoids (<LINK REF="REF-Knapp--2008" TYPE="REFERENCE">Knapp 2008</LINK>). Several studies also show wide variability in hospital admission rates between communities for children with croup (<LINK REF="REF-To-1994" TYPE="REFERENCE">To 1994</LINK>; <LINK REF="REF-Wennberg--1990" TYPE="REFERENCE">Wennberg 1990</LINK>) further suggesting that there is an evidence-practice gap and that glucocorticoids are underused. Research is required to establish the best methods for ensuring physicians employ best evidence.</P>
</SUBSECTION>
<SUMMARY_OF_RESULTS MODIFIED="2010-11-07 22:10:07 +1000" MODIFIED_BY="[Empty name]">
<P>Compared to placebo, glucocorticoid treatment resulted in significant improvement in the Westley score at six hours (mean difference -1.2, -1.6 to -0.8) and at 12 hours (mean difference-1.9, -2.4 to -1.3 but the difference was no longer significant at 24 hours (mean difference -1.3, -2.7 to 0.2). Typically children who present to the emergency department recover from croup quickly and are rapidly discharged. Therefore, the change in croup score at 24 hours may not be significant because it is under powered to find a significant difference (452 children at six hours versus 110 children at 24 hours). There were fewer return visits and/or (re)admissions among those treated with glucocorticoids versus placebo (RR 0.49, 95% CI 0.34 to 0.71). There was a significant reduction in time spent in accident and emergency or hospital among children who received glucocorticoids compared to placebo (mean difference 12 hours, five to 19 hours). There was statistically significant 'improvement' at six, 12 and 24 hours with glucocorticoid treatment compared to placebo. There was no significant difference in dosage of dexamethasone or route of administration.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-11-07 22:10:33 +1000" MODIFIED_BY="[Empty name]">
<P>We searched for trials that compared glucocorticoids to placebo or any other active treatment. The number of included studies was large (n = 41) and many of these studies addressed the role of glucocorticoids versus placebo. Fewer studies compared one glucocorticoid to another or the optimal dose or route of administration of the specific glucocorticoid. The majority of studies examined change in croup score at similar time points. In addition, many studies used the Westley croup score and this has been shown to be a valid and reliable measure of croup severity. The meta-analysis results are comprised of several studies and could be subgrouped by setting. Studies were primarily conducted among children with mild to moderate croup in an outpatient or emergency department setting and this is the clinical setting where the majority of children who presented to the emergency department with croup are treated. There was no evidence of publication bias for either of the two outcomes examined: Westley score and return visits and/or (re)admissions.<BR/>
</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-11-07 22:10:38 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation concealment was deemed adequate in almost half of the studies (44%), whereas in most other studies, adequate concealment was conducted in 10% to 15% of the trials (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Also, the majority of studies were conducted in a double-blind fashion (85%). Few studies were funded by a pharmaceutical company (12%).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-11-07 22:11:14 +1000" MODIFIED_BY="[Empty name]">
<P>A thorough and extensive search was conducted in many electronic databases. This systematic review did not have a language restriction and three non-English studies were included in the review. Also, an attempt to identify grey literature was made by contacting authors of included studies and reviewing reference lists of included studies. Two review authors independently screened potentially relevant studies, assessed for inclusion and assessed methodological quality. One review author extracted data and a second review author checked for accuracy and completeness. There was no evidence of publication bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-11-29 09:08:55 +1000" MODIFIED_BY="[Empty name]">
<P>Griffin conducted a systematic review examining nebulized steroids versus placebo for the treatment of croup (<LINK REF="REF-Griffin-2000" TYPE="REFERENCE">Griffin 2000</LINK>). They found that nebulized steroids significantly improved croup score at five hours (RR 1.48, 95% CI 1.27 to 1.74) and significantly reduced the need for hospital admission (RR 0.56, 95% CI 0.42 to 0.75). The authors concluded that nebulized steroids are an effective treatment option for children presenting to the emergency department with croup.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-05-25 15:44:54 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-05-25 15:44:44 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Glucocorticoids bring about clinical improvement in children with croup within six hours.</LI>
<LI>Nebulised budesonide or dexamethasone, given either orally or intramuscularly, is effective in treating croup.</LI>
<LI>The use of glucocorticoids is associated with a lower rate of epinephrine use, fewer return visits and/or (re)admission (NNT = 17, range three to 100 depending on baseline rate) and shorter time spent in hospital.</LI>
</OL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-05-25 15:44:54 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>The optimal dose of dexamethasone (0.15 mg/kg to 0.6 mg/kg) needs to be defined.</LI>
<LI>Research regarding effective methods of disseminating croup guidelines and increasing physician uptake of evidence is required.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-29 09:17:51 +1000" MODIFIED_BY="[Empty name]">
<P>We thank Lisa Tjosvold for her assistance in executing the search strategies. We also thank Lisa Hartling, Ba' Pham, Jim Kellner, Natasha Wiebe and David Moher for their contribution to previous versions of this review. Finally, we thank the following people for commenting on this updated draft: Amanda Young, Gina Neto, Mark Jones, and Chris Del Mar.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>David Johnson received research funding from Astra Pharmaceutical Inc. to complete one of his trials (<LINK REF="STD-Johnson-1998a" TYPE="STUDY">Johnson 1998a</LINK>).<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-11-07 22:12:39 +1000" MODIFIED_BY="[Empty name]">
<P>Kelly Russell (KR): study selection, quality assessment, data extraction and contribution to the final manuscript.<BR/>Yuanyuan Liang (YL): statistical analyses and contribution to the final manuscript.<BR/>Kathleen O'Gorman (KO): study selection, quality assessment, data extraction and contribution to the final manuscript.<BR/>David Johnson (DJ): contribution to the final manuscript.<BR/>Terry P Klassen (TPK): contribution to the final manuscript.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-07 23:22:14 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-11-07 23:21:48 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-11-07 22:25:16 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alshehri--2005" MODIFIED="2009-09-09 13:43:33 +1000" MODIFIED_BY="[Empty name]" NAME="Alshehri  2005" YEAR="2005">
<REFERENCE MODIFIED="2009-09-09 13:43:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alshehri M, Almegamsi T, Hammdi A</AU>
<TI>Efficacy of a small dose of oral dexamethasone in croup</TI>
<SO>Biomedical Research</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>1</NO>
<PG>65-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amir--2006" NAME="Amir  2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amir L, Hubermann, Halevi A, Mor M, Mimouni M, Waisman Y</AU>
<TI>Oral betamethasone versus intramuscular dexamethasone for the treatment of mild to moderate viral croup</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2006</YR>
<VL>22</VL>
<PG>541-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bjornson-2004" MODIFIED="2009-09-09 13:43:53 +1000" MODIFIED_BY="[Empty name]" NAME="Bjornson 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-09 13:43:53 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The abstract was published at the Pediatric Academic Societies meeting (2003).  The title was: The use of dexamethasone in mild croup:  A multi-center randomized controlled trial&lt;/p&gt;" NOTES_MODIFIED="2009-09-09 13:43:53 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjornson C, Klassen TP, Williamson J, Brant R, Plint A, Bulloch B, et al</AU>
<TI>A randomized trial of single dose of oral dexamethasone for mild croup</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>13</NO>
<PG>1306-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cetinkaya-2004" NAME="Cetinkaya 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cetinkaya F, Tufekci BS, Kutluk G</AU>
<TI>A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2004</YR>
<VL>68</VL>
<PG>453-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-1995" NAME="Cruz 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Cruz MN, Stewart G, Rosenberg N. Use of dexamethasone in the outpatient management of acute laryngotracheitis. Pediatrics 1995;96:220-223.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz MN, Stewart G, Rosenberg N</AU>
<TI>Use of dexamethasone in the outpatient management of acute laryngotracheitis</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<PG>220-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donaldson-2003" MODIFIED="2009-09-09 13:44:16 +1000" MODIFIED_BY="[Empty name]" NAME="Donaldson 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-09-09 13:44:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donaldson D, Poleski D, Knipple E, Filips K, Reetz L, Pascula RG, et al</AU>
<TI>Intramuscular versus oral dexamethasone for the treatment of moderate-to-severe croup: a randomized double-blind trial</TI>
<SO>Academy of Emergency Medicine</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>1</NO>
<PG>16-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duman-2005" NAME="Duman 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duman M, Ozdemir D, Atasever S</AU>
<TI>Nebulized L-epinephrine and steroid combination in the treatment of moderate to severe croup</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>183-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eden-1964" NAME="Eden 1964" YEAR="1964">
<REFERENCE NOTES="&lt;p&gt;Eden A, Larkin VP. Corticosteroid treatment of Croup. Pediatrics 1964; 33:768-769.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eden A, Larkin VP</AU>
<TI>Corticosteroid treatment of croup</TI>
<SO>Pediatrics</SO>
<YR>1964</YR>
<VL>33</VL>
<PG>768-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eden-1967" NAME="Eden 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Eden AN, Kaufman A, Yu R. Corticosteroids and croup. Controlled double-blind study. JAMA 1967; 200:403- 404.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eden AN, Kaufman A, Yu R</AU>
<TI>Corticosteroids and croup. Controlled double-blind study</TI>
<SO>JAMA</SO>
<YR>1967</YR>
<VL>200</VL>
<PG>403-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fifoot--2007" MODIFIED="2010-11-07 22:24:20 +1000" MODIFIED_BY="[Empty name]" NAME="Fifoot  2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-07 22:24:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fifot AA, Ting JYS</AU>
<TI>Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blinded clinical trial</TI>
<SO>Emergency Medicine Australasia</SO>
<YR>2007</YR>
<VL>19</VL>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzgerald-1996" NAME="Fitzgerald 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Fitzgerald D, Mellis C, Johnson M, Allen H, Cooper P, Van AP. Nebulized budesonide is as effective as nebulized adrenaline in moderately severe croup. Pediatrics 1996; 97:722-725.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald D, Mellis C, Johnson M, Allen H, Cooper P, Van AP</AU>
<TI>Nebulized budesonide is as effective as nebulized adrenaline in moderately severe croup</TI>
<SO>Pediatrics</SO>
<YR>1996</YR>
<VL>97</VL>
<PG>722-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1995-C_x0026_D" NAME="Geelhoed 1995 C&amp;D" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC, Macdonald WB</AU>
<TI>Oral and inhaled steroids in croup: a randomized, placebo-controlled trial</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1995</YR>
<VL>20</VL>
<PG>355-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1995a" NAME="Geelhoed 1995a" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Geelhoed GC, Macdonald WB. Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg. Pediatric Pulmonology 1995; 20:362-368.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC, Macdonald WB</AU>
<TI>Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1995</YR>
<VL>20</VL>
<PG>362-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1995c" NAME="Geelhoed 1995c" YEAR="1995c">
<REFERENCE NOTES="&lt;p&gt;Geelhoed GC, Macdonald WB. Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Pediatric Pulmonology 1995; 20:355-361.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC, Macdonald WB</AU>
<TI>Oral and inhaled steroids in croup: a randomized, placebo-controlled trial</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1995</YR>
<VL>20</VL>
<PG>355-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1995d" NAME="Geelhoed 1995d" YEAR="1995d">
<REFERENCE NOTES="&lt;p&gt;Geelhoed GC, Macdonald WB. Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Pediatric Pulmonology 1995; 20:355-361.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC, Macdonald WB</AU>
<TI>Oral and inhaled steroids in croup: a randomized, placebo-controlled trial</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1995</YR>
<VL>20</VL>
<PG>355-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1996a" MODIFIED="2010-11-07 22:24:36 +1000" MODIFIED_BY="[Empty name]" NAME="Geelhoed 1996a" YEAR="1996">
<REFERENCE MODIFIED="2010-11-07 22:24:36 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Geelhoed GC, Turner J, Macdonald WB. Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial. BMJ 1996; 313:140-142.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:24:36 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC, Turner J, Macdonald WB</AU>
<TI>Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>140-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-2005" NAME="Geelhoed 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC</AU>
<TI>Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>6</NO>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godden-1997" NAME="Godden 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Godden CW, Campbell MJ, Hussey M, Cogswell JJ. Double blind placebo controlled trial of nebulised budesonide for croup. Archives of Disease in Childhood 1997; 76:155-158.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godden CW, Campbell MJ, Hussey M, Cogswell JJ</AU>
<TI>Double blind placebo controlled trial of nebulised budesonide for croup</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Husby-1993" NAME="Husby 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Husby S, Agertoft L, Mortensen S, Pedersen S. Treatment of croup with nebulised steroid (budesonide): a double blind, placebo controlled study. Archives of Disease in Childhood 1993; 68:352-355.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Husby S, Agertoft L, Mortensen S, Pedersen S</AU>
<TI>Treatment of croup with nebulised steroid (budesonide): a double blind, placebo controlled study</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>68</VL>
<PG>352-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-James-1969" NAME="James 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;James JA. Dexamethasone in croup. A controlled study. American Journal of Diseases of Children 1969; 117:511- 516.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>James JA</AU>
<TI>Dexamethasone in croup. A controlled study</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1969</YR>
<VL>117</VL>
<PG>511- 6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1996" NAME="Johnson 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Johnson DW, Schuh S, Koren G, Jaffee DM. Outpatient treatment of croup with nebulized dexamethasone [see comments]. Archives of Pediatrics &amp;amp; Adolescent Medicine 1996; 150:349-355.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Schuh S, Koren G, Jaffee DM</AU>
<TI>Outpatient treatment of croup with nebulized dexamethasone</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1996</YR>
<VL>150</VL>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1998-A_x0026_B" NAME="Johnson 1998 A&amp;B" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Jacobson S, Edney PC, Hadfield P, Mundy ME, Schuh S</AU>
<TI>A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>498-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1998a" NAME="Johnson 1998a" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Johnson DW, Jacobson S, Edney PC, Hadfield P, Mundy ME, Schuh S. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. New England Journal of Medicine 1998; 339:498-503.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Jacobson S, Edney PC, Hadfield P, Mundy ME, Schuh S</AU>
<TI>A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>498-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1998b" NAME="Johnson 1998b" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Johnson DW, Jacobson S, Edney PC, Hadfield P, Mundy ME, Schuh S. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. New England Journal of Medicine 1998; 339:498-503.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Jacobson S, Edney PC, Hadfield P, Mundy ME, Schuh S</AU>
<TI>A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>498-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-1994" NAME="Klassen 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Klassen TP, Feldman ME, Watters LK, Sutcliffe T, Rowe PC. Nebulized budesonide for children with mild-to- moderate croup [see comments]. New England Journal of Medicine 1994; 331:285-289.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Feldman ME, Watters LK, Sutcliffe T, Rowe PC</AU>
<TI>Nebulized budesonide for children with mild-to-moderate croup</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<PG>285-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-1996" NAME="Klassen 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Klassen TP, Watters LK, Feldman ME, Sutcliffe T, Rowe PC. The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup. Pediatrics 1996; 97:463-466.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Watters LK, Feldman ME, Sutcliffe T, Rowe PC</AU>
<TI>The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup</TI>
<SO>Pediatrics</SO>
<YR>1996</YR>
<VL>97</VL>
<PG>463-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-1998" NAME="Klassen 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Klassen, T. P., Craig, W. R., Moher, D., Osmond, M. H., Pasterkamp, H., Sutcliffe, T., Watters, L. K., and Rowe, P. C. Nebulized budesonide and oral dexamethasone for treatment of croup: A randomized controlled trial. JAMA 1998; 279:1629-1632.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Craig WR, Moher D, Osmond MH, Pasterkamp H, Sutcliffe T</AU>
<TI>Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>279</VL>
<PG>1629-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koren-1983" NAME="Koren 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Koren GF. Corticosteroid treatment of laryngotracheitis v spasmodic croup in children. American.Journal.of.Diseases.of.Children.Vol.137.(10.)(pp.941.944.) 1983;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koren GF</AU>
<TI>Corticosteroid treatment of laryngotracheitis v spasmodic croup in children</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1983</YR>
<VL>137</VL>
<NO>10</NO>
<PG>941-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuusela-1988" NAME="Kuusela 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Kuusela AL, Vesikari T. A randomized double-blind, placebo-controlled trial of dexamethasone and racemic epinephrine in the treatment of croup. Acta Paediatrica Scandinavica 1988; 77:99-104.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuusela AL, Vesikari T</AU>
<TI>A randomized double-blind, placebo-controlled trial of dexamethasone and racemic epinephrine in the treatment of croup</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1988</YR>
<VL>77</VL>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leipzig-1979" NAME="Leipzig 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Leipzig B, Oski FA, Cummings CW, Stockman JA, Swender P. A prospective randomized study to determine the efficacy of steroids in treatment of croup. Journal of Pediatrics 1979; 94:194-196.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leipzig B, Oski FA, Cummings CW, Stockman JA, Swender P</AU>
<TI>A prospective randomized study to determine the efficacy of steroids in treatment of croup</TI>
<SO>Journal of Pediatrics</SO>
<YR>1979</YR>
<VL>94</VL>
<PG>194-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luria-2001" NAME="Luria 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luria JW, Gonzalez-del-Rey JA, DiGuilio GA, McAneney CM, Olsen JJ, Ruddy RM</AU>
<TI>Effectiveness of oral or nebulized dexamethasone for children with mild croup</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>1340-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-1993" MODIFIED="2010-11-07 22:24:54 +1000" MODIFIED_BY="[Empty name]" NAME="Martinez 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-07 22:24:54 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Martinez FA, Sanchez GE, Rica EI, Echaniz UI, Alonso DM, Vilella CM, et al. [Randomized double-blind study of treatment of croup with adrenaline and/or dexamethasone in children]. [Spanish]. Anales Espanoles de Pediatria 1993; 38:29-32.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:24:54 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez FA, Sanchez GE, Rica EI, Echaniz UI, Alonso DM, Vilella CM, et al</AU>
<TI>Randomized double-blind study of treatment of croup with adrenaline and/or dexamethasone in children [Spanish]</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1993</YR>
<VL>38</VL>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massicotte-1973" NAME="Massicotte 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Massicotte P, Tetreault L. [Evaluation of methyl-prednisolone in the treatment of acute laryngitis in children]. [French]. Union Medicale du Canada 1973; 102:2064-2072.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massicotte P, Tetreault L</AU>
<TI>Evaluation of methyl-prednisolone in the treatment of acute laryngitis in children [French]</TI>
<SO>Union Medicale du Canada</SO>
<YR>1973</YR>
<VL>102</VL>
<PG>2064-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rittichier-2000" NAME="Rittichier 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rittichier KK, Ledwith CA</AU>
<TI>Outpatient treatment of moderate croup with dexamethasone: intramuscular versus oral dosing</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1344-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1999" MODIFIED="2009-09-09 13:48:11 +1000" MODIFIED_BY="[Empty name]" NAME="Roberts 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-09-09 13:48:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts GW, Master VV, Staugas RE, Raftos JV, Parsons DW, Coulthard KP, et al</AU>
<TI>Repeated dose inhaled budesonide versus placebo in the treatment of croup</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>170-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roorda-1998" MODIFIED="2010-11-07 22:25:07 +1000" MODIFIED_BY="[Empty name]" NAME="Roorda 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-07 22:25:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roorda RJ, Walhof CM</AU>
<TI>Effects of inhaled fluticasone propionate administered with metered dose inhaler and spacer in mild to moderate croup: a negative preliminary report</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1998</YR>
<VL>25</VL>
<PG>114-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skowron-1966-A_x0026_B" NAME="Skowron 1966 A&amp;B" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skowron PN, Turner JA, McNaughton GA</AU>
<TI>The use of corticosteroid (dexamethasone) in the treatment of acute laryngotracheitis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1966</YR>
<VL>94</VL>
<PG>528-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skowron-1966a" NAME="Skowron 1966a" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Skowron PN, Turner JA, McNaughton GA. The use of corticosteroid (dexamethasone) in the treatment of acute laryngotracheitis. Canadian Medical Association Journal 1966; 94:528-531.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skowron PN, Turner JA, McNaughton GA</AU>
<TI>The use of corticosteroid (dexamethasone) in the treatment of acute laryngotracheitis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1966</YR>
<VL>94</VL>
<PG>528-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skowron-1966b" NAME="Skowron 1966b" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Skowron PN, Turner JA, McNaughton GA. The use of corticosteroid (dexamethasone) in the treatment of acute laryngotracheitis. Canadian Medical Association Journal 1966; 94:528-531.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skowron PN, Turner JA, McNaughton GA</AU>
<TI>The use of corticosteroid (dexamethasone) in the treatment of acute laryngotracheitis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1966</YR>
<VL>94</VL>
<PG>528-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparrow--2006" MODIFIED="2009-09-09 13:50:11 +1000" MODIFIED_BY="[Empty name]" NAME="Sparrow  2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-09 13:50:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparrow A, Geelhoed G</AU>
<TI>Prednisolone versus dexamethasone in croup: a randomised equivalence trial</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>7</NO>
<PG>580-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Super-1989" NAME="Super 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Super DM, Cartelli NA, Brooks LJ, Lembo RM, Kumar ML. A prospective randomized double-blind study to evaluate the effect of dexamethasone in acute laryngotracheitis. Journal of Pediatrics 1989; 115:323-329.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Super DM, Cartelli NA, Brooks LJ, Lembo RM, Kumar ML</AU>
<TI>A prospective randomized double-blind study to evaluate the effect of dexamethasone in acute laryngotracheitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>115</VL>
<PG>323-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tibballs-1992" NAME="Tibballs 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tibballs J, Shann FA, Landau LI</AU>
<TI>Placebo-controlled trial of prednisolone in children intubated for croup</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>745-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vad-Pedersen-1998" MODIFIED="2010-11-07 22:25:16 +1000" MODIFIED_BY="[Empty name]" NAME="Vad Pedersen 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-07 22:25:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vad Pedersen L, Dahl M, Falk-Petersen HE, Larsen SE</AU>
<TI>Inhaled budesonide versus intramuscular dexamethasone in the treatment of pseudocroup</TI>
<TO>Inhaleret budesonid versus dexamethasone i.m. til behandling at pseudocroup</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1998</YR>
<VL>160</VL>
<NO>15</NO>
<PG>2253-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Muhlendahl-1982" NAME="von Muhlendahl 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;von Muhlendal KE, Kahn D, Spohr HL, Dressler F. Steroid treatment of pseudo-croup. Helvetica Paediatrica Acta 1982; 37:431-436.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Muhlendal KE, Kahn D, Spohr HL, Dressler F</AU>
<TI>Steroid treatment of pseudo-croup</TI>
<SO>Helvetica Paediatrica Acta</SO>
<YR>1982</YR>
<VL>37</VL>
<PG>431-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-07 23:21:48 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adelman-1996" NAME="Adelman 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Adelman A. Treatment of croup with nebulized dexamethasone. Journal of Family Practice 1996; 43:19-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adelman A</AU>
<TI>Treatment of croup with nebulized dexamethasone</TI>
<SO>Journal of Family Practice</SO>
<YR>1996</YR>
<VL>43</VL>
<PG>19-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anene-1996" MODIFIED="2010-11-07 22:25:25 +1000" MODIFIED_BY="[Empty name]" NAME="Anene 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-07 22:25:25 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Anene OMKU. Dexamethasone for the prevention of postextubation airway obstruction: A prospective, randomized, double-blind, placebo-controlled trial. Critical.Care Medicine.Vol.24.(10.) (pp.1666.1669.) 1996;&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:25:25 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anene O, Meert KL, Uy H, Simpson P, Sarnaik AP</AU>
<TI>Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial</TI>
<SO>Critical Care Medicine</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>10</NO>
<PG>1666-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1989" NAME="Anonymous 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Steroids and croup. Lancet.Vol.2.(8672.) (pp.1134.1136.) 1989;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Steroids and croup</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>8672</NO>
<PG>1134-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1992" NAME="Anonymous 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Steroid therapy for croup in children admitted to hospital. Infectious Diseases and Immunization Committee, Canadian Paediatric Society [published erratum appears in Can Med Assoc J 1993 Feb 15;148(4):492] [see comments]. Canadian Medical As sociation Journal 1992; 147:429-432.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Steroid therapy for croup in children admitted to hospital. Infectious Diseases and Immunization Committee, Canadian Paediatric Society</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1992</YR>
<VL>147</VL>
<NO>4</NO>
<PG>429-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1994" NAME="Anonymous 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Anonymous. The treatment of laryngotracheitis (croup) with steroids. Original Title TRATAMIENTO DE LARINGOTRAQUEITIS (CROUP) CON ESTEROIDES. Practica.Pediatrica.Vol.3.(7.) (pp.10.17.) 1994;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>The treatment of laryngotracheitis (croup) with steroids</TI>
<TO>Tratamiento de laringotraqueitis (croup) con esteroides</TO>
<SO>Practica Pediatrica</SO>
<YR>1994</YR>
<VL>3</VL>
<NO>7</NO>
<PG>10-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1995" NAME="Anonymous 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Nebulized steroids for mild-to-moderate croup. Indian Pediatrics 1995; 32:395-396.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Nebulized steroids for mild-to-moderate croup</TI>
<SO>Indian Pediatrics</SO>
<YR>1995</YR>
<VL>32</VL>
<PG>395-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1996" NAME="Anonymous 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Inhaled budesonide and adrenaline for croup. Drug &amp;amp; Therapeutics.Bulletin.Vol.34.(3.) (pp.23.24.) 1996;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Inhaled budesonide and adrenaline for croup</TI>
<SO>Drug and Therapeutics Bulletin</SO>
<YR>1996</YR>
<VL>34</VL>
<NO>3</NO>
<PG>23-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asher-1981" NAME="Asher 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Asher MI Beaudry PH Tunnessen WW Jr. Croup and corticosteroid therapy. Journal.of.Pediatrics.Vol.98.(3.)(pp.506.507.) 1981;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asher MI, Beaudry PH, Tunnessen WW Jr</AU>
<TI>Croup and corticosteroid therapy</TI>
<SO>Journal of Pediatrics</SO>
<YR>1981</YR>
<VL>98</VL>
<NO>3</NO>
<PG>506-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bass-1972" NAME="Bass 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Bass JW. Corticosteroids in croup. JAMA 1972; 221:1164&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bass JW</AU>
<TI>Corticosteroids in croup</TI>
<SO>JAMA</SO>
<YR>1972</YR>
<VL>221</VL>
<PG>1164</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bass-1980" MODIFIED="2010-03-31 12:25:27 +1000" MODIFIED_BY="[Empty name]" NAME="Bass 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Bass JW Bruhn FW Merritt WT. Corticosteroids and racemic epinephrine with IPPB in the treatment of croup. Journal.of.Pediatrics.Vol.96.(1.)(pp.173.174.) 1980;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bass JW, Bruhn FW, Merritt WT</AU>
<TI>Corticosteroids and racemic epinephrine with IPPB in the treatment of croup</TI>
<SO>Journal of Pediatrics</SO>
<YR>1980</YR>
<VL>96</VL>
<NO>1</NO>
<PG>173-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baugh-1986" MODIFIED="2010-11-07 22:25:36 +1000" MODIFIED_BY="[Empty name]" NAME="Baugh 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-07 22:25:36 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Baugh RGBJ. Infectious croup: A critical review. Otolaryngology.&amp;amp; Head.&amp;amp; Neck Surgery.Vol.95.(1.)(pp.40.46.) 1986;&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:25:36 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baugh RGBJ</AU>
<TI>Infectious croup: a critical review</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1986</YR>
<VL>95</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauman-1996" NAME="Bauman 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Bauman BH, Vilke G, Chan T. Dexamethasone use in croup. Western Journal of Medicine 1996; 164:66-67.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauman BH, Vilke G, Chan T</AU>
<TI>Dexamethasone use in croup</TI>
<SO>Western Journal of Medicine</SO>
<YR>1996</YR>
<VL>164</VL>
<PG>66-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berni-1999" NAME="Berni 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berni Canani F, Mansi N, Natale A, De Vita C</AU>
<TI>Acute epiglottitis in children: current criteria for diagnosis and treatment</TI>
<TO>Epiglottite acuta in eta infantile: attuali criteri di diagnosi e trattamento</TO>
<SO>Acta Otorhinolaryngologica Italica</SO>
<YR>1999</YR>
<VL>19</VL>
<PG>272-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bollobas--1965" MODIFIED="2010-03-31 12:25:43 +1000" MODIFIED_BY="[Empty name]" NAME="Bollobas  1965" YEAR="1965">
<REFERENCE NOTES="&lt;p&gt;Bollobas B. [On local adrenocortical hormone treatment of rhinolaryngologic diseases]. [German]. Zeitschrift fur Laryngologie, Rhinologie, Otologie und Ihre Grenzgebiete 1965; 44:476-481.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bollobas B</AU>
<TI>On local adrenocortical hormone treatment of rhinolaryngologic diseases. [German]</TI>
<SO>Zeitschrift fur Laryngologie, Rhinologie, Otologie und Ihre Grenzgebiete</SO>
<YR>1965</YR>
<VL>44</VL>
<PG>476-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chub_x002d_Uppakarn-2007" MODIFIED="2010-03-31 11:52:52 +1000" MODIFIED_BY="[Empty name]" NAME="Chub-Uppakarn 2007" YEAR="">
<REFERENCE MODIFIED="2010-03-31 11:52:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chub-Uppakarn S, Sangsupawanich P</AU>
<TI>A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup</TI>
<SO>International Journal of Pediatric Otorhinolaryngology</SO>
<YR>2007</YR>
<VL>71</VL>
<PG>473-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cichy-1983" NAME="Cichy 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Cichy M, Pawlik J. [Treatment of subglottic laryngitis in children]. [Polish]. Otolaryngologia Polska 1983; 37:11- 13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cichy M, Pawlik J</AU>
<TI>Treatment of subglottic laryngitis in children. [Polish]</TI>
<SO>Otolaryngologia Polska</SO>
<YR>1983</YR>
<VL>37</VL>
<PG>11- 3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cluster--2005" NAME="Cluster  2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cluster J</AU>
<TI>A randomized trial of a single dose of oral dexamethasone for mild croup</TI>
<SO>Journal of Pediatrics</SO>
<YR>2005</YR>
<VL>146</VL>
<NO>3</NO>
<PG>434-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connolly-1969" NAME="Connolly 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Connolly JH, Field C, Glasgow J. A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus. Acta Pediatrica Scandinavica 1969; 58:116&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connolly JH, Field C, Glasgow J</AU>
<TI>A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus</TI>
<SO>Acta Pediatrica Scandinavica</SO>
<YR>1969</YR>
<VL>58</VL>
<PG>116</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Couser-1992" NAME="Couser 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Couser RJ FTF. Effectiveness of dexamethasone in preventing extubation failure in preterm infants at increased risk for airway edema. J-Pediatr.1992; 121: 591-6 121:591-596.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Couser RJ, Ferrara TB, Falde B, Johnson K, Schilling CG, Hoekstra RE</AU>
<TI>Effectiveness of dexamethasone in preventing extubation failure in preterm infants at increased risk for airway edema</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>121</VL>
<PG>591-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boeck-1995" MODIFIED="2010-11-07 22:25:50 +1000" MODIFIED_BY="[Empty name]" NAME="De Boeck 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-07 22:25:50 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;De Boeck. Croup: A review. European.Journal.of.Pediatrics.Vol.154.(6.) (pp.432.436.) 1995;&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:25:50 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Boeck</AU>
<TI>Croup: a review</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>6</NO>
<PG>432-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denoyelle-1992" NAME="Denoyelle 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Denoyelle F. Laryngitis in children. Original Title LARYNGITES DE L'ENFANT: COMMENT LES TRAITER?. Pediatre.Vol.28.(135.) (pp.141.143.) 1992;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denoyelle F</AU>
<TI>Laryngitis in children</TI>
<TO>Laryngites de l'enfant: Comment les traiter?</TO>
<SO>Pediatre</SO>
<YR>1992</YR>
<VL>28</VL>
<NO>135</NO>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doull-1995" MODIFIED="2010-11-07 22:25:57 +1000" MODIFIED_BY="[Empty name]" NAME="Doull 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-07 22:25:57 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Doull I. Corticosteroids in the management of croup [editorial] [see comments]. BMJ 1995; 311:1244&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:25:57 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doull I</AU>
<TI>Corticosteroids in the management of croup</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>1244</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eden-1971" MODIFIED="2010-11-07 22:26:12 +1000" MODIFIED_BY="[Empty name]" NAME="Eden 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-11-07 22:26:12 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Eden AN. Corticosteroids in croup: is a controlled clinical trial needed?. Pediatrics 1971; 47:635-636.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:26:12 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eden AN</AU>
<TI>Corticosteroids in croup: is a controlled clinical trial needed?</TI>
<SO>Pediatrics</SO>
<YR>1971</YR>
<VL>47</VL>
<PG>635-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feingold-1999" MODIFIED="2010-11-07 22:26:05 +1000" MODIFIED_BY="[Empty name]" NAME="Feingold 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-07 22:26:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feingold AR, Nairn S</AU>
<TI>Demonstrated benefit of glucocorticoids does not mean prednisone is beneficial in the routine office setting</TI>
<SO>Western Journal of Medicine</SO>
<YR>1999</YR>
<VL>171</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flisberg-1973" NAME="Flisberg 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Flisberg K, Olsholt R. Pseudocroup with stridor. Acta Oto-Laryngologica 1973; 76:295-299.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flisberg K, Olsholt R</AU>
<TI>Pseudocroup with stridor</TI>
<SO>Acta Oto-Laryngologica</SO>
<YR>1973</YR>
<VL>76</VL>
<PG>295-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Folland-1997" MODIFIED="2010-11-07 22:26:20 +1000" MODIFIED_BY="[Empty name]" NAME="Folland 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-07 22:26:20 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Folland DS. Treatment of Croup. Sending home an improved child and relieved parents. Postgraduate Medicine 1997; 101:271-273.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:26:20 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Folland DS</AU>
<TI>Treatment of croup. Sending home an improved child and relieved parents</TI>
<SO>Postgraduate Medicine</SO>
<YR>1997</YR>
<VL>101</VL>
<PG>271-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freezer-1990" NAME="Freezer 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Freezer N, Butt W, Phelan P. Steroids in croup: do they increase the incidence of successful extubation?. Anaesthesia &amp;amp; Intensive Care 1990; 18:224-228.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freezer N, Butt W, Phelan P</AU>
<TI>Steroids in croup: do they increase the incidence of successful extubation?</TI>
<SO>Anaesthesia and Intensive Care</SO>
<YR>1990</YR>
<VL>18</VL>
<PG>224-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-1990" NAME="Friedman 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Friedman AB. Advances in pediatrics [published erratum appears in Ohio Med 1990 Apr;86(4):248]. Ohio Medicine 1990; 86:132-134.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman AB</AU>
<TI>Advances in pediatrics</TI>
<SO>Ohio Medicine</SO>
<YR>1990</YR>
<VL>86</VL>
<NO>2</NO>
<PG>132-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1994" NAME="Geelhoed 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Geelhoed GC, Macdonald W. Comparison of oral and inhaled steroids in the treatment of croup. Am J Respir Crit Care Med 1994; 149:A375&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC, Macdonald W</AU>
<TI>Comparison of oral and inhaled steroids in the treatment of croup</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1994</YR>
<VL>149</VL>
<PG>A375</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1996b" MODIFIED="2010-11-07 22:26:42 +1000" MODIFIED_BY="[Empty name]" NAME="Geelhoed 1996b" YEAR="1996">
<REFERENCE MODIFIED="2010-11-07 22:26:42 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Geelhoud GC. Croup: New perspectives on corticosteroid therapy. Clinical.Immunotherapeutics.Vol.5.(4.) (pp.260.267.) 1996;&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:26:42 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC</AU>
<TI>Croup: new perspectives on corticosteroid therapy</TI>
<SO>Clinical Immunotherapeutics</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>4</NO>
<PG>260-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geelhoed-1997" NAME="Geelhoed 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Geelhoed GC. Croup. Pediatric.Pulmonology.Vol.23.(5.) (pp.370.374.) 1997;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC</AU>
<TI>Croup</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>5</NO>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goddard--1967" MODIFIED="2010-11-07 22:26:50 +1000" MODIFIED_BY="[Empty name]" NAME="Goddard  1967" YEAR="1967">
<REFERENCE MODIFIED="2010-11-07 22:26:50 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Goddard JJ, Phillips OC, Marcy JH. Betamethasone for prophylaxis of postintubation inflammation..a double-blind study. Anesthesia &amp;amp; Analgesia 1967; 46:348-353.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:26:50 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goddard JJ, Phillips OC, Marcy JH</AU>
<TI>Betamethasone for prophylaxis of postintubation inflammation: a double-blind study</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>1967</YR>
<VL>46</VL>
<PG>348-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldhagen-1983" NAME="Goldhagen 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Goldhagen JL. Croup: pathogenesis and management. [Review] [32 refs]. Journal of Emergency Medicine 1983; 1:3-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldhagen JL</AU>
<TI>Croup: pathogenesis and management</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>1983</YR>
<VL>1</VL>
<PG>3-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haque-1981" NAME="Haque 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Haque KN. Efficacy of dexamethasone in acute laryngotracheobronchitis (croup). Saudi.Medical.Journal.Vol.2.(3.)(pp.143.145.) 1981;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haque KN</AU>
<TI>Efficacy of dexamethasone in acute laryngotracheobronchitis (croup)</TI>
<SO>Saudi Medical Journal</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>3</NO>
<PG>143-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harel-1995" NAME="Harel 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Harel Y, Levin DL. Aerosolized corticosteroids for croup [letter; comment]. New England Journal of Medicine 1995; 332:400&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harel Y, Levin DL</AU>
<TI>Aerosolized corticosteroids for croup</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<PG>400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Havaldar-1997" NAME="Havaldar 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Havaldar PV. Dexamethasone in laryngeal diphtheritic croup. Annals.of.Tropical.Paediatrics.Vol.17.(1.) (pp.21.23.) 1997;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Havaldar PV</AU>
<TI>Dexamethasone in laryngeal diphtheritic croup</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>21-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawkins-1980" MODIFIED="2010-11-07 22:27:01 +1000" MODIFIED_BY="[Empty name]" NAME="Hawkins 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-11-07 22:27:01 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hawkins DB. Corticosteroids in the management of laryngotracheobronchitis. [Review] [15 refs]. Otolaryngology &amp;amp; Head &amp;amp; Neck Surgery 1980; 88:207-210.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:27:01 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkins DB</AU>
<TI>Corticosteroids in the management of laryngotracheobronchitis</TI>
<SO>Otolaryngology - Head and Neck Surgery</SO>
<YR>1980</YR>
<VL>88</VL>
<PG>207-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helowicz-1996" MODIFIED="2010-11-07 22:27:16 +1000" MODIFIED_BY="[Empty name]" NAME="Helowicz 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-07 22:27:16 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Helowicz R, Walton J. Single dose of oral dexamethasone for outpatient croup. Failure to follow up all patients is a concern [letter]. BMJ 1996; 313:1081&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:27:16 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helowicz R, Walton J</AU>
<TI>Single dose of oral dexamethasone for outpatient croup. Failure to follow up all patients is a concern</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1081</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herxheimer-1996" MODIFIED="2010-11-07 22:27:27 +1000" MODIFIED_BY="[Empty name]" NAME="Herxheimer 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-07 22:27:27 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Herxheimer A. Single dose of oral dexamethasone for outpatient croup. Authors should have stated how drug was given [letter]. BMJ 1996; 313:1081&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:27:27 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herxheimer A</AU>
<TI>Single dose of oral dexamethasone for outpatient croup. Authors should have stated how drug was given</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7064</NO>
<PG>1081</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kairys-1989" MODIFIED="2010-11-07 22:27:36 +1000" MODIFIED_BY="[Empty name]" NAME="Kairys 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-07 22:27:36 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Kairys SW, Olmstead EM, O'Connor GT. Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials [see comments]. Pediatrics 1989; 83:683-693.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:27:36 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kairys SW, Olmstead EM, O'Connor GT</AU>
<TI>Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials</TI>
<SO>Pediatrics</SO>
<YR>1989</YR>
<VL>83</VL>
<PG>683-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karoliny-1990" NAME="Karoliny 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Karoliny G, Osvath P, Horvath A. [Subglottic laryngitis treated with corticosteroid inhalation]. [Hungarian]. Orvosi Hetilap 1990; 131:2257-2258.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karoliny G, Osvath P, Horvath A</AU>
<TI>Subglottic laryngitis treated with corticosteroid inhalation [Hungarian]</TI>
<SO>Orvosi Hetilap</SO>
<YR>1990</YR>
<VL>131</VL>
<PG>2257-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelley-1992" NAME="Kelley 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Kelley PB, Simon JE. Racemic epinephrine use in croup and disposition. American Journal of Emergency Medicine 1992; 10:181-183.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelley PB, Simon JE</AU>
<TI>Racemic epinephrine use in croup and disposition</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1992</YR>
<VL>10</VL>
<PG>181-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-1997a" NAME="Klassen 1997a" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Klassen TP, Rowe PC. Outpatiant management of croup. Current Opinion in Pediatrics 1997; 8:449-452.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Rowe PC</AU>
<TI>Outpatient management of croup</TI>
<SO>Current Opinion in Pediatrics</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>449-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-1997b" NAME="Klassen 1997b" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Klassen TP. Recent advances in the treatment of bronchiolitis and laryngitis. Pediatric Clinics of North America 1997; 44:249-261.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP</AU>
<TI>Recent advances in the treatment of bronchiolitis and laryngitis</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>1997</YR>
<VL>44</VL>
<PG>249-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kunkel-1996" NAME="Kunkel 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Kunkel NC, Baker MD. Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup. Pediatric Emergency Care 1996; 12:156-159.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kunkel NC, Baker MD</AU>
<TI>Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup</TI>
<SO>Pediatric Emergency Care</SO>
<YR>1996</YR>
<VL>12</VL>
<PG>156-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ledwith-1995" NAME="Ledwith 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Ledwith CA, Shea LM, Mauro RD. Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup. Annals of Emergency Medicine 1995; 25:331-337.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ledwith CA, Shea LM, Mauro RD</AU>
<TI>Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1995</YR>
<VL>25</VL>
<PG>331-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukina-1991" NAME="Lukina 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Lukina TN. Analysis of the effectiveness of drug therapy of acute laryngo-tracheitis and croup in children with acute respiratory viral infections. Pediatriia 1991; 10:112&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukina TN</AU>
<TI>Analysis of the effectiveness of drug therapy of acute laryngo-tracheitis and croup in children with acute respiratory viral infections</TI>
<SO>Pediatriia</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>112</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lynk-1993" NAME="Lynk 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Lynk AD. Dexamethasone for severe croup: what route? [letter; comment]. Canadian Medical Association Journal 1993; 149:264-265.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lynk AD</AU>
<TI>Dexamethasone for severe croup: What route?</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1993</YR>
<VL>149</VL>
<PG>264-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchi-1993" NAME="Marchi 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Marchi AR. Cortisone therapy in pediatric emergencies. Original Title LA TERAPIA CORTISONICA NELL'EMERGENZA PEDIATRICA. Pediatria.Oggi.Vol.13.(1.) (pp.9.11.) 1993;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchi AR</AU>
<TI>Cortisone therapy in pediatric emergencies</TI>
<TO>La terapia cortisonica nel'emergenza pediatrica</TO>
<SO>Pediatria Oggi Medica e Chirurgica</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>1</NO>
<PG>9-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martensson-1960" MODIFIED="2009-09-09 13:54:19 +1000" MODIFIED_BY="[Empty name]" NAME="Martensson 1960" YEAR="1960">
<REFERENCE MODIFIED="2009-09-09 13:54:19 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Martensson B, Nilsson G, Torbjar J. The effect of corticosteroids in the treatment of pseudo-croup. Acta Otolaryngol 1960; 158 (suppl):62-71.&lt;/p&gt;" NOTES_MODIFIED="2009-09-09 13:54:19 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martensson B, Nilsson G, Torbjar J</AU>
<TI>The effect of corticosteroids in the treatment of pseudo-croup</TI>
<SO>Acta Oto-Laryngologica</SO>
<YR>1960</YR>
<VL>158</VL>
<NO>Suppl</NO>
<PG>62-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDonogh-1994" NAME="McDonogh 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;McDonogh AJ. The use of steroids and nebulised adrenaline in the treatment of viral croup over a seven year period at a district hospital. Anaesthesia &amp;amp; Intensive Care 1994; 22:175-178.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDonogh AJ</AU>
<TI>The use of steroids and nebulised adrenaline in the treatment of viral croup over a seven year period at a district hospital</TI>
<SO>Anaesthesia and Intensive Care</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>175-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mortensen-1994" MODIFIED="2010-11-07 22:28:35 +1000" MODIFIED_BY="[Empty name]" NAME="Mortensen 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-07 22:28:35 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mortensen S, Agertoft L, Husby S, Pedersen S. [Pseudocroup treated with inhaled steroid (budesonide). A double- blind placebo-controlled trial]. [Danish]. Ugeskrift for Laeger 1994; 156:6661-6663.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:28:35 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mortensen S, Agertoft L, Husby S, Pedersen S</AU>
<TI>Pseudocroup treated with inhaled steroid (budesonide): a double-blind placebo-controlled trial [Danish]</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1994</YR>
<VL>156</VL>
<PG>6661-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novik-1960" MODIFIED="2010-11-07 22:28:46 +1000" MODIFIED_BY="[Empty name]" NAME="Novik 1960" YEAR="1960">
<REFERENCE MODIFIED="2010-11-07 22:28:46 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Novik A. Corticosteroid treatment of Non-diphteric Croup. Acta Otolaryngol 1960; 158 (Suppl):20-22.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:28:46 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novik A</AU>
<TI>Corticosteroid treatment of non-diphteric croup</TI>
<SO>Acta Oto-Laryngologica</SO>
<YR>1960</YR>
<VL>158</VL>
<NO>Suppl</NO>
<PG>20-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oski-1961" NAME="Oski 1961" YEAR="1961">
<REFERENCE NOTES="&lt;p&gt;Oski F, Salitsky S, Barness L. Steroid therapy in bronchiolitis: a double blind study (abstract). Am J Dis Child 1961; 102:759&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oski F, Salitsky S, Barness L</AU>
<TI>Steroid therapy in bronchiolitis: a double blind study</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1961</YR>
<VL>102</VL>
<PG>759</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osvath-1994" NAME="Osvath 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Osvath P, Kelenhegyi K, Szantho A. [Management of childhood pseudocroup with budesonide inhalation]. [Hungarian]. Orvosi Hetilap 1994; 135:2535-2537.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osvath P, Kelenhegyi K, Szantho A</AU>
<TI>Management of childhood pseudocroup with budesonide inhalation [Hungarian]</TI>
<SO>Orvosi Hetilap</SO>
<YR>1994</YR>
<VL>135</VL>
<PG>2535-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prendergast-1994" MODIFIED="2010-11-07 22:29:07 +1000" MODIFIED_BY="[Empty name]" NAME="Prendergast 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-11-07 22:29:07 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Prendergast M, Jones JS, Hartman D. Racemic epinephrine in the treatment of laryngotracheitis: can we identify children for outpatient therapy?. American Journal of Emergency Medicine 1994; 12:613-616.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:29:07 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prendergast M, Jones JS, Hartman D</AU>
<TI>Racemic epinephrine in the treatment of laryngotracheitis: can we identify children for outpatient therapy?</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>613-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quan-1992" NAME="Quan 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Quan L. Diagnosis and treatment of croup [see comments]. [Review] [22 refs]. American Family Physician 1992; 46:747-755.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quan L</AU>
<TI>Diagnosis and treatment of croup</TI>
<SO>American Family Physician</SO>
<YR>1992</YR>
<VL>46</VL>
<PG>747-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-1983" NAME="Richter 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Richter O, Ern B, Reinhardt D, Becker B. Pharmacokinetics of dexamethasone in children. Pediatric Pharmacology 1983; 3:329-337.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter O, Ern B, Reinhardt D, Becker B</AU>
<TI>Pharmacokinetics of dexamethasone in children</TI>
<SO>Pediatric Pharmacology</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>329-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizos-1998" MODIFIED="2010-11-07 22:29:45 +1000" MODIFIED_BY="[Empty name]" NAME="Rizos 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-07 22:29:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rizos J, DiGravio B, Sehl M, Tallon J</AU>
<TI>The disposition of children with croup treated with racemic epinephrine and dexamethasone in the emergency department</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>4</NO>
<PG>535-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roosevelt-1996" MODIFIED="2010-11-07 22:29:52 +1000" MODIFIED_BY="[Empty name]" NAME="Roosevelt 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-07 22:29:52 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Roosevelt G, Sheehan K, Grupp-Phelan J. Dexamethasone in bronchiolitis:a randomised controlled trial. Lancet 1996; 348:292&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:29:52 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roosevelt G, Sheehan K, Grupp-Phelan J</AU>
<TI>Dexamethasone in bronchiolitis: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<PG>292</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ross-1969" NAME="Ross 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Ross JA. Special problems in acute laryngotracheobronchitis. Laryngoscope 1969; 79:1218-1226.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ross JA</AU>
<TI>Special problems in acute laryngotracheobronchitis</TI>
<SO>Laryngoscope</SO>
<YR>1969</YR>
<VL>79</VL>
<PG>1218-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoooff--2005" NAME="Schoooff  2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schooff M</AU>
<TI>Glucocorticoids for the treatment of croup</TI>
<SO>American Family Physician</SO>
<YR>2005</YR>
<VL>71</VL>
<NO>1</NO>
<PG>66-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serra-1997" MODIFIED="2010-11-07 22:30:22 +1000" MODIFIED_BY="[Empty name]" NAME="Serra 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-07 22:30:22 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Serra A. Bonarrigo A. Cupido GF. Manciagli M. Pantalena V. Raso D. Solarino G. Biraghi M. Experience with flunisolide in inflammatory diseases in otorhinolaryngology. Multicentric trial. Otorinolaringologia. Vol 47(3) (pp 137-144), 1997.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:30:22 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serra A, Bonarrigo A, Cupido GF, Manciagli M, Pantalena V, Raso, D et al</AU>
<TI>Experience with flunisolide in inflammatory diseases in otorhinolaryngology. Multicentric trial</TI>
<TO>Impiego di flunisolide nel trattamento di laringiti e sinusiti</TO>
<SO>Otorinolaringologia</SO>
<YR>1997</YR>
<VL>47</VL>
<NO>3</NO>
<PG>137-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-1972" NAME="Shaw 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Shaw EB. Corticosteroids and croup: comments from a grass rooted ivory tower. Pediatrics 1972; 49:312-313.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw EB</AU>
<TI>Corticosteroids and croup: comments from a grass rooted ivory tower</TI>
<SO>Pediatrics</SO>
<YR>1972</YR>
<VL>49</VL>
<PG>312-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skolnik-1993" NAME="Skolnik 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Skolnik N. Croup. [Review] [37 refs]. Journal of Family Practice 1993; 37:165-170.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skolnik N</AU>
<TI>Croup</TI>
<SO>Journal of Family Practice</SO>
<YR>1993</YR>
<VL>37</VL>
<PG>165-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slawson-1996" NAME="Slawson 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Slawson JG. Efficacy of oral dexamethasone for outpatient croup. Journal of Family Practice 1996; 43:436&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slawson JG</AU>
<TI>Efficacy of oral dexamethasone for outpatient croup</TI>
<SO>Journal of Family Practice</SO>
<YR>1996</YR>
<VL>43</VL>
<PG>436</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slolnik-1989" NAME="Slolnik 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Skolnik NS. Treatment of croup. A critical review [see comments]. [Review] [42 refs]. American Journal of Diseases of Children 1989; 143:1045-1049.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skolnik NS</AU>
<TI>Treatment of croup. A critical review</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1989</YR>
<VL>143</VL>
<PG>1045-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spaulding-1996" NAME="Spaulding 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Spaulding C. Treating croup with dexamethasone. Journal of Family Practice 1996; 42:111&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spaulding C</AU>
<TI>Treating croup with dexamethasone</TI>
<SO>Journal of Family Practice</SO>
<YR>1996</YR>
<VL>42</VL>
<PG>111</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sumboonnanonda-1997" MODIFIED="2010-11-07 23:21:48 +1000" MODIFIED_BY="[Empty name]" NAME="Sumboonnanonda 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-07 23:21:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sumboonnanonda A, Suwanjutha S, Sirinavin S</AU>
<TI>Randomized controlled trial of dexamethasone in infectious croup</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1997</YR>
<VL>80</VL>
<NO>4</NO>
<PG>262-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sussman-1964" MODIFIED="2010-11-07 22:30:55 +1000" MODIFIED_BY="[Empty name]" NAME="Sussman 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-11-07 22:30:55 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sussman S, Grossman M, Magoffin R, Schieble J. Dexamethasone (16 Alpha-Methyl, 9 Alpha Fluoroprednisolone) in obstructive respiratory tract infections in children. Pediatrics 1964; 34:851-855.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:30:55 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sussman S, Grossman M, Magoffin R, Schieble J</AU>
<TI>Dexamethasone (16 alpha-methyl, 9 alpha fluoroprednisolone) in obstructive respiratory tract infections in children</TI>
<SO>Pediatrics</SO>
<YR>1964</YR>
<VL>34</VL>
<PG>851-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabachnik-1980" NAME="Tabachnik 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Tabachnik E, Levison H. Clinical application of aerosols in pediatrics. American Review of Respiratory Disease 1980; 122:97-103.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabachnik E, Levison H</AU>
<TI>Clinical application of aerosols in pediatrics</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1980</YR>
<VL>122</VL>
<PG>97-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tal-1983" NAME="Tal 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Tal A, Bavilski C, Yohai D. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. Pediatrics 1983; 71:13&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal A, Bavilski C, Yohai D</AU>
<TI>Dexamethasone and salbutamol in the treatment of acute wheezing in infants</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tellez-1991" NAME="Tellez 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Tellez DW GASSAHH. Dexamethasone in the prevention of postextubation stridor in children. J-Pediatr.1991; 118: 289-94 118:289-294.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tellez DW</AU>
<TI>Dexamethasone in the prevention of postextubation stridor in children</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>118</VL>
<PG>289-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terregino-1998" NAME="Terregino 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terregino CA, Nairn SJ, Chansky ME, Kass JE</AU>
<TI>The effect of heliox on croup: a pilot study</TI>
<SO>Academic Emergency Medicine</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>11</NO>
<PG>1130-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-2000" MODIFIED="2010-05-25 15:49:09 +1000" MODIFIED_BY="[Empty name]" NAME="Thomas 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-25 15:49:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas M, Del Mar C, Glasziou P</AU>
<TI>How effective are treatments other than antibiotics for acute sore throat?</TI>
<SO>British Journal of General Practice</SO>
<YR>2000</YR>
<VL>50</VL>
<PG>817-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tunnessen-1980" MODIFIED="2010-11-07 22:31:05 +1000" MODIFIED_BY="[Empty name]" NAME="Tunnessen 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-11-07 22:31:05 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tunnessen WJ, Feinstein AR. The steroid-croup controversy: an analytic review of methodologic problems. Journal of Pediatrics 1980; 96:751-756.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:31:05 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tunnessen WJ, Feinstein AR</AU>
<TI>The steroid-croup controversy: an analytic review of methodologic problems</TI>
<SO>Journal of Pediatrics</SO>
<YR>1980</YR>
<VL>96</VL>
<PG>751-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veerappan-1996" NAME="Veerappan 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Veerappan AK. Role of steroids in croup and beta agonists in bronchiolitis. Indian Journal.of.Pediatrics.Vol.63.(5.) (pp.577.581.) 1996;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veerappan AK</AU>
<TI>Role of steroids in croup and beta agonists in bronchiolitis</TI>
<SO>Indian Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>63</VL>
<NO>5</NO>
<PG>577-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Mulhendal-1978" MODIFIED="2010-11-07 22:31:15 +1000" MODIFIED_BY="[Empty name]" NAME="von Mulhendal 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-11-07 22:31:15 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;von Muhlendal. [On the pharmacological treatment of acute spasmodic laryngitis (Pseudo-Croup) (author's transl)]. [German]. Monatsschrift fur Kinderheilkunde 1978; 126:359-361.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:31:15 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Muhlendal</AU>
<TI>On the pharmacological treatment of acute spasmodic laryngitis (pseudo-croup) [German]</TI>
<SO>Monatsschrift fur Kinderheilkunde</SO>
<YR>1978</YR>
<VL>126</VL>
<PG>359-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vrabec-1993" NAME="Vrabec 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Vrabec DP. Fungal infections of the larynx. [Review] [64 refs]. Otolaryngologic Clinics of North America 1993; 26:1091-1114.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vrabec DP</AU>
<TI>Fungal infections of the larynx</TI>
<SO>Otolaryngologic Clinics of North America</SO>
<YR>1993</YR>
<VL>26</VL>
<PG>1091-114</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whelan-1996" MODIFIED="2010-11-07 22:31:24 +1000" MODIFIED_BY="[Empty name]" NAME="Whelan 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-11-07 22:31:24 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Whelan TR. Corticosteroids in the management of croup [letter]. British Journal of General Practice 1996; 46:493- 494.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:31:24 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whelan TR</AU>
<TI>Corticosteroids in the management of croup</TI>
<SO>British Journal of General Practice</SO>
<YR>1996</YR>
<VL>46</VL>
<PG>493-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whilhelmi-1976" NAME="Whilhelmi 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Wilhelmi J. [High dosage rectal prednisone therapy (Rectodelt 100) in viral croup of the small child]. [German]. Medizinische Monatsschrift 1976; 30:467-469.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmi J</AU>
<TI>High dosage rectal prednisone therapy (Rectodelt 100) in viral croup of the small child [German]</TI>
<SO>Medizinische Monatsschrift</SO>
<YR>1976</YR>
<VL>30</VL>
<PG>467-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yates-1997" MODIFIED="2010-10-02 03:57:28 +1000" MODIFIED_BY="[Empty name]" NAME="Yates 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Yates RW, Doull IJ. A risk-benefit assessment of corticosteroids in the management of croup. Drug Safety 1997; 16:48-55.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yates RW, Doull IJ</AU>
<TI>A risk-benefit assessment of corticosteroids in the management of croup</TI>
<SO>Drug Safety</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-10-02 03:58:32 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Eboriadou-2010" MODIFIED="2010-10-02 03:58:32 +1000" MODIFIED_BY="[Empty name]" NAME="Eboriadou 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-02 03:58:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eboriadou M, Chryssanthopoulou D, Stamoulis P, Damianidou L, Haidopoulou K</AU>
<TI>The effectiveness of local corticosteroids therapy in the management of mild to moderate viral croup</TI>
<SO>Minerva Pediatrica</SO>
<YR>2010</YR>
<VL>62</VL>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-07 23:22:14 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-07 23:22:14 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barrowman-2003" NAME="Barrowman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Barrowman NJ, Fang M, Sampson M, Moher D</AU>
<TI>Identifying null meta-analyses that are ripe for updating</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2003</YR>
<VL>3</VL>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" NAME="Begg 1994" NOTES="&lt;p&gt;Begg CB, Mazundar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazundar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<PG>1088-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cho-1996" NAME="Cho 1996" NOTES="&lt;p&gt;Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-489 An&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cho MK, Bero LA</AU>
<TI>The quality of drug studies published in symposium proceedings</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>124</VL>
<PG>485-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denny-1983" NAME="Denny 1983" NOTES="&lt;p&gt;Denny FW, Murphy TF, Clyde WA, Collier AM, Henderson FW. Croup: an 11 year study in pediatric practice. Pediatrics 1983; 71:871-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Denny FW, Murphy TF, Clyde WA, Collier AM, Henderson FW</AU>
<TI>Croup: an 11 year study in pediatric practice</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<PG>871-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-11-07 22:31:43 +1000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" NOTES="&lt;p&gt;Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:31:43 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" NAME="Follmann 1992" NOTES="&lt;p&gt;Follman D, Elliott P, Sul Il, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45:769-773&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Sul Il, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geelhoed-1996b" MODIFIED="2010-11-07 22:31:55 +1000" MODIFIED_BY="[Empty name]" NAME="Geelhoed 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Geelhoed GC</AU>
<TI>Sixteen years of croup in a Western Australian teaching hospital: effects of routine steroid treatment</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>6</NO>
<PG>621-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-2000" MODIFIED="2010-05-25 08:17:12 +1000" MODIFIED_BY="[Empty name]" NAME="Griffin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Griffin S, Ellis S, Fitzgerald-Barron A, Rose J, Egger M</AU>
<TI>Nebulized steroid in the treatment of croup: a systematic review of randomised controlled trials</TI>
<SO>British Journal of General Practice</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>451</NO>
<PG>135-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henrickson-1994" NAME="Henrickson 1994" NOTES="&lt;p&gt;Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis 1994;18:770-779.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Henrickson KJ, Kuhn SM, Savatski LL</AU>
<TI>Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>770-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2010-11-07 22:32:08 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-11-07 22:32:33 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated February 2009]. The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2009" MODIFIED="2010-11-07 22:32:58 +1000" MODIFIED_BY="[Empty name]" NAME="Johnson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW</AU>
<TI>Croup</TI>
<SO>Clinical Evidence (online)</SO>
<YR>2009</YR>
<VL>Mar 10</VL>
<PG>pii: 0321</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kairys-1989" NAME="Kairys 1989" NOTES="&lt;p&gt;Kairys SW, Olmstead EM, O'Connor GT. Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials [see comments]. Pediatrics 1989; 83:683-693.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kairys SW, Olmstead EM, O'Connor GT</AU>
<TI>Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials</TI>
<SO>Pediatrics</SO>
<YR>1989</YR>
<VL>83</VL>
<PG>683-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klassen-1995" NAME="Klassen 1995" NOTES="&lt;p&gt;Klassen TP, Rowe PC. The croup score as an evaluative instrument in clinical trials. Arch Pediatr Adolesc Med 1995; 149:60 Abstract.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Rowe PC</AU>
<TI>The croup score as an evaluative instrument in clinical trials</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>1995</YR>
<VL>149</VL>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klassen-1996c" NAME="Klassen 1996c" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Rowe PC</AU>
<TI>Outpatient management of croup</TI>
<SO>Current Opinion Pediatrics</SO>
<YR>1996</YR>
<VL>8</VL>
<PG>449-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klassen-1997" MODIFIED="2010-11-07 23:22:04 +1000" MODIFIED_BY="[Empty name]" NAME="Klassen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP</AU>
<TI>Recent advances in the treatment of bronchiolitis and laryngitis</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>1997</YR>
<VL>44</VL>
<PG>249-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knapp--2008" MODIFIED="2010-10-02 03:04:36 +1000" MODIFIED_BY="[Empty name]" NAME="Knapp  2008" TYPE="JOURNAL_ARTICLE">
<AU>Knapp JF, Simon SD, Sharma V</AU>
<TI>Quality of care for common pediatric respiratory illnesses in United States emergency departments: analysis of 2005 National Hospital Ambulatory Medical Care Survey Data</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<PG>1165-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lavine-2001" MODIFIED="2010-11-07 22:33:08 +1000" MODIFIED_BY="[Empty name]" NAME="Lavine 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lavine E, Scolnik D</AU>
<TI>Lack of efficacy of humidification in the treatment of croup. Why do physicians persist in using an unproven modality?</TI>
<SO>Canadian Journal of Emergency Medicine</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2010-05-25 08:17:45 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-12-10 17:58:35 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Light-1984" NAME="Light 1984" NOTES="&lt;p&gt;Light RS, Pillemar DB. Summing up: the science of reviewing research. Cambridge, Massachusetts: Havard University Press; 1984.&lt;/p&gt;" TYPE="BOOK">
<AU>Light RS, Pillemar DB</AU>
<SO>Summing up: the science of reviewing research</SO>
<YR>1984</YR>
<PB>Harvard University Press</PB>
<CY>Cambridge</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marx-1997" NAME="Marx 1997" NOTES="&lt;p&gt;Marx A, Torok TJ, Holman RC, Clarke MJ, Anderson. Pediatric hospitalizations for croup (laryngotracheitis): biennal increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997;176:1423-7&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Marx A, Torok TJ, Holman RC, Clarke MJ, Anderson</AU>
<TI>Pediatric hospitalizations for croup (laryngotracheitis): biennial increases associated with human parainfluenza virus 1 epidemics</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>1423-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonogh--1994" MODIFIED="2010-11-07 22:33:20 +1000" MODIFIED_BY="[Empty name]" NAME="McDonogh  1994" TYPE="JOURNAL_ARTICLE">
<AU>McDonogh AJ</AU>
<TI>The use of steroids and nebulised adrenaline in the treatment of viral croup over a seven year period at a district hospital</TI>
<SO>Anaesthesia and Intensive Care</SO>
<YR>1994</YR>
<VL>2</VL>
<PG>175-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2010-11-07 22:33:34 +1000" MODIFIED_BY="[Empty name]" NAME="Moher 1998" NOTES="&lt;p&gt;Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does the poor quality of reports of randomized trials exaggerate estimates of intervention effectiveness reported in meta-analysis? Lancet 1998; 352:609-613.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:33:34 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2007" MODIFIED="2009-09-02 09:40:20 +1000" MODIFIED_BY="[Empty name]" NAME="Moore 2007" TYPE="JOURNAL_ARTICLE">
<AU>Moore M, Little P</AU>
<TI>Humidified air inhalation for treating croup: a systematic review and metaanalysis</TI>
<SO>Family Practice</SO>
<YR>2007</YR>
<VL>24</VL>
<PG>295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neto-2002" MODIFIED="2010-11-07 22:33:54 +1000" MODIFIED_BY="[Empty name]" NAME="Neto 2002" TYPE="JOURNAL_ARTICLE">
<AU>Neto GM, Kentab O, Klassen TP, Osmond MH</AU>
<TI>A randomized controlled trial of mist in the acute treatment of moderate croup. A randomized controlled trial of mist in the acute treatment of moderate croup</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>9</NO>
<PG>873-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosychuk-2010" MODIFIED="2010-11-07 22:34:18 +1000" MODIFIED_BY="[Empty name]" NAME="Rosychuk 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rosychuk RJ, Klassen TP, Metes D, Voaklander DC, Senthilselvan A, Rowe BH</AU>
<TI>Croup presentations to emergency departments in Alberta, Canada: a large population-based study</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>1</NO>
<PG>83-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-11-07 22:34:29 +1000" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" NOTES="&lt;p&gt;Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias: dimensions of&lt;br&gt;methodological quality associated with estimates of treatment effects in controlled trials. Journal&lt;br&gt;of the American Medical Association 1995;273:408-412.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:34:29 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scolnick-2006" MODIFIED="2010-11-07 22:34:41 +1000" MODIFIED_BY="[Empty name]" NAME="Scolnick 2006" NOTES="&lt;p&gt;Skolnik NS. Treatment of croup. A critical review [see comments]. Am.J.Dis.Child 1989; 143:1045-1049.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 22:34:41 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Scolnik D, Coates AL, Stephens D, Da Silva Z, Lavine E, Schuh S</AU>
<TI>Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>1274-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1998" NAME="Taylor 1998" NOTES="&lt;p&gt;Taylor S, Tweedie R. Trim and fill: a simple funnel plot based method of testing and adjusting for publication bias in meta-analyses. Submitted for publication.&lt;/p&gt;" TYPE="BOOK">
<AU>Taylor S, Tweedie R</AU>
<SO>Trim and fill: a simple funnel plot based method of testing and adjusting for publication bias in meta-analyses</SO>
<YR>1998</YR>
<PB>Colorado State University</PB>
<CY>Fort Collins</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-To-1994" MODIFIED="2010-08-28 05:38:53 +1000" MODIFIED_BY="[Empty name]" NAME="To 1994" NOTES="&lt;p&gt;To T, Dick P, Young W, Hernandez R. Hospitalization rates of children with croup in Ontario Canada.. Working paper series #31-November, 1994. Institute for Clinical Evaluative Sciences in Ontario (ICES).&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-08-28 05:38:53 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>To T, Dick P, Young W, Hernandez R</AU>
<TI>Hospitalization rates of children with croup in Ontario Canada</TI>
<SO>Working paper series #31</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waisman-1992" MODIFIED="2010-11-07 23:22:14 +1000" MODIFIED_BY="[Empty name]" NAME="Waisman 1992" NOTES="&lt;p&gt;Waiisman Y, Klein BL, Boenning DA, Young GM, Chamberlain JM, O'Donnell R, et al. Prospective randomized double-blind study compaing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup). Pediatrics 1992; 89:302-306.&lt;/p&gt;" NOTES_MODIFIED="2010-11-07 23:22:14 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Waisman Y, Klein BL, Boenning DA, Young GM, Chamberlain JM, O'Donnell R et al</AU>
<TI>Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup)</TI>
<SO>Pediatrics</SO>
<YR>1992</YR>
<VL>89</VL>
<PG>302-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wennberg--1990" NAME="Wennberg  1990" NOTES="&lt;p&gt;Conference Proceedings Research Methodology: Strengthening Causal Interpretations of Nonexperimental Data. Rockville, MD: Agency for Health Care Policy and Research, US Department of Health&lt;/p&gt;" TYPE="CONFERENCE_PROC">
<AU>Wennberg JE</AU>
<TI>Small area analysis and the medical case outcome problem</TI>
<SO>Conference Proceedings Research Methodology: Strengthening Causal Interpretations of Nonexperimental Data</SO>
<YR>1990</YR>
<ED>Agency for Health Care Policy and Research</ED>
<PB>US Department of Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Westley-1978" NAME="Westley 1978" NOTES="&lt;p&gt;Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup. Am J Dis Child 1978;132:484-487&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Westley CR, Cotton EK, Brooks JG</AU>
<TI>Nebulized racemic epinephrine by IPPB for the treatment of croup</TI>
<SO>American Journal of Diseases in Children</SO>
<YR>1978</YR>
<VL>132</VL>
<PG>484-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-11-07 22:35:14 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ausejo-1999" MODIFIED="2010-11-07 22:34:54 +1000" MODIFIED_BY="[Empty name]" NAME="Ausejo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ausejo M, Saenz A, Pham B, Kellner J, Johnson DW, Moher D, et al</AU>
<TI>The effectiveness of glucocorticoids in treating croup: meta-analysis</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>595-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ausejo-2000" MODIFIED="2010-11-07 22:35:07 +1000" MODIFIED_BY="[Empty name]" NAME="Ausejo 2000" TYPE="COCHRANE_REVIEW">
<AU>Ausejo M, Saenz A, Pham B, Kellner JD, Johnson DW, Moher D, et al</AU>
<TI>Glucocorticoids for croup</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-09-09 14:02:07 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-09 14:02:07 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001955.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Russell-2004" MODIFIED="2010-11-07 22:35:14 +1000" MODIFIED_BY="[Empty name]" NAME="Russell 2004" TYPE="COCHRANE_REVIEW">
<AU>Russell K, Wiebe N, Saenz A, Ausejo Segura M, Johnson D, Hartling L, et al</AU>
<TI>Glucocorticoids for croup</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-09-09 13:59:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-09 13:59:55 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001955.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-12-01 06:58:25 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-12-01 06:58:25 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alshehri--2005">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:06 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blinded controlled trial. 12 children withdrew</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:13:25 +1000" MODIFIED_BY="[Empty name]">
<P>72 children aged 3 months to 9 years with croup (Westley croup score &gt; 3) who were treated in the emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 15:48:10 +1000" MODIFIED_BY="[Empty name]">
<P>Oral 0.6 mg/kg dexamethasone (n = 36) or oral 0.15 mg/kg dexamethasone (n = 36)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:29:48 +1000" MODIFIED_BY="[Empty name]">
<P>Westley Croup score<BR/>Re-visit and/or (re)-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:16:43 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amir--2006">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:09 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial. No drop-outs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:13:03 +1000" MODIFIED_BY="[Empty name]">
<P>52 children aged 6 months to 6 years with mild to moderate croup who were treated in the emergency department (Westley 1-11)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:30:17 +1000" MODIFIED_BY="[Empty name]">
<P>Intramuscular 0.6 mg/kg dexamethasone (n = 26) or oral 0.4 mg/kg betamethasone (n = 26)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-29 09:11:53 +1000" MODIFIED_BY="[Empty name]">
<P>Westley Croup score<BR/>Additional treatment in the ED<BR/>ED hospitalizations rate<BR/>Follow-up visits<BR/>Additional treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:16:46 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjornson-2004">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:10 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized by the pharmacy, placebo-controlled, double-blind trial. 13 were lost to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:13:19 +1000" MODIFIED_BY="[Empty name]">
<P>720 children aged 3 months to 9 years with mild croup treated in the emergency department (Westley &lt;= 2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:31:51 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 352) or single dose of 0.6 mg/kg of oral dexamethasone (n = 352)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:56:19 +1000" MODIFIED_BY="[Empty name]">
<P>Return visits to any healthcare provider<BR/>Telephone Out Patient (TOP) Score on days 1, 2 and 3<BR/>Hospitalizations<BR/>Economic costs<BR/>Adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:16:50 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cetinkaya-2004">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:10 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:13:45 +1000" MODIFIED_BY="[Empty name]">
<P>60 children aged 6 to 36 months who presented to the emergency department with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:08:55 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulised budesonide 500 ug and placebo (n = 15) or intramuscular dexamethasone 0.6 mg/kg and placebo (n = 15) or oral dexamethasone 0.6 mg/kg and placebo (n = 15) or nebulized salbutamol and placebo (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 23:19:45 +1000" MODIFIED_BY="[Empty name]">
<P>Westley croup score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:17:04 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruz-1995">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:11 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized by the pharmacy, placebo-controlled, double-blind trial. 3 children required hospitalizations, 2 withdrew and 2 were lost to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-01 06:54:20 +1000" MODIFIED_BY="[Empty name]">
<P>45 children aged 6 months to 5 years with moderate croup in the emergency department. Exclusion: patients who required more than one racemic epinephrine treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:40:56 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 19) or intramuscular dexamethasone 0.6 mg/kg (n = 19), unique dose. Dexamethasone maximum dose of 10 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:40:46 +1000" MODIFIED_BY="[Empty name]">
<P>Re-presented and re-admitted to the hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:17:08 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donaldson-2003">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:11 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized by the pharmacy, controlled, double-blind trial. 1 child withdrew (treatment group and reason not stated)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:13:52 +1000" MODIFIED_BY="[Empty name]">
<P>96 children aged 3 to 84 months with croup (Westley &gt;= 2) in the emergency department were enrolled (collected complete follow-up data for 95)<BR/>Exclusion: croup score &lt; 2, epiglottitis, bacterial tracheitis, foreign body, chronic lung disease, severe co-morbidities, inability of parents to give informed consent, or glucocorticoids therapy within 4 weeks of presenting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:41:47 +1000" MODIFIED_BY="[Empty name]">
<P>Intramuscular dexamethasone 0.6 mg/kg (n = 49) or oral dexamethasone 0.6 mg/kg (n = 46)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:13:57 +1000" MODIFIED_BY="[Empty name]">
<P>Parental assessment of symptom relief at 24 hours<BR/>Presence of stridor, barky cough, expiratory sounds and normal sleeping patterns at 24 hours<BR/>Unscheduled visits<BR/>All symptoms absent at 24 hours and 4 days<BR/>Co-interventions: mist tent</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:17:11 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duman-2005">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:12 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:14:09 +1000" MODIFIED_BY="[Empty name]">
<P>76 children aged &gt;= 6 months with croup (Westley &gt;= 2) in the emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:00 +1000" MODIFIED_BY="[Empty name]">
<P>Cool mist therapy and intramuscular 0.6 mg/kg dexamethasone (n = 26) or 2.5 mL for 0 to 20 kg or 5.0 mL for 20 to 40 kg nebulized epinephrine and intramuscular dexamethasone 0.6 mg/kg (n = 31) or 2.5 mL for 0 to 20 kg or 5.0 mL for 20 to 40 kg nebulized epinephrine and nebulized budesonide 2 mg (n = 19)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:56:45 +1000" MODIFIED_BY="[Empty name]">
<P>Croup score at 0.5, 1, 1.5 and 2 hours<BR/>Hospitalization<BR/>Readmitted<BR/>Co-intervention: epinephrine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-19 05:29:36 +1000" MODIFIED_BY="[Empty name]">
<P>Quality = 1<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eden-1964">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:12 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial. 3 drop-outs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:55 +1000" MODIFIED_BY="[Empty name]">
<P>50 children hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:43:25 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 25) or intramuscular methyl-prednisolone 4 mg/kg/day (n = 25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:43:07 +1000" MODIFIED_BY="[Empty name]">
<P>Percentage of improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:23:15 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eden-1967">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:13 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:55 +1000" MODIFIED_BY="[Empty name]">
<P>50 children hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:43:53 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 25) or intramuscular dexamethasone 0.4 mg/kg/day (n = 25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:43:41 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on a multi-item scale (stridor, dyspnoea, retraction, cyanosis) at 0, 6,12,18 and 24 hours<BR/>Co-intervention: intubation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:23:19 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fifoot--2007">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:13 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:14:37 +1000" MODIFIED_BY="[Empty name]">
<P>99 children aged 6 months to 6 years who present to the emergency department with croup (2 or more on Westley croup score). 86 parents/guardians were available for 1 week telephone follow up</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:44:43 +1000" MODIFIED_BY="[Empty name]">
<P>Oral prednisolone 1 mg/kg (n = 34), oral dexamethasone 0.15 mg/kg (n = 34) or oral dexamethasone 0.60 mg/kg (n = 31). Single doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-29 09:09:00 +1000" MODIFIED_BY="[Empty name]">
<P>Westley croup score at 0, 1, 2, 3 and 4 hours<BR/>Admitted<BR/>Requiring salvage therapy (nebulized epinephrine)<BR/>Follow up: return to medical care with croup or the need for further treatment with steroids in the week following discharge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:23:21 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:54:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fitzgerald-1996">
<CHAR_METHODS MODIFIED="2011-12-01 06:54:25 +1000" MODIFIED_BY="[Empty name]">
<P>Block randomization, controlled, double-blind trial. 14 children withdrew. Followed an intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>67 children aged 6 months to 6 years hospitalized with croup. 1 withdrawal before treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:01 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulised budesonide 2 mg (n = 35) or nebulized L-epinephrine 4 mg (n = 31). Single doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:15:00 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (Westley modified) at 0, 0.5, 1, 1.5, 2, 12 and 24 hours<BR/>Co-intervention: supplemental steroids<BR/>Length of stay<BR/>Return visits/re-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:23:28 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-07 22:15:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<CHAR_METHODS MODIFIED="2010-11-07 22:15:25 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Geelhoed-1995c" TYPE="STUDY">Geelhoed 1995c</LINK> and <LINK REF="STD-Geelhoed-1995d" TYPE="STUDY">Geelhoed 1995d</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geelhoed-1995a">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:14 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, controlled, double-blind trial. 1 withdrew</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:16:02 +1000" MODIFIED_BY="[Empty name]">
<P>120 patients aged 6 months to 13 years presenting to the emergency department with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:46:37 +1000" MODIFIED_BY="[Empty name]">
<P>Oral dexamethasone 0.6 mg/kg (n = 31) or oral dexamethasone 0.3 mg/kg (n = 29) (trial A). Single doses. Oral dexamethasone 0.15 mg/kg (n = 29) or oral dexamethasone 0.3 mg/kg (n = 31) (trial B)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:46:41 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (stridor and retraction) at 0, 1, 2, 3, 4 and 8<BR/>Length of stay<BR/>Return visits/re-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:23:38 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geelhoed-1995c">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:14 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind. 11 withdrawals (7 children from the placebo group)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:14:27 +1000" MODIFIED_BY="[Empty name]">
<P>80 children aged 3 months to 12 years presenting to the emergency department with croup and then admitted to the hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:01 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 30) or nebulized budesonide 2 mg single dose (n = 27) or oral dexamethasone 0.6 mg/kg maximum 12 mg single dose (n = 23)<BR/>Budesonide branch</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:54:30 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (stridor, retractions modified-modified Westley) at 0, 1, 3, 6, 9 and 12 hours<BR/>Length of stay<BR/>Co-interventions: racemic epinephrine<BR/>Return visits/re-admissions<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:23:45 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 08:47:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geelhoed-1995d">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:47:39 +1000" MODIFIED_BY="[Empty name]">
<P>Dexamethasone branch</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geelhoed-1996a">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:15 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial. 4 patients were lost to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:14:35 +1000" MODIFIED_BY="[Empty name]">
<P>100 children aged 0.4 to 11 years presenting with mild croup to emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:48:02 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 50) or oral dexamethasone 0.15 mg/kg single dose (n = 50)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:47:44 +1000" MODIFIED_BY="[Empty name]">
<P>Return visits/re-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:23:53 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geelhoed-2005">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:15 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized trial. Children and all staff except nurses administering the drug were blinded to treatments. 1 lost to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:14:41 +1000" MODIFIED_BY="[Empty name]">
<P>71 children older than 3 months who presented to the emergency department with croup requiring admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:02 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo and dexamethasone 0.15 mg/kg (n = 36) or nebulized budesonide 2 mg and dexamethasone 0.15 mg/kg (n = 36)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:17:23 +1000" MODIFIED_BY="[Empty name]">
<P>Croup score<BR/>Length of stay<BR/>Return visits/re-admissions<BR/>Duration of symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godden-1997">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:16 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial with 7 withdrawals</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>87 children aged 0.6 to 10 years hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:02 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 42) or nebulized budesonide 2 mg initially and 1 mg every 12 hours (n = 47)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:54:30 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score of a multi-item scale (Westley modified) at 0, 0.5, 1, 2, 4, 12 and 24 hours. Co-interventions: racemic epinephrine, intubation<BR/>Length of stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:07 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Husby-1993">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:16 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>37 children aged 0.4 to 4.9 years hospitalized with croup. 1 drop-out before placebo was administered</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:03 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 16) or nebulized budesonide 1 mg twice (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:49:50 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (Westley modified). Average differences between 0 and 6 hours<BR/>Co-intervention: antibiotics</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:10 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-James-1969">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:17 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>88 children (median age of 14 months) hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-07 22:17:39 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 43) or intramuscular dexamethasone 4 to 12 mg single dose (n = 45)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:50:20 +1000" MODIFIED_BY="[Empty name]">
<P>Co-intervention: antibiotics, tracheostomy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:15 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1996">
<CHAR_METHODS MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Block randomization by the hospital pharmacy, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:14:48 +1000" MODIFIED_BY="[Empty name]">
<P>55 children aged 9 months to 2.5 years presenting to the emergency department with moderate croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:05 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 27) or nebulized dexamethasone 10 to 20 mg (n = 28)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:50:49 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score of a multi-item scale (Westley modified) at 0, 2, 4 and last score<BR/>Return visits/re-admissions<BR/>Co-intervention: mist-tent, supplemental steroids</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:23 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-07 22:17:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<CHAR_METHODS MODIFIED="2010-11-07 22:17:52 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Johnson-1998a" TYPE="STUDY">Johnson 1998a</LINK> and <LINK REF="STD-Johnson-1998b" TYPE="STUDY">Johnson 1998b</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1998a">
<CHAR_METHODS MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Block randomization (by the pharmaceutical company), placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:14:54 +1000" MODIFIED_BY="[Empty name]">
<P>144 children aged from 3 months to 9 years with moderate croup presenting to the emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:06 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 49) or nebulized budesonide 4 mg single dose (n = 48) or intramuscular dexamethasone 0.6 mg/kg single dose (n = 47)<BR/>Dexamethasone branch</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on a multi-item scale (Westley modified) at 0 and 2 hours<BR/>Return visits/re-admissions<BR/>Co-interventions: racemic epinephrine, intubation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:29 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 08:51:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1998b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:51:55 +1000" MODIFIED_BY="[Empty name]">
<P>Budesonide branch</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klassen-1994">
<CHAR_METHODS MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Block randomization by the pharmacy department, placebo-controlled, double-blind trial. 4 patients were lost to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:18:53 +1000" MODIFIED_BY="[Empty name]">
<P>54 children aged from 3 months to 5 years presenting to the emergency department with mild to moderate croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:08 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 27 ) or nebulized budesonide 2 mg (n = 27). Single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:52:20 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on a multi-item scale (Westley modified) at 0 and 4 hours. Co-intervention: supplemental steroids<BR/>Return visits/re-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:36 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klassen-1996">
<CHAR_METHODS MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Block randomization by pharmacy department, controlled, double-blind trial with a matching placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:19:05 +1000" MODIFIED_BY="[Empty name]">
<P>50 children aged from 3 months to 5 years presenting to the emergency department with mild to moderate croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:08 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo plus oral dexamethasone 0.6 mg/kg (n = 25) or 2 mg nebulized budesonide plus oral dexamethasone 0.6 mg/kg (n = 25). Unique doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (Westley modified) at 0 and 4 hours<BR/>Co-intervention: racemic epinephrine<BR/>Return visits/re-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:40 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klassen-1998">
<CHAR_METHODS MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Block randomization by the hospital pharmacy, controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:15:13 +1000" MODIFIED_BY="[Empty name]">
<P>198 children with croup presenting to the emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-07 22:19:15 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulised budesonide 2 mg single dose (n = 65) or oral dexamethasone 0.6 mg/kg single dose (n = 69) or budesonide + dexamethasone (n = 64)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (Westley modified)<BR/>Return visits/re-admissions<BR/>Length of stay<BR/>Co-interventions: racemic epinephrine, supplemental steroids</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:43 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koren-1983">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:17 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial. No description of drop-outs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>78 children aged from 8 months to 8 years hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:54:23 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 38) or intramuscular dexamethasone 0.6 mg/kg single dose (n = 40)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:53:55 +1000" MODIFIED_BY="[Empty name]">
<P>Respirations per minute at 0, 1, 2, 3, 4, 5 and 6 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:46 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuusela-1988">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:18 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial; pre-numbered unlabelled ampoules in random order</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>72 children from 6 months to 11 years of age hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:12 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo plus placebo (n = 21) or nebulized L-epinephrine 2.25% 0.25 ml/kg plus placebo (n = 16) or intramuscular dexamethasone 0.6 mg/kg plus placebo (n = 16) or dexamethasone plus L-epinephrine (n = 19). L-epinephrine every 2 hours if necessary. Dexamethasone maximum dose of 10 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:19:33 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on dyspnoea and cough scale at 0, 6, 12 and 24 hours<BR/>Length of stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:50 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leipzig-1979">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:18 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:15:19 +1000" MODIFIED_BY="[Empty name]">
<P>30 children aged from 8 months to 6 years presenting with croup to the emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:55:54 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 14) or intramuscular dexamethasone 0.3 mg/kg twice (n = 16)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:55:35 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on a multi-item scale (stridor, cyanosis, retractions, respiration rate, pulse rate) at 0 and 24 hours<BR/>Length of stay<BR/>Co-interventions: intubation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:53 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luria-2001">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-07 22:19:50 +1000" MODIFIED_BY="[Empty name]">
<P>264 children aged 6 months to 6 years presenting to the emergency department with mild croup of less than 48 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:12 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 88) or 0.6 mg/kg of oral dexamethasone (n = 85), or 160 ug of nebulized dexamethasone sodium phosphate (n = 91)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:54:35 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment failure (requiring corticosteroids or racemic epinephrine up to 7 days after treatment)<BR/>Return visits/re-admissions<BR/>Parental's assessments of child's condition (improvement)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:24:56 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinez-1993">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>66 children hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:12 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 17) or nebulized L-epinephrine 0.14% quid if necessary (n = 15) or intramuscular dexamethasone 0.5 mg/kg single dose (n = 16) or L-epinephrine+dexamethasone (n = 18)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:57:08 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (stridor, dyspnoea, cough, cyanosis) at 0, 6,12,18 and 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:01 +1000" MODIFIED_BY="[Empty name]">
<P>Language = Spanish</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massicotte-1973">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized by table of random numbers, matching placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>42 children less than 4 years hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:58:08 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 17) or intravenous methyl-prednisolone 4 mg (n = 25) at 0, 4 and 8 hours. Total dose day = 12 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:58:12 +1000" MODIFIED_BY="[Empty name]">
<P>Percentage of improved patients at 4, 8, 14 and 20 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:05 +1000" MODIFIED_BY="[Empty name]">
<P>Language = French</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rittichier-2000">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized (computer-generated) controlled trial. 27 children withdrew (unable to be contacted by phone, treatment arm not specified)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:15:31 +1000" MODIFIED_BY="[Empty name]">
<P>277 children aged 3 months to 12 years with moderate croup of &lt; 48 hours onset presenting to the emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 08:58:57 +1000" MODIFIED_BY="[Empty name]">
<P>Intramuscular dexamethasone 0.6 mg/kg (n = 139) or oral dexamethasone 0.6 mg/kg (n = 138). Maximum dosage of both routes of administration was 8 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 08:58:32 +1000" MODIFIED_BY="[Empty name]">
<P>Unscheduled return visit<BR/>Caretaker's report of symptoms (improvement)<BR/>Additional treatments given at unscheduled visits<BR/>Co-interventions: all children received cool mist therapy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:09 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roberts-1999">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:21 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized by a computer-generated random numbers table, double-blind, placebo controlled trial. Randomization code kept at Astra Draco (gave funding). 1 child withdrew</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>82 children hospitalized with croup (0.5 to 8 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-29 09:09:12 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulised placebo (n = 40) or nebulized budesonide (n = 42). Dose of 2 mg/4 mL every 12 hours for a maximum of four doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:20:26 +1000" MODIFIED_BY="[Empty name]">
<P>Croup score similar to <LINK REF="STD-Leipzig-1979" TYPE="STUDY">Leipzig 1979</LINK> with alterations to stridor assessment, oxygen saturation and temperature<BR/>Co-interventions: intubation, use or epinephrine<BR/>Return visits/re-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:12 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roorda-1998">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial (preliminary study)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>17 children hospitalized with croup (4 to 52 months)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 09:00:32 +1000" MODIFIED_BY="[Empty name]">
<P>Metered dose inhaler placebo (n = 8) or metered dose inhaler fustians with a dose of 2000 ug/day (n = 9)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:20:37 +1000" MODIFIED_BY="[Empty name]">
<P>Westley croup score up to 24 hours<BR/>Co-interventions: supplemental corticosteroids, intubation<BR/>Length of stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:14 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-07 22:20:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<CHAR_METHODS MODIFIED="2010-11-07 22:20:46 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="STD-Skowron-1966a" TYPE="STUDY">Skowron 1966a</LINK> and <LINK REF="STD-Skowron-1966b" TYPE="STUDY">Skowron 1966b</LINK>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skowron-1966a">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>200 children (average age of 2.3 years) hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 09:01:12 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 44) or subcutaneous dexamethasone 6 mg single dose (n = 56) (Trial a)<BR/>Placebo (n = 53) or subcutaneous dexamethasone 4 mg single dose (n = 41) (Trial b)<BR/>Branch 6 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 09:00:51 +1000" MODIFIED_BY="[Empty name]">
<P>Co-intervention: tracheostomy<BR/>Return visits/re-admissions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:20 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Skowron-1966b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS>
<P>Branch 4 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sparrow--2006">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:23 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized by the pharmacy, double-blind controlled trial. No drop-outs</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-04 14:15:37 +1000" MODIFIED_BY="[Empty name]">
<P>133 children aged 3 to 142 months with mild to moderate croup treated at the emergency department</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 09:01:52 +1000" MODIFIED_BY="[Empty name]">
<P>Oral 0.15 mg/kg dexamethasone (n = 68) or oral 1 mg/kg prednisolone (n = 65)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Admissions<BR/>Duration of croup symptoms<BR/>Duration of viral symptoms<BR/>Return visits<BR/>Additional interventions<BR/>Time in ED<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:24 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Super-1989">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:24 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>29 children aged from 6 months to 3 years hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 09:02:28 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 13) or intramuscular dexamethasone 0.6 mg/kg single dose (n = 16)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 09:02:36 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale (Westley modified) at 0, 12 and 24 hours<BR/>Percentage of improvement<BR/>Co-interventions: supplemental steroids, mist tent<BR/>Length of stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:27 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tibballs-1992">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:24 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial. Interventions were supplied by the pharmacy in an order determined by a table of random numbers. 3 withdrawals from the placebo group and were excluded from the analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>73 hospitalized children aged 6 months to 8 years, were eligible if endotracheal intubation had been required for upper airway obstruction caused by croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 09:03:17 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 35) or nasogastric prednisolone 2 mg/kg/day (n = 38), until 24 hours after extubation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-01 06:54:37 +1000" MODIFIED_BY="[Empty name]">
<P>Intubation duration<BR/>Re-intubation rates<BR/>Co-intervention: racemic epinephrine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:30 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:54:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vad-Pedersen-1998">
<CHAR_METHODS MODIFIED="2011-12-01 06:54:37 +1000" MODIFIED_BY="[Empty name]">
<P>Variable block randomization (2 to 6), non-blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 09:03:52 +1000" MODIFIED_BY="[Empty name]">
<P>59 were included, but 2 were later excluded, children between 3 months to 6 years admitted to the hospital with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 09:04:00 +1000" MODIFIED_BY="[Empty name]">
<P>Inhaled budesonide (n = 28) dose of 1000 ug twice or intramuscular dexamethasone (n = 29) at a dose of 0.6 mg/kg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:22:19 +1000" MODIFIED_BY="[Empty name]">
<P>7-point croup score a 0, 3, 6 and 12 hours<BR/>Length of stay<BR/>Need for further dexamethasone injections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-07 22:22:10 +1000" MODIFIED_BY="[Empty name]">
<P>Language = Danish</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-01 06:58:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-von-Muhlendahl-1982">
<CHAR_METHODS MODIFIED="2011-12-01 06:58:25 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind trial with 57 withdrawals</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-29 09:11:56 +1000" MODIFIED_BY="[Empty name]">
<P>406 children aged less than 10 years hospitalized with croup</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 09:05:01 +1000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 173) or oral dexamethasone 6 mg (n = 176), unique dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-07 22:22:27 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score based on multi-item scale at 0, 6, 12 and 18 hours<BR/>Improvement<BR/>Co-interventions: tracheostomy<BR/>Length of stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-26 02:25:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ED = emergency department<BR/>ITT = intention-to-treat</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adelman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anene-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-07 22:27:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-07 22:27:51 +1000" MODIFIED_BY="[Empty name]">
<P>Letter to Kairys' meta-analysis (1989)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Position statement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Summary of Klassen's study (1994)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Asher-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bass-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to Eden's study (1971)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bass-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to Leipzig's study (1979)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baugh-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bauman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comment about croup management</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berni-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Diagnostic and treatment guidelines</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bollobas--1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-07 22:23:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chub_x002d_Uppakarn-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-07 22:23:04 +1000" MODIFIED_BY="[Empty name]">
<P>All children received epinephrine prior to corticosteroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cichy-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-07 22:23:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cluster--2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-07 22:23:05 +1000" MODIFIED_BY="[Empty name]">
<P>Review of Bjornson's trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Connolly-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Couser-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Boeck-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-07 22:23:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Denoyelle-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-07 22:23:13 +1000" MODIFIED_BY="[Empty name]">
<P>Comments/review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doull-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eden-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feingold-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Flisberg-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>No clinical outcomes reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Folland-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Commentary about croup management</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Freezer-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Friedman-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Geelhoed-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Geelhoed-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Geelhoed-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goddard--1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldhagen-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haque-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harel-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Havaldar-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hawkins-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Helowicz-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herxheimer-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kairys-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karoliny-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kelley-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klassen-1997a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klassen-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kunkel-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ledwith-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lukina-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lynk-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marchi-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martensson-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McDonogh-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mortensen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplication of Husby's study (1993)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Novik-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oski-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Osvath-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prendergast-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Quan-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Richter-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rizos-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roosevelt-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ross-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-07 22:23:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schoooff--2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-07 22:23:32 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serra-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shaw-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Skolnik-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Slawson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Summary of Geelhoed's study (1996)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Slolnik-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spaulding-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Summary of Cruz's study (1995)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sumboonnanonda-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No treatment given to the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sussman-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tabachnik-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-25 09:10:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tal-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-25 09:10:13 +1000" MODIFIED_BY="[Empty name]">
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tellez-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Terregino-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No glucocorticoid treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thomas-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tunnessen-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Veerappan-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-von-Mulhendal-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vrabec-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>No diagnosis of croup</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whelan-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to the editor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whilhelmi-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 09:09:17 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yates-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-10-02 03:56:11 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Eboriadou-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-10 13:43:19 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-06-26 02:28:43 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:26:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alshehri--2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:20:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amir--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bjornson-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cetinkaya-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cruz-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:19:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duman-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eden-1964">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eden-1967">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:28:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fifoot--2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fitzgerald-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Godden-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Husby-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-James-1969">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Koren-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kuusela-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leipzig-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luria-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martinez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rittichier-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roorda-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:28:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sparrow--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Super-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tibballs-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vad-Pedersen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-von-Muhlendahl-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-07 22:20:54 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:26:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alshehri--2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Amir--2006">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjornson-2004">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetinkaya-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:34 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cruz-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Donaldson-2003">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duman-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1964">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eden-1967">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:31:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fifoot--2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:31:43 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fitzgerald-1996">
<DESCRIPTION>
<P>Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:15:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<DESCRIPTION>
<P>See <LINK REF="STD-Geelhoed-1995c" TYPE="STUDY">Geelhoed 1995c</LINK> and <LINK REF="STD-Geelhoed-1995d" TYPE="STUDY">Geelhoed 1995d</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:31:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:34:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995c">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:17:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995d">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:35:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1996a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:35:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-2005">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:37:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godden-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:37:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Husby-1993">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:37:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-James-1969">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:37:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:18:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<DESCRIPTION>
<P>See <LINK REF="STD-Johnson-1998a" TYPE="STUDY">Johnson 1998a</LINK> and <LINK REF="STD-Johnson-1998b" TYPE="STUDY">Johnson 1998b</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:45:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1998a">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:45:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1998b">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:53:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klassen-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:54:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klassen-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:57:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klassen-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:57:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koren-1983">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:57:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuusela-1988">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leipzig-1979">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luria-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinez-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Massicotte-1973">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:59:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rittichier-2000">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:59:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1999">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:59:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roorda-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:20:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<DESCRIPTION>
<P>See <LINK REF="STD-Skowron-1966a" TYPE="STUDY">Skowron 1966a</LINK> and <LINK REF="STD-Skowron-1966b" TYPE="STUDY">Skowron 1966b</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:00:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:00:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:00:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sparrow--2006">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:03:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Super-1989">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:03:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tibballs-1992">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:04:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vad-Pedersen-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:04:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-von-Muhlendahl-1982">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-11-10 13:43:19 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-26 02:26:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alshehri--2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Amir--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Bjornson-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Cetinkaya-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Cruz-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-26 02:19:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duman-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1964">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1967">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-26 02:28:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fifoot--2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Fitzgerald-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Godden-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Husby-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-James-1969">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Koren-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-10 13:43:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuusela-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Leipzig-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Luria-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Rittichier-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Roorda-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-06-26 02:28:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sparrow--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Super-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Tibballs-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Vad-Pedersen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-von-Muhlendahl-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-06-26 02:28:47 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-26 02:27:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alshehri--2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Amir--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Bjornson-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Cetinkaya-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Cruz-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-26 02:23:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duman-2005">
<DESCRIPTION>
<P>ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1964">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1967">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-26 02:28:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fifoot--2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Fitzgerald-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Godden-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Husby-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-James-1969">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Koren-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuusela-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Leipzig-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Luria-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Rittichier-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Roorda-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-26 02:28:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sparrow--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Super-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Tibballs-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Vad-Pedersen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-von-Muhlendahl-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-06-26 02:28:49 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:27:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alshehri--2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:21:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amir--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bjornson-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cetinkaya-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cruz-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:23:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duman-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eden-1964">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eden-1967">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:28:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fifoot--2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fitzgerald-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Godden-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Husby-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-James-1969">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Koren-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kuusela-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leipzig-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luria-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martinez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rittichier-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roorda-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:28:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sparrow--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Super-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tibballs-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vad-Pedersen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-von-Muhlendahl-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-06-26 02:28:50 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:27:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alshehri--2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:21:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Amir--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bjornson-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cetinkaya-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cruz-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:19:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duman-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eden-1964">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eden-1967">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:28:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fifoot--2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fitzgerald-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1996a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Godden-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Husby-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-James-1969">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Koren-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kuusela-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Leipzig-1979">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luria-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martinez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-1973">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rittichier-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roorda-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:28:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sparrow--2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Super-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tibballs-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vad-Pedersen-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-von-Muhlendahl-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-11-07 22:20:54 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Pharmaceutical funding?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:27:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alshehri--2005">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:27:47 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Amir--2006">
<DESCRIPTION>
<P>No funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:28:12 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bjornson-2004">
<DESCRIPTION>
<P>Other funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:28:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetinkaya-2004">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:28:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cruz-1995">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:29:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-2003">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:29:30 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Duman-2005">
<DESCRIPTION>
<P>No funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:29:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1964">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:30:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eden-1967">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-26 02:23:25 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fifoot--2007">
<DESCRIPTION>
<P>Other funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:31:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzgerald-1996">
<DESCRIPTION>
<P>Pharmaceutical support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:15:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995-C_x0026_D">
<DESCRIPTION>
<P>See <LINK REF="STD-Geelhoed-1995c" TYPE="STUDY">Geelhoed 1995c</LINK> and <LINK REF="STD-Geelhoed-1995d" TYPE="STUDY">Geelhoed 1995d</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:31:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995a">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:34:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995c">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:34:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-1995d">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:35:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Geelhoed-1996a">
<DESCRIPTION>
<P>Other funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:35:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geelhoed-2005">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:36:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godden-1997">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:37:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Husby-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:37:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-James-1969">
<DESCRIPTION>
<P>Pharmaceutical support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:37:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1996">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:18:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1998-A_x0026_B">
<DESCRIPTION>
<P>See <LINK REF="STD-Johnson-1998a" TYPE="STUDY">Johnson 1998a</LINK> and <LINK REF="STD-Johnson-1998b" TYPE="STUDY">Johnson 1998b</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:45:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1998a">
<DESCRIPTION>
<P>Pharmaceutical support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:46:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1998b">
<DESCRIPTION>
<P>Pharmaceutical support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:53:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klassen-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:53:59 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klassen-1996">
<DESCRIPTION>
<P>Other funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:57:28 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klassen-1998">
<DESCRIPTION>
<P>Other funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:57:43 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koren-1983">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:57:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuusela-1988">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leipzig-1979">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:22 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luria-2001">
<DESCRIPTION>
<P>Other funding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinez-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:58:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Massicotte-1973">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:59:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rittichier-2000">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:59:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roberts-1999">
<DESCRIPTION>
<P>Pharmaceutical support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 05:59:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roorda-1998">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:20:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966-A_x0026_B">
<DESCRIPTION>
<P>See <LINK REF="STD-Skowron-1966a" TYPE="STUDY">Skowron 1966a</LINK> and <LINK REF="STD-Skowron-1966b" TYPE="STUDY">Skowron 1966b</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:00:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966a">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:00:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Skowron-1966b">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:00:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sparrow--2006">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:03:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Super-1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:03:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tibballs-1992">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:04:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vad-Pedersen-1998">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-19 06:04:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-von-Muhlendahl-1982">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-11-07 22:24:08 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-11-07 22:24:08 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-10-04 15:01:12 +1000" MODIFIED_BY="[Empty name]">NNTs for return visits and/or (re)admissions in any glucocorticoid versus placebo</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TH>
<P>Baseline rate (%)</P>
</TH>
<TH>
<P>NNT (95% CI)</P>
</TH>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>100 (78 to 167)</P>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>17 (13 to 28)</P>
</TD>
</TR>
<TR>
<TD>
<P>16</P>
</TD>
<TD>
<P>12 (10 to 21)</P>
</TD>
</TR>
<TR>
<TD>
<P>30</P>
</TD>
<TD>
<P>7 (5 to 11)</P>
</TD>
</TR>
<TR>
<TD>
<P>44</P>
</TD>
<TD>
<P>5 (4 to 8)</P>
</TD>
</TR>
<TR>
<TD>
<P>58</P>
</TD>
<TD>
<P>3 (3 to 6)</P>
</TD>
</TR>
<TR>
<TD>
<P>72</P>
</TD>
<TD>
<P>3 (2 to 5)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-07-18 14:49:01 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-11-07 22:49:03 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Any glucocorticoid versus placebo</NAME>
<CONT_OUTCOME CHI2="38.98550386140128" CI_END="-0.34623456938087926" CI_START="-0.8320547847177291" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5891446770493042" ESTIMABLE="YES" I2="66.65427219764364" I2_Q="77.03821327705693" ID="CMP-001.01" MODIFIED="2010-11-07 22:46:14 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.010120640617563E-4" P_Q="0.036899331101851396" P_Z="1.9980641010042666E-6" Q="4.3550617905566344" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.12960894126780684" TOTALS="YES" TOTAL_1="552" TOTAL_2="479" UNITS="" WEIGHT="100.0" Z="4.7536200110548705">
<NAME>Croup score (change baseline - 6 hours) by score</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.367662781371966" CI_END="-0.5354071107123654" CI_START="-0.9922123511634716" DF="8" EFFECT_SIZE="-0.7638097309379185" ESTIMABLE="YES" I2="22.836996450405863" ID="CMP-001.01.01" MODIFIED="2010-11-07 22:46:10 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24016305890086098" P_Z="5.587024911034372E-11" STUDIES="9" TAU2="0.02751507956418515" TOTAL_1="262" TOTAL_2="190" WEIGHT="59.941814708784726" Z="6.554388746509066">
<NAME>Westley score</NAME>
<CONT_DATA CI_END="-0.13961702311198432" CI_START="-1.4515889343693815" EFFECT_SIZE="-0.795602978740683" ESTIMABLE="YES" MEAN_1="-2.21" MEAN_2="-1.08" ORDER="28774" SD_1="1.39" SD_2="1.4" SE="0.334692862115341" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="27" TOTAL_2="15" WEIGHT="6.356927767344912"/>
<CONT_DATA CI_END="-0.46184778179985586" CI_START="-1.8763343084647077" EFFECT_SIZE="-1.1690910451322818" ESTIMABLE="YES" MEAN_1="-2.73" MEAN_2="-1.08" ORDER="28775" SD_1="1.37" SD_2="1.4" SE="0.3608450302715103" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="23" TOTAL_2="15" WEIGHT="5.911880224704235"/>
<CONT_DATA CI_END="-0.027434405887410473" CI_START="-0.9016132635315757" EFFECT_SIZE="-0.4645238347094931" ESTIMABLE="YES" MEAN_1="-2.96" MEAN_2="-1.74" ORDER="28776" SD_1="2.25" SD_2="2.95" SE="0.22300890846453722" STUDY_ID="STD-Godden-1997" TOTAL_1="44" TOTAL_2="39" WEIGHT="8.564720390949022"/>
<CONT_DATA CI_END="-0.3496053315022286" CI_START="-1.7623620192279779" EFFECT_SIZE="-1.0559836753651033" ESTIMABLE="YES" MEAN_1="-3.86" MEAN_2="-0.88" ORDER="28777" SD_1="3.19" SD_2="2.09" SE="0.3604037367189892" STUDY_ID="STD-Husby-1993" TOTAL_1="20" TOTAL_2="16" WEIGHT="5.919131280951364"/>
<CONT_DATA CI_END="-0.3905105207064441" CI_START="-1.7683360356449844" EFFECT_SIZE="-1.0794232781757143" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.0" ORDER="28778" SD_1="1.08" SD_2="0.74" SE="0.351492559507892" STUDY_ID="STD-Johnson-1996" TOTAL_1="17" TOTAL_2="21" WEIGHT="6.067458764446185"/>
<CONT_DATA CI_END="-0.4897079572295143" CI_START="-1.5169382405996452" EFFECT_SIZE="-1.0033230989145798" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-1.4" ORDER="28779" SD_1="1.37" SD_2="1.4" SE="0.26205335696798315" STUDY_ID="STD-Johnson-1998a" TOTAL_1="47" TOTAL_2="25" WEIGHT="7.746652994491882"/>
<CONT_DATA CI_END="0.06918577951134225" CI_START="-0.9211933876535552" EFFECT_SIZE="-0.4260038040711065" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.4" ORDER="28780" SD_1="1.39" SD_2="1.4" SE="0.252652389272681" STUDY_ID="STD-Johnson-1998b" TOTAL_1="48" TOTAL_2="24" WEIGHT="7.94042655611923"/>
<CONT_DATA CI_END="-0.3632196272389464" CI_START="-1.4901656770726897" EFFECT_SIZE="-0.926692652155818" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-1.0" ORDER="28781" SD_1="1.89" SD_2="2.34" SE="0.2874915199266287" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="27" WEIGHT="7.23646033460543"/>
<CONT_DATA CI_END="1.0169345951818978" CI_START="-0.8884452851276631" EFFECT_SIZE="0.06424465502711738" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="28782" SD_1="1.0" SD_2="1.88" SE="0.4860752277437122" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" WEIGHT="4.19815639517246"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.551919286003116" CI_END="0.04189315253406928" CI_START="-0.6694148067875636" DF="4" EFFECT_SIZE="-0.3137608271267472" ESTIMABLE="YES" I2="68.13236359430326" ID="CMP-001.01.02" MODIFIED="2010-11-07 22:46:14 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.013685985709786186" P_Z="0.08379189114601408" STUDIES="5" TAU2="0.10396652703521894" TOTAL_1="290" TOTAL_2="289" WEIGHT="40.05818529121528" Z="1.729096133029085">
<NAME>Non-Westley score</NAME>
<CONT_DATA CI_END="-0.2368192514905033" CI_START="-1.1525558411774828" EFFECT_SIZE="-0.6946875463339931" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-4.8" ORDER="28783" SD_1="0.86" SD_2="0.85" SE="0.2336105655282936" STUDY_ID="STD-Koren-1983" TOTAL_1="40" TOTAL_2="38" WEIGHT="8.33961172671889"/>
<CONT_DATA CI_END="0.06902685677350939" CI_START="-1.2632371314508588" EFFECT_SIZE="-0.5971051373386747" ESTIMABLE="YES" MEAN_1="-1.65" MEAN_2="-0.65" ORDER="28784" SD_1="1.65" SD_2="1.63" SE="0.3398695074840906" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="21" WEIGHT="6.266367299474428"/>
<CONT_DATA CI_END="1.1078931425551979" CI_START="-0.2741982857569237" EFFECT_SIZE="0.4168474283991371" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-1.0" ORDER="28785" SD_1="1.45" SD_2="1.36" SE="0.35258082271253" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="17" WEIGHT="6.049150040749602"/>
<CONT_DATA CI_END="-0.11149699597722329" CI_START="-0.9947356252775822" EFFECT_SIZE="-0.5531163106274027" ESTIMABLE="YES" MEAN_1="-2.26" MEAN_2="-0.8" ORDER="28786" SD_1="2.25" SD_2="2.95" SE="0.2253201171723645" STUDY_ID="STD-Roberts-1999" TOTAL_1="42" TOTAL_2="40" WEIGHT="8.51552035595237"/>
<CONT_DATA CI_END="0.1316583759710911" CI_START="-0.28817743167821724" EFFECT_SIZE="-0.07825952785356306" ESTIMABLE="YES" MEAN_1="-3.14" MEAN_2="-3.0" ORDER="28787" SD_1="1.79" SD_2="1.78" SE="0.10710293938075383" STUDY_ID="STD-von-Muhlendahl-1982" TOTAL_1="176" TOTAL_2="173" WEIGHT="10.88753586831999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="26.97026458989122" CI_END="-0.27364430464141454" CI_START="-1.0335095424817995" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.653576923561607" ESTIMABLE="YES" I2="74.04549007419199" I2_Q="86.26491568434919" ID="CMP-001.02" MODIFIED="2010-11-07 22:46:26 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.374127235530322E-4" P_Q="0.006970255447178664" P_Z="7.472832258509656E-4" Q="7.280625127728729" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.2061184342248066" TOTALS="YES" TOTAL_1="259" TOTAL_2="273" UNITS="" WEIGHT="100.0" Z="3.3716168802455946">
<NAME>Croup score (change baseline - 12 hours) by score</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.46701180323459" CI_END="-0.5194743174270523" CI_START="-1.8294837927143561" DF="3" EFFECT_SIZE="-1.1744790550707043" ESTIMABLE="YES" I2="73.83799675558225" ID="CMP-001.02.01" MODIFIED="2010-11-07 22:46:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00945093865864377" P_Z="4.4077898912730633E-4" STUDIES="4" TAU2="0.31976485634410645" TOTAL_1="110" TOTAL_2="83" WEIGHT="45.60343306101612" Z="3.514381677323925">
<NAME>Westley score</NAME>
<CONT_DATA CI_END="-0.24492666903657478" CI_START="-1.571582786849233" EFFECT_SIZE="-0.9082547279429039" ESTIMABLE="YES" MEAN_1="-2.24" MEAN_2="-0.95" ORDER="28788" SD_1="1.39" SD_2="1.4" SE="0.3384389020097186" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="27" TOTAL_2="15" WEIGHT="11.71852921327836"/>
<CONT_DATA CI_END="-0.6657634955217042" CI_START="-2.1258842122487147" EFFECT_SIZE="-1.3958238538852095" ESTIMABLE="YES" MEAN_1="-2.92" MEAN_2="-0.95" ORDER="28789" SD_1="1.37" SD_2="1.4" SE="0.37248661920429565" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="23" TOTAL_2="15" WEIGHT="10.89602818688656"/>
<CONT_DATA CI_END="-0.10549336135988086" CI_START="-0.9724018983346304" EFFECT_SIZE="-0.5389476298472556" ESTIMABLE="YES" MEAN_1="-3.41" MEAN_2="-1.99" ORDER="28790" SD_1="2.25" SD_2="2.95" SE="0.22115420074369055" STUDY_ID="STD-Godden-1997" TOTAL_1="44" TOTAL_2="41" WEIGHT="14.734308937516724"/>
<CONT_DATA CI_END="-1.2509784672315085" CI_START="-3.2074230978398965" EFFECT_SIZE="-2.2292007825357025" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-1.0" ORDER="28791" SD_1="1.13" SD_2="1.03" SE="0.49910218913219156" STUDY_ID="STD-Super-1989" TOTAL_1="16" TOTAL_2="12" WEIGHT="8.254566723334475"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6755901435337752" CI_END="-0.008281079961737658" CI_START="-0.4412500456728234" DF="3" EFFECT_SIZE="-0.22476556281728052" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" MODIFIED="2010-11-07 22:46:26 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6423743082609357" P_Z="0.04185715481008293" STUDIES="4" TAU2="0.0" TOTAL_1="149" TOTAL_2="190" WEIGHT="54.39656693898388" Z="2.034937572780707">
<NAME>Non-Westley score</NAME>
<CONT_DATA CI_END="0.2647828218067441" CI_START="-1.049700048050879" EFFECT_SIZE="-0.39245861312206737" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.2" ORDER="28792" SD_1="1.64" SD_2="1.82" SE="0.3353334245491489" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="21" WEIGHT="11.795497878350114"/>
<CONT_DATA CI_END="0.6826853903640876" CI_START="-0.6826853903640876" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.1" ORDER="28793" SD_1="1.5" SD_2="1.55" SE="0.34831527300961795" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="17" WEIGHT="11.47579137786042"/>
<CONT_DATA CI_END="0.02118741409871633" CI_START="-0.8546503479208301" EFFECT_SIZE="-0.4167314669110569" ESTIMABLE="YES" MEAN_1="-2.39" MEAN_2="-1.29" ORDER="28794" SD_1="2.25" SD_2="2.95" SE="0.22343210613257256" STUDY_ID="STD-Roberts-1999" TOTAL_1="42" TOTAL_2="40" WEIGHT="14.676029796730054"/>
<CONT_DATA CI_END="0.1458228390839636" CI_START="-0.43982182457531144" EFFECT_SIZE="-0.14699949274567392" ESTIMABLE="YES" MEAN_1="-3.31" MEAN_2="-3.05" ORDER="28795" SD_1="1.67" SD_2="1.82" SE="0.14940189418753747" STUDY_ID="STD-von-Muhlendahl-1982" TOTAL_1="75" TOTAL_2="112" WEIGHT="16.449247886043295"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="41.35336918682282" CI_END="-0.0033330711652141964" CI_START="-1.100344391596065" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5518387313806395" ESTIMABLE="YES" I2="83.07272143080777" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-11-07 22:48:43 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="6.924574607047873E-7" P_Q="0.5724130425166729" P_Z="0.04862399443353607" Q="0.31866187966385573" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.49559331323534855" TOTALS="YES" TOTAL_1="172" TOTAL_2="216" UNITS="" WEIGHT="100.0" Z="1.9718739791227227">
<NAME>Croup score (change baseline - 24 hours) by score</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.59579658625796" CI_END="0.17293707299182048" CI_START="-1.7216238780908806" DF="2" EFFECT_SIZE="-0.77434340254953" ESTIMABLE="YES" I2="76.73281376623795" ID="CMP-001.03.01" MODIFIED="2010-11-07 22:48:40 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01359713854193656" P_Z="0.10912249803387244" STUDIES="3" TAU2="0.5313600965446655" TOTAL_1="57" TOTAL_2="52" WEIGHT="35.362224619394034" Z="1.602149753794889">
<NAME>Westley score</NAME>
<CONT_DATA CI_END="-0.2717031565552548" CI_START="-1.2673714894176176" EFFECT_SIZE="-0.7695373229864362" ESTIMABLE="YES" MEAN_1="-4.14" MEAN_2="-2.11" ORDER="28796" SD_1="2.25" SD_2="2.95" SE="0.25400169103005654" STUDY_ID="STD-Godden-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="13.982749746905471"/>
<CONT_DATA CI_END="1.18996634730052" CI_START="-0.7231700149859885" EFFECT_SIZE="0.23339816615726577" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-2.4" ORDER="28797" SD_1="1.22" SD_2="1.22" SE="0.4880539584852283" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" WEIGHT="10.673190677356523"/>
<CONT_DATA CI_END="-0.8333004501720348" CI_START="-2.737306329012864" EFFECT_SIZE="-1.7853033895924493" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-1.5" ORDER="28798" SD_1="1.13" SD_2="1.03" SE="0.48572471072412154" STUDY_ID="STD-Super-1989" TOTAL_1="13" TOTAL_2="12" WEIGHT="10.706284195132044"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="27.65143576187088" CI_END="0.2690237948841944" CI_START="-1.1380206492259275" DF="4" EFFECT_SIZE="-0.43449842717086656" ESTIMABLE="YES" I2="85.53420504292338" ID="CMP-001.03.02" MODIFIED="2010-11-07 22:48:43 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.4675239670913776E-5" P_Z="0.22609386212893656" STUDIES="5" TAU2="0.5335588970393822" TOTAL_1="115" TOTAL_2="164" WEIGHT="64.63777538060596" Z="1.210482401119588">
<NAME>Non-Westley score</NAME>
<CONT_DATA CI_END="0.2991105726503926" CI_START="-1.0130181382288992" EFFECT_SIZE="-0.3569537827892533" ESTIMABLE="YES" MEAN_1="-2.11" MEAN_2="-1.5" ORDER="28799" SD_1="1.62" SD_2="1.71" SE="0.3347328627539066" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="21" WEIGHT="12.889026510863536"/>
<CONT_DATA CI_END="-1.4800988900941205" CI_START="-3.4402801987813976" EFFECT_SIZE="-2.460189544437759" ESTIMABLE="YES" MEAN_1="-7.27" MEAN_2="-2.56" ORDER="28800" SD_1="1.39" SD_2="2.29" SE="0.5000554408522139" STUDY_ID="STD-Leipzig-1979" TOTAL_1="16" TOTAL_2="14" WEIGHT="10.503444543412972"/>
<CONT_DATA CI_END="1.0877602454921016" CI_START="-0.2928211014350395" EFFECT_SIZE="0.39746957202853106" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.4" ORDER="28801" SD_1="1.18" SD_2="1.27" SE="0.3521955907906958" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="17" WEIGHT="12.639505144960223"/>
<CONT_DATA CI_END="0.04340018153525399" CI_START="-0.8314015007852524" EFFECT_SIZE="-0.3940006596249992" ESTIMABLE="YES" MEAN_1="-2.55" MEAN_2="-1.51" ORDER="28802" SD_1="2.25" SD_2="2.95" SE="0.22316779523012423" STUDY_ID="STD-Roberts-1999" TOTAL_1="42" TOTAL_2="40" WEIGHT="14.359957632197572"/>
<CONT_DATA CI_END="0.6860391612624208" CI_START="-0.22632573742750878" EFFECT_SIZE="0.22985671191745605" ESTIMABLE="YES" MEAN_1="-2.89" MEAN_2="-3.31" ORDER="28803" SD_1="1.85" SD_2="1.8" SE="0.23275042446865032" STUDY_ID="STD-von-Muhlendahl-1982" TOTAL_1="25" TOTAL_2="72" WEIGHT="14.245841549171653"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.59622097976322" CI_END="-0.8190924647761263" CI_START="-1.61826775772705" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2186801112515881" ESTIMABLE="YES" I2="41.16012080189564" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2010-11-07 22:36:10 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09291609273928059" P_Q="0.687012107973314" P_Z="2.2646975133097268E-9" Q="0.16233925866268856" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.14418419474778857" TOTALS="YES" TOTAL_1="262" TOTAL_2="190" UNITS="" WEIGHT="99.99999999999999" Z="5.977585012441215">
<NAME>Westley score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.891616002821396" CI_END="-0.5913269575974537" CI_START="-2.0448714145302094" DF="4" EFFECT_SIZE="-1.3180991860638316" ESTIMABLE="YES" I2="49.31329655966627" ID="CMP-001.04.01" NO="1" P_CHI2="0.09563014216576438" P_Z="3.7847060698874394E-4" STUDIES="5" TAU2="0.32812747060076" TOTAL_1="123" TOTAL_2="93" WEIGHT="42.7273453758732" Z="3.5546582980862826">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="-0.24861327050993942" CI_START="-2.0113867294900603" EFFECT_SIZE="-1.13" ESTIMABLE="YES" MEAN_1="-2.21" MEAN_2="-1.08" ORDER="28804" SD_1="1.39" SD_2="1.4" SE="0.44969537014063854" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="27" TOTAL_2="15" WEIGHT="11.998787241614972"/>
<CONT_DATA CI_END="-0.7469881722807395" CI_START="-2.5530118277192604" EFFECT_SIZE="-1.65" ESTIMABLE="YES" MEAN_1="-2.73" MEAN_2="-1.08" ORDER="28805" SD_1="1.37" SD_2="1.4" SE="0.4607287862644938" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="23" TOTAL_2="15" WEIGHT="11.660655332157562"/>
<CONT_DATA CI_END="-0.08018725647894343" CI_START="-2.3598127435210565" EFFECT_SIZE="-1.22" ESTIMABLE="YES" MEAN_1="-2.96" MEAN_2="-1.74" ORDER="28806" SD_1="2.25" SD_2="2.95" SE="0.5815478001186521" STUDY_ID="STD-Godden-1997" TOTAL_1="44" TOTAL_2="39" WEIGHT="8.616617129075498"/>
<CONT_DATA CI_END="-1.2469980604654822" CI_START="-4.713001939534518" EFFECT_SIZE="-2.98" ESTIMABLE="YES" MEAN_1="-3.86" MEAN_2="-0.88" ORDER="28807" SD_1="3.19" SD_2="2.09" SE="0.8842009104270363" STUDY_ID="STD-Husby-1993" TOTAL_1="20" TOTAL_2="16" WEIGHT="4.4886844313129055"/>
<CONT_DATA CI_END="1.5573898808615243" CI_START="-1.3573898808615246" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="28808" SD_1="1.0" SD_2="1.88" SE="0.7435799292013678" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" WEIGHT="5.962601241712267"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.234115076940105" CI_END="-0.6506710188965045" CI_START="-1.62571743780591" DF="3" EFFECT_SIZE="-1.1381942283512072" ESTIMABLE="YES" I2="42.68372101299275" ID="CMP-001.04.02" NO="2" P_CHI2="0.15543520072072692" P_Z="4.743525002969834E-6" STUDIES="4" TAU2="0.10399594278268688" TOTAL_1="139" TOTAL_2="97" WEIGHT="57.27265462412679" Z="4.575822548991889">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="-0.3968914851805989" CI_START="-1.603108514819401" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.0" ORDER="28809" SD_1="1.08" SD_2="0.74" SE="0.3077140802467005" STUDY_ID="STD-Johnson-1996" TOTAL_1="17" TOTAL_2="21" WEIGHT="17.400527175422155"/>
<CONT_DATA CI_END="-0.7257779656861164" CI_START="-2.0742220343138835" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-1.4" ORDER="28810" SD_1="1.37" SD_2="1.4" SE="0.3439971548620591" STUDY_ID="STD-Johnson-1998a" TOTAL_1="47" TOTAL_2="25" WEIGHT="15.833190787200788"/>
<CONT_DATA CI_END="0.08435798935608385" CI_START="-1.2843579893560841" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.4" ORDER="28811" SD_1="1.39" SD_2="1.4" SE="0.34916865552337306" STUDY_ID="STD-Johnson-1998b" TOTAL_1="48" TOTAL_2="24" WEIGHT="15.619899810750253"/>
<CONT_DATA CI_END="-0.8412675045728173" CI_START="-3.1587324954271825" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-1.0" ORDER="28812" SD_1="1.93" SD_2="2.39" SE="0.5912009121428337" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="27" WEIGHT="8.419036850753582"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.7872546574065815" CI_END="-1.2709740730167303" CI_START="-2.421730162445121" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8463521177309257" ESTIMABLE="YES" I2="37.333603188237284" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2010-11-07 22:36:22 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.18805499378292723" P_Q="1.0" P_Z="3.186918290067858E-10" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.12843732252574858" TOTALS="YES" TOTAL_1="110" TOTAL_2="84" UNITS="" WEIGHT="100.0" Z="6.28940170167496">
<NAME>Westley score (change baseline - 12 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.7872546574065815" CI_END="-1.2709740730167303" CI_START="-2.421730162445121" DF="3" EFFECT_SIZE="-1.8463521177309257" ESTIMABLE="YES" I2="37.333603188237284" ID="CMP-001.05.01" NO="1" P_CHI2="0.18805499378292723" P_Z="3.186918290067858E-10" STUDIES="4" TAU2="0.12843732252574858" TOTAL_1="110" TOTAL_2="84" WEIGHT="100.0" Z="6.28940170167496">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="-0.4086132705099398" CI_START="-2.171386729490061" EFFECT_SIZE="-1.2900000000000003" ESTIMABLE="YES" MEAN_1="-2.24" MEAN_2="-0.95" ORDER="28813" SD_1="1.39" SD_2="1.4" SE="0.44969537014063854" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="27" TOTAL_2="15" WEIGHT="26.063003485562604"/>
<CONT_DATA CI_END="-1.0669881722807397" CI_START="-2.8730118277192602" EFFECT_SIZE="-1.97" ESTIMABLE="YES" MEAN_1="-2.92" MEAN_2="-0.95" ORDER="28814" SD_1="1.37" SD_2="1.4" SE="0.4607287862644938" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="23" TOTAL_2="15" WEIGHT="25.294589126756353"/>
<CONT_DATA CI_END="-0.29867975702421745" CI_START="-2.541320242975783" EFFECT_SIZE="-1.4200000000000002" ESTIMABLE="YES" MEAN_1="-3.41" MEAN_2="-1.99" ORDER="28815" SD_1="2.25" SD_2="2.95" SE="0.572112677488267" STUDY_ID="STD-Godden-1997" TOTAL_1="44" TOTAL_2="41" WEIGHT="18.909649789070222"/>
<CONT_DATA CI_END="-1.7125579307270298" CI_START="-3.28744206927297" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-1.0" ORDER="28816" SD_1="1.13" SD_2="1.03" SE="0.40176354029166494" STUDY_ID="STD-Super-1989" TOTAL_1="16" TOTAL_2="13" WEIGHT="29.732757598610817"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.178187689113106" CI_END="0.20876508312339626" CI_START="-2.7310869207956134" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2611609188361086" ESTIMABLE="YES" I2="82.10801199958486" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2010-11-07 22:36:34 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0037384205940104165" P_Q="1.0" P_Z="0.09264611184958552" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.3775093148582793" TOTALS="YES" TOTAL_1="57" TOTAL_2="53" UNITS="" WEIGHT="100.0" Z="1.681601642758281">
<NAME>Westley score (change baseline - 24 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.178187689113106" CI_END="0.20876508312339626" CI_START="-2.7310869207956134" DF="2" EFFECT_SIZE="-1.2611609188361086" ESTIMABLE="YES" I2="82.10801199958486" ID="CMP-001.06.01" NO="1" P_CHI2="0.0037384205940104165" P_Z="0.09264611184958552" STUDIES="3" TAU2="1.3775093148582793" TOTAL_1="57" TOTAL_2="53" WEIGHT="100.0" Z="1.681601642758281">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="-0.7649560046115345" CI_START="-3.295043995388465" EFFECT_SIZE="-2.03" ESTIMABLE="YES" MEAN_1="-4.14" MEAN_2="-2.11" ORDER="28817" SD_1="2.25" SD_2="2.95" SE="0.6454424700489249" STUDY_ID="STD-Godden-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="31.35067054535014"/>
<CONT_DATA CI_END="1.461892997130708" CI_START="-0.8618929971307083" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-2.4" ORDER="28818" SD_1="1.22" SD_2="1.22" SE="0.5928134426426056" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" WEIGHT="32.53236010119549"/>
<CONT_DATA CI_END="-1.1688486932611197" CI_START="-2.8311513067388803" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-1.5" ORDER="28819" SD_1="1.13" SD_2="1.03" SE="0.42406458143868747" STUDY_ID="STD-Super-1989" TOTAL_1="13" TOTAL_2="13" WEIGHT="36.11696935345436"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.59622097976322" CI_END="-0.8190924647761264" CI_START="-1.6182677577270503" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2186801112515884" ESTIMABLE="YES" I2="41.16012080189564" I2_Q="41.02399821876448" ID="CMP-001.07" MODIFIED="2010-11-07 22:45:55 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.09291609273928059" P_Q="0.18348844440269485" P_Z="2.2646975133097185E-9" Q="3.391209881298435" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1441841947477886" TOTALS="YES" TOTAL_1="262" TOTAL_2="190" UNITS="" WEIGHT="100.00000000000001" Z="5.9775850124412155">
<NAME>Westley score (change baseline - 6 hours) by glucocorticoid</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.841526556877916" CI_END="-0.6756285556179972" CI_START="-2.061753360841166" DF="4" EFFECT_SIZE="-1.3686909582295814" ESTIMABLE="YES" I2="54.75894378343117" ID="CMP-001.07.01" NO="1" P_CHI2="0.06518500191818544" P_Z="1.0855646853991793E-4" STUDIES="5" TAU2="0.3272185215141396" TOTAL_1="166" TOTAL_2="121" WEIGHT="49.14302546350723" Z="3.8706254645860616">
<NAME>Budesonide</NAME>
<CONT_DATA CI_END="-0.24861327050993942" CI_START="-2.0113867294900603" EFFECT_SIZE="-1.13" ESTIMABLE="YES" MEAN_1="-2.21" MEAN_2="-1.08" ORDER="28820" SD_1="1.39" SD_2="1.4" SE="0.44969537014063854" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="27" TOTAL_2="15" WEIGHT="11.998787241614975"/>
<CONT_DATA CI_END="-0.08018725647894343" CI_START="-2.3598127435210565" EFFECT_SIZE="-1.22" ESTIMABLE="YES" MEAN_1="-2.96" MEAN_2="-1.74" ORDER="28821" SD_1="2.25" SD_2="2.95" SE="0.5815478001186521" STUDY_ID="STD-Godden-1997" TOTAL_1="44" TOTAL_2="39" WEIGHT="8.6166171290755"/>
<CONT_DATA CI_END="-1.2469980604654822" CI_START="-4.713001939534518" EFFECT_SIZE="-2.98" ESTIMABLE="YES" MEAN_1="-3.86" MEAN_2="-0.88" ORDER="28822" SD_1="3.19" SD_2="2.09" SE="0.8842009104270363" STUDY_ID="STD-Husby-1993" TOTAL_1="20" TOTAL_2="16" WEIGHT="4.488684431312907"/>
<CONT_DATA CI_END="0.08435798935608385" CI_START="-1.2843579893560841" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.4" ORDER="28823" SD_1="1.39" SD_2="1.4" SE="0.34916865552337306" STUDY_ID="STD-Johnson-1998b" TOTAL_1="48" TOTAL_2="24" WEIGHT="15.61989981075026"/>
<CONT_DATA CI_END="-0.8412675045728173" CI_START="-3.1587324954271825" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-1.0" ORDER="28824" SD_1="1.93" SD_2="2.39" SE="0.5912009121428337" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="27" WEIGHT="8.419036850753583"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5929172040448218" CI_END="-0.8691632391448777" CI_START="-1.6739795726605853" DF="2" EFFECT_SIZE="-1.2715714059027314" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" MODIFIED="2010-05-21 03:00:25 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.45092321176739036" P_Z="5.891775120412556E-10" STUDIES="3" TAU2="0.0" TOTAL_1="87" TOTAL_2="61" WEIGHT="44.89437329478052" Z="6.193299155481604">
<NAME>Dexamethasone</NAME>
<CONT_DATA CI_END="-0.7469881722807395" CI_START="-2.5530118277192604" EFFECT_SIZE="-1.65" ESTIMABLE="YES" MEAN_1="-2.73" MEAN_2="-1.08" ORDER="28826" SD_1="1.37" SD_2="1.4" SE="0.4607287862644938" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="23" TOTAL_2="15" WEIGHT="11.660655332157567"/>
<CONT_DATA CI_END="-0.3968914851805989" CI_START="-1.603108514819401" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.0" ORDER="28827" SD_1="1.08" SD_2="0.74" SE="0.3077140802467005" STUDY_ID="STD-Johnson-1996" TOTAL_1="17" TOTAL_2="21" WEIGHT="17.40052717542216"/>
<CONT_DATA CI_END="-0.7257779656861164" CI_START="-2.0742220343138835" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-1.4" ORDER="28828" SD_1="1.37" SD_2="1.4" SE="0.3439971548620591" STUDY_ID="STD-Johnson-1998a" TOTAL_1="47" TOTAL_2="25" WEIGHT="15.833190787200795"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.5573898808615243" CI_START="-1.3573898808615246" DF="0" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" NO="3" P_CHI2="1.0" P_Z="0.8930194403877737" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="5.962601241712269" Z="0.13448453363635507">
<NAME>Fluticasone</NAME>
<CONT_DATA CI_END="1.5573898808615243" CI_START="-1.3573898808615246" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="28829" SD_1="1.0" SD_2="1.88" SE="0.7435799292013678" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" WEIGHT="5.962601241712269"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.787254657406582" CI_END="-1.2709740730167294" CI_START="-2.4217301624451206" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.846352117730925" ESTIMABLE="YES" I2="37.3336031882373" I2_Q="75.0227129188228" ID="CMP-001.08" MODIFIED="2010-11-07 22:36:56 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.18805499378292734" P_Q="0.04540226228656241" P_Z="3.1869182900678924E-10" Q="4.003637371624706" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.12843732252574866" TOTALS="YES" TOTAL_1="110" TOTAL_2="84" UNITS="" WEIGHT="99.99999999999999" Z="6.289401701674958">
<NAME>Westley score (change baseline - 12 hours) by glucocorticoid</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.03191456163393702" CI_END="-0.6467001402581297" CI_START="-2.032591425540993" DF="1" EFFECT_SIZE="-1.3396457828995614" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="0.8582153463305983" P_Z="1.511789849608737E-4" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="56" WEIGHT="44.97265327463282" Z="3.7891247522899354">
<NAME>Budesonide</NAME>
<CONT_DATA CI_END="-0.4086132705099398" CI_START="-2.171386729490061" EFFECT_SIZE="-1.2900000000000003" ESTIMABLE="YES" MEAN_1="-2.24" MEAN_2="-0.95" ORDER="28830" SD_1="1.39" SD_2="1.4" SE="0.44969537014063854" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="27" TOTAL_2="15" WEIGHT="26.0630034855626"/>
<CONT_DATA CI_END="-0.29867975702421745" CI_START="-2.541320242975783" EFFECT_SIZE="-1.4200000000000002" ESTIMABLE="YES" MEAN_1="-3.41" MEAN_2="-1.99" ORDER="28831" SD_1="2.25" SD_2="2.95" SE="0.572112677488267" STUDY_ID="STD-Godden-1997" TOTAL_1="44" TOTAL_2="41" WEIGHT="18.909649789070222"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7517027241479388" CI_END="-1.6775785491060051" CI_START="-2.8645523937311625" DF="1" EFFECT_SIZE="-2.271065471418584" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.38593770637791713" P_Z="6.37730472702638E-14" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="28" WEIGHT="55.02734672536717" Z="7.500092020845802">
<NAME>Dexamethasone</NAME>
<CONT_DATA CI_END="-1.0669881722807397" CI_START="-2.8730118277192602" EFFECT_SIZE="-1.97" ESTIMABLE="YES" MEAN_1="-2.92" MEAN_2="-0.95" ORDER="28832" SD_1="1.37" SD_2="1.4" SE="0.4607287862644938" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="23" TOTAL_2="15" WEIGHT="25.294589126756353"/>
<CONT_DATA CI_END="-1.7125579307270298" CI_START="-3.28744206927297" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-1.0" ORDER="28833" SD_1="1.13" SD_2="1.03" SE="0.40176354029166494" STUDY_ID="STD-Super-1989" TOTAL_1="16" TOTAL_2="13" WEIGHT="29.732757598610814"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.178187689113106" CI_END="0.20876508312339603" CI_START="-2.7310869207956134" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2611609188361086" ESTIMABLE="YES" I2="82.10801199958486" I2_Q="82.10801199958486" ID="CMP-001.09" MODIFIED="2010-11-07 22:37:08 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0037384205940104165" P_Q="0.0037384205940104165" P_Z="0.09264611184958546" Q="11.178187689113106" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.377509314858279" TOTALS="YES" TOTAL_1="57" TOTAL_2="53" UNITS="" WEIGHT="99.99999999999999" Z="1.6816016427582812">
<NAME>Westley score (change baseline - 24 hours) by glucocorticoid</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7649560046115347" CI_START="-3.2950439953884647" DF="0" EFFECT_SIZE="-2.03" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="1.0" P_Z="0.0016601346030416233" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="31.35067054535014" Z="3.145129262792585">
<NAME>Budesonide</NAME>
<CONT_DATA CI_END="-0.7649560046115345" CI_START="-3.295043995388465" EFFECT_SIZE="-2.03" ESTIMABLE="YES" MEAN_1="-4.14" MEAN_2="-2.11" ORDER="28834" SD_1="2.25" SD_2="2.95" SE="0.6454424700489249" STUDY_ID="STD-Godden-1997" TOTAL_1="35" TOTAL_2="32" WEIGHT="31.35067054535014"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1688486932611197" CI_START="-2.8311513067388803" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="1.0" P_Z="2.402161499208386E-6" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="36.11696935345436" Z="4.716262775860158">
<NAME>Dexamethasone</NAME>
<CONT_DATA CI_END="-1.1688486932611197" CI_START="-2.8311513067388803" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-1.5" ORDER="28835" SD_1="1.13" SD_2="1.03" SE="0.42406458143868747" STUDY_ID="STD-Super-1989" TOTAL_1="13" TOTAL_2="13" WEIGHT="36.11696935345436"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.461892997130708" CI_START="-0.8618929971307083" DF="0" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.03" NO="3" P_CHI2="1.0" P_Z="0.6128135497825267" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="32.53236010119549" Z="0.5060613987811733">
<NAME>Fluticasone</NAME>
<CONT_DATA CI_END="1.461892997130708" CI_START="-0.8618929971307083" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-2.4" ORDER="28836" SD_1="1.22" SD_2="1.22" SE="0.5928134426426056" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" WEIGHT="32.53236010119549"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="17.77498165534702" CI_END="0.7128625084928208" CI_START="0.33723189095288303" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49030599805473485" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="155" I2="49.367036351946695" I2_Q="53.736734569185025" ID="CMP-001.10" LOG_CI_END="-0.14699422549299537" LOG_CI_START="-0.47207136225025886" LOG_EFFECT_SIZE="-0.3095327938716271" METHOD="MH" MODIFIED="2010-11-07 22:37:22 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0378757770400493" P_Q="0.14150267984577214" P_Z="1.8959832485369407E-4" Q="2.161542188359928" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12561729781747538" TOTALS="YES" TOTAL_1="918" TOTAL_2="761" WEIGHT="100.0" Z="3.732487212568597">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3357945733271465" CI_END="0.6809467029470877" CI_START="0.06556443735359999" DF="2" EFFECT_SIZE="0.21129573456772568" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-0.16688687857442444" LOG_CI_START="-1.183331661371089" LOG_EFFECT_SIZE="-0.6751092699727567" MODIFIED="2010-10-02 03:11:53 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8454406952047251" P_Z="0.00922598643621568" STUDIES="3" TAU2="0.0" TOTAL_1="173" TOTAL_2="153" WEIGHT="8.975146817545111" Z="2.6035646543141926">
<NAME>Inpatient</NAME>
<DICH_DATA CI_END="1.4460445515565234" CI_START="0.05645237760714565" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.16018167345443104" LOG_CI_START="-1.2483177621549826" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="28837" O_E="0.0" SE="0.8273595406616217" STUDY_ID="STD-Geelhoed-1995-C_x0026_D" TOTAL_1="42" TOTAL_2="24" VAR="0.6845238095238095" WEIGHT="4.500775870985478"/>
<DICH_DATA CI_END="1.0329189383317927" CI_START="0.01750168255433071" EFFECT_SIZE="0.13445378151260504" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.014066240187036647" LOG_CI_START="-1.7569201976602487" LOG_EFFECT_SIZE="-0.871426978736606" ORDER="28838" O_E="0.0" SE="1.0402862001157474" STUDY_ID="STD-Roberts-1999" TOTAL_1="34" TOTAL_2="32" VAR="1.0821953781512605" WEIGHT="3.0188982286434416"/>
<DICH_DATA CI_END="4.112322554851963" CI_START="0.009726863461331753" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6140871717212555" LOG_CI_START="-2.012027180393293" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="28839" O_E="0.0" SE="1.5425925699077816" STUDY_ID="STD-Skowron-1966-A_x0026_B" TOTAL_1="97" TOTAL_2="97" VAR="2.379591836734694" WEIGHT="1.4554727179161902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.329320067602756" CI_END="0.7893280021521535" CI_START="0.3602911844131995" DF="6" EFFECT_SIZE="0.5332803397706537" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="142" I2="58.12781086825302" ID="CMP-001.10.02" LOG_CI_END="-0.10274248991673712" LOG_CI_START="-0.4433463640432387" LOG_EFFECT_SIZE="-0.27304442697998793" MODIFIED="2010-10-02 03:12:15 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.026166230518178568" P_Z="0.0016756747625212938" STUDIES="7" TAU2="0.12548231326565512" TOTAL_1="745" TOTAL_2="608" WEIGHT="91.02485318245489" Z="3.1424025603501713">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="0.7658479375607892" CI_START="0.3142334471074402" EFFECT_SIZE="0.49056603773584906" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="53" LOG_CI_END="-0.11585745286618546" LOG_CI_START="-0.5027475903937568" LOG_EFFECT_SIZE="-0.30930252162997107" MODIFIED="2010-10-02 03:12:13 +1000" MODIFIED_BY="[Empty name]" ORDER="28840" O_E="0.0" SE="0.22726118192076308" STUDY_ID="STD-Bjornson-2004" TOTAL_1="352" TOTAL_2="352" VAR="0.05164764480802217" WEIGHT="20.569569447910894"/>
<DICH_DATA CI_END="2.035451507772689" CI_START="0.030705717999831503" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.30866076028574596" LOG_CI_START="-1.5127807429416706" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-10-02 03:11:49 +1000" MODIFIED_BY="[Empty name]" ORDER="28841" O_E="0.0" SE="1.069923755276638" STUDY_ID="STD-Cruz-1995" TOTAL_1="19" TOTAL_2="19" VAR="1.1447368421052633" WEIGHT="2.8702732831939866"/>
<DICH_DATA CI_END="0.9913700440728749" CI_START="0.003490328997879615" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.003764208176887389" LOG_CI_START="-2.4571336345796606" LOG_EFFECT_SIZE="-1.2304489213782739" MODIFIED="2010-10-02 03:12:14 +1000" MODIFIED_BY="[Empty name]" ORDER="28842" O_E="0.0" SE="1.4411213454435117" STUDY_ID="STD-Geelhoed-1996a" TOTAL_1="48" TOTAL_2="48" VAR="2.0768307322929176" WEIGHT="1.6555503231703277"/>
<DICH_DATA CI_END="1.333787724735291" CI_START="0.5976917186797733" EFFECT_SIZE="0.8928571428571429" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.12508671615336542" LOG_CI_START="-0.2235227614937286" LOG_EFFECT_SIZE="-0.04921802267018159" MODIFIED="2010-10-02 03:11:48 +1000" MODIFIED_BY="[Empty name]" ORDER="28843" O_E="0.0" SE="0.20477493281464823" STUDY_ID="STD-Johnson-1996" TOTAL_1="28" TOTAL_2="25" VAR="0.0419327731092437" WEIGHT="21.762232196307863"/>
<DICH_DATA CI_END="0.6072318332801748" CI_START="0.30078094938864663" EFFECT_SIZE="0.42736842105263156" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="-0.21664546923455258" LOG_CI_START="-0.5217496741887547" LOG_EFFECT_SIZE="-0.3691975717116537" MODIFIED="2010-10-02 03:11:47 +1000" MODIFIED_BY="[Empty name]" ORDER="28844" O_E="0.0" SE="0.17921972028027053" STUDY_ID="STD-Johnson-1998-A_x0026_B" TOTAL_1="95" TOTAL_2="49" VAR="0.032119708137338415" WEIGHT="23.116094577449"/>
<DICH_DATA CI_END="1.0836545067538899" CI_START="0.018832721257662836" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.03489084149502887" LOG_CI_START="-1.7250869215235427" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2010-10-02 03:11:47 +1000" MODIFIED_BY="[Empty name]" ORDER="28845" O_E="0.0" SE="1.0338196500275416" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="27" VAR="1.0687830687830688" WEIGHT="3.0527984166590345"/>
<DICH_DATA CI_END="1.2440166340025214" CI_START="0.4192909676725012" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.09482618743455039" LOG_CI_START="-0.377484493027489" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2010-10-02 03:12:15 +1000" MODIFIED_BY="[Empty name]" ORDER="28846" O_E="0.0" SE="0.27743763167897656" STUDY_ID="STD-Luria-2001" TOTAL_1="176" TOTAL_2="88" VAR="0.07697163947163947" WEIGHT="17.998334937763783"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.06987001833939" CI_END="0.7006062048266637" CI_START="0.3582173315845601" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5009683474877362" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="153" I2="42.31738344613068" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.15452602072936203" LOG_CI_START="-0.4458534055627971" LOG_EFFECT_SIZE="-0.30018971314607956" METHOD="MH" MODIFIED="2010-11-07 22:46:39 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.059850845357130034" P_Q="0.5724352943019091" P_Z="5.363972096446582E-5" Q="0.31862495629504073" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10822683469481581" TOTALS="YES" TOTAL_1="918" TOTAL_2="763" WEIGHT="100.00000000000001" Z="4.039174186334172">
<NAME>Return visits and/or (re)admissions by glucocorticoid</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.263319173349441" CI_END="0.9241045892026505" CI_START="0.16772620375297" DF="3" EFFECT_SIZE="0.39369601803632504" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" I2="29.63229169532068" ID="CMP-001.11.01" LOG_CI_END="-0.034278872997377925" LOG_CI_START="-0.7753990825560044" LOG_EFFECT_SIZE="-0.40483897777669126" NO="1" P_CHI2="0.23439856533889125" P_Z="0.0322521446909149" STUDIES="4" TAU2="0.2646624927103464" TOTAL_1="131" TOTAL_2="97" WEIGHT="25.39443285143256" Z="2.141271566330316">
<NAME>Budesonide</NAME>
<DICH_DATA CI_END="11.792999994125225" CI_START="0.11843417413480936" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0716242983234043" LOG_CI_START="-0.9265229640261811" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="28847" O_E="0.0" SE="1.173721592892615" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="22" TOTAL_2="13" VAR="1.3776223776223777" WEIGHT="1.9708931781920902"/>
<DICH_DATA CI_END="0.8082788169704057" CI_START="0.3356111225676762" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="-0.0924388028585223" LOG_CI_START="-0.47416365454857684" LOG_EFFECT_SIZE="-0.28330122870354957" ORDER="28848" O_E="0.0" SE="0.2242270674512285" STUDY_ID="STD-Johnson-1998b" TOTAL_1="48" TOTAL_2="25" VAR="0.050277777777777775" WEIGHT="18.47548806748065"/>
<DICH_DATA CI_END="1.0836545067538899" CI_START="0.018832721257662836" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.03489084149502887" LOG_CI_START="-1.7250869215235427" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="28849" O_E="0.0" SE="1.0338196500275416" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="27" VAR="1.0687830687830688" WEIGHT="2.4880420017919342"/>
<DICH_DATA CI_END="1.0329189383317927" CI_START="0.01750168255433071" EFFECT_SIZE="0.13445378151260504" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.014066240187036647" LOG_CI_START="-1.7569201976602487" LOG_EFFECT_SIZE="-0.871426978736606" ORDER="28850" O_E="0.0" SE="1.0402862001157474" STUDY_ID="STD-Roberts-1999" TOTAL_1="34" TOTAL_2="32" VAR="1.0821953781512605" WEIGHT="2.460009603967883"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.382484939506677" CI_END="0.7899179199134616" CI_START="0.3395321107457704" DF="7" EFFECT_SIZE="0.5178827074387848" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="120" I2="51.32969004005714" ID="CMP-001.11.02" LOG_CI_END="-0.10241803374832234" LOG_CI_START="-0.46911914668469107" LOG_EFFECT_SIZE="-0.28576859021650675" NO="2" P_CHI2="0.04478197097321002" P_Z="0.002252234899417169" STUDIES="8" TAU2="0.14181525783225432" TOTAL_1="787" TOTAL_2="666" WEIGHT="74.60556714856746" Z="3.0547829007234473">
<NAME>Dexamethasone</NAME>
<DICH_DATA CI_END="0.7658479375607892" CI_START="0.3142334471074402" EFFECT_SIZE="0.49056603773584906" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="53" LOG_CI_END="-0.11585745286618546" LOG_CI_START="-0.5027475903937568" LOG_EFFECT_SIZE="-0.30930252162997107" ORDER="28851" O_E="0.0" SE="0.22726118192076308" STUDY_ID="STD-Bjornson-2004" TOTAL_1="352" TOTAL_2="352" VAR="0.05164764480802217" WEIGHT="18.317182864236088"/>
<DICH_DATA CI_END="2.035451507772689" CI_START="0.030705717999831503" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.30866076028574596" LOG_CI_START="-1.5127807429416706" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="28852" O_E="0.0" SE="1.069923755276638" STUDY_ID="STD-Cruz-1995" TOTAL_1="19" TOTAL_2="19" VAR="1.1447368421052633" WEIGHT="2.3372186525446312"/>
<DICH_DATA CI_END="5.0747263058569505" CI_START="0.009731109240785676" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7054126245042007" LOG_CI_START="-2.011837652054888" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="28853" O_E="0.0" SE="1.5961262630566064" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="20" TOTAL_2="13" VAR="2.5476190476190474" WEIGHT="1.1026430772506584"/>
<DICH_DATA CI_END="0.9913700440728749" CI_START="0.003490328997879615" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.003764208176887389" LOG_CI_START="-2.4571336345796606" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="28854" O_E="0.0" SE="1.4411213454435117" STUDY_ID="STD-Geelhoed-1996a" TOTAL_1="48" TOTAL_2="48" VAR="2.0768307322929176" WEIGHT="1.3402164412606927"/>
<DICH_DATA CI_END="1.333787724735291" CI_START="0.5976917186797733" EFFECT_SIZE="0.8928571428571429" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.12508671615336542" LOG_CI_START="-0.2235227614937286" LOG_EFFECT_SIZE="-0.04921802267018159" ORDER="28855" O_E="0.0" SE="0.20477493281464823" STUDY_ID="STD-Johnson-1996" TOTAL_1="28" TOTAL_2="25" VAR="0.0419327731092437" WEIGHT="19.50224910149824"/>
<DICH_DATA CI_END="0.5886015590566753" CI_START="0.1854782061668827" EFFECT_SIZE="0.3304130162703379" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="-0.23017859189863288" LOG_CI_START="-0.7317071129896877" LOG_EFFECT_SIZE="-0.48094285244416035" ORDER="28856" O_E="0.0" SE="0.294600335895104" STUDY_ID="STD-Johnson-1998a" TOTAL_1="47" TOTAL_2="24" VAR="0.08678935790950809" WEIGHT="15.016445748788135"/>
<DICH_DATA CI_END="1.2440166340025214" CI_START="0.4192909676725012" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.09482618743455039" LOG_CI_START="-0.377484493027489" LOG_EFFECT_SIZE="-0.14132915279646932" ORDER="28857" O_E="0.0" SE="0.27743763167897656" STUDY_ID="STD-Luria-2001" TOTAL_1="176" TOTAL_2="88" VAR="0.07697163947163947" WEIGHT="15.812495699861836"/>
<DICH_DATA CI_END="4.112322554851963" CI_START="0.009726863461331753" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6140871717212555" LOG_CI_START="-2.012027180393293" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="28858" O_E="0.0" SE="1.5425925699077816" STUDY_ID="STD-Skowron-1966-A_x0026_B" TOTAL_1="97" TOTAL_2="97" VAR="2.379591836734694" WEIGHT="1.177115563127175"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.069870018339394" CI_END="0.7006062048266637" CI_START="0.35821733158456015" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5009683474877363" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="153" I2="42.31738344613069" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.15452602072936203" LOG_CI_START="-0.445853405562797" LOG_EFFECT_SIZE="-0.30018971314607945" METHOD="MH" MODIFIED="2010-11-07 22:49:03 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.059850845357130145" P_Q="0.6666283146157037" P_Z="5.3639720964466024E-5" Q="0.1855714502053476" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10822683469481587" TOTALS="YES" TOTAL_1="918" TOTAL_2="763" WEIGHT="99.99999999999999" Z="4.039174186334171">
<NAME>Return visits and/or (re)admissions by croup severity</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.820507716901251" CI_END="0.9490286003172237" CI_START="0.30414712166013497" DF="2" EFFECT_SIZE="0.5372562862914033" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="79" I2="47.650936781193934" ID="CMP-001.12.01" LOG_CI_END="-0.02272069929790494" LOG_CI_START="-0.5169162891896668" LOG_EFFECT_SIZE="-0.26981849424378584" MODIFIED="2010-11-07 22:48:59 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14804292387667362" P_Z="0.032339970340980365" STUDIES="3" TAU2="0.11188921744669497" TOTAL_1="576" TOTAL_2="488" WEIGHT="35.46989500535861" Z="2.1401831254563524">
<NAME>Mild croup</NAME>
<DICH_DATA CI_END="0.7658479375607892" CI_START="0.3142334471074402" EFFECT_SIZE="0.49056603773584906" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="53" LOG_CI_END="-0.11585745286618546" LOG_CI_START="-0.5027475903937568" LOG_EFFECT_SIZE="-0.30930252162997107" MODIFIED="2010-10-02 03:31:02 +1000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.22726118192076308" STUDY_ID="STD-Bjornson-2004" TOTAL_1="352" TOTAL_2="352" VAR="0.05164764480802217" WEIGHT="18.31718286423608"/>
<DICH_DATA CI_END="0.9913700440728749" CI_START="0.003490328997879615" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.003764208176887389" LOG_CI_START="-2.4571336345796606" LOG_EFFECT_SIZE="-1.2304489213782739" MODIFIED="2010-10-02 03:31:08 +1000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="1.4411213454435117" STUDY_ID="STD-Geelhoed-1996a" TOTAL_1="48" TOTAL_2="48" VAR="2.0768307322929176" WEIGHT="1.3402164412606925"/>
<DICH_DATA CI_END="1.2440166340025214" CI_START="0.4192909676725012" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.09482618743455039" LOG_CI_START="-0.377484493027489" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2010-10-02 03:31:15 +1000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.27743763167897656" STUDY_ID="STD-Luria-2001" TOTAL_1="176" TOTAL_2="88" VAR="0.07697163947163947" WEIGHT="15.812495699861831"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.808666266977829" CI_END="0.7455574188103531" CI_START="0.27806183566921133" DF="8" EFFECT_SIZE="0.45531424804326714" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="74" I2="49.39484542911175" ID="CMP-001.12.02" LOG_CI_END="-0.12751890390484963" LOG_CI_START="-0.5558586145002933" LOG_EFFECT_SIZE="-0.3416887592025714" MODIFIED="2010-11-07 22:49:03 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04520209015684207" P_Z="0.0017663211568317236" STUDIES="9" TAU2="0.19023906546103542" TOTAL_1="342" TOTAL_2="275" WEIGHT="64.53010499464138" Z="3.12694641843157">
<NAME>Moderate croup</NAME>
<DICH_DATA CI_END="2.035451507772689" CI_START="0.030705717999831503" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.30866076028574596" LOG_CI_START="-1.5127807429416706" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2010-10-02 03:44:08 +1000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.069923755276638" STUDY_ID="STD-Cruz-1995" TOTAL_1="19" TOTAL_2="19" VAR="1.1447368421052633" WEIGHT="2.3372186525446312"/>
<DICH_DATA CI_END="11.792999994125225" CI_START="0.11843417413480936" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0716242983234043" LOG_CI_START="-0.9265229640261811" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2010-10-02 03:43:10 +1000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.173721592892615" STUDY_ID="STD-Geelhoed-1995c" TOTAL_1="22" TOTAL_2="13" VAR="1.3776223776223777" WEIGHT="1.9708931781920902"/>
<DICH_DATA CI_END="5.0747263058569505" CI_START="0.009731109240785676" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7054126245042007" LOG_CI_START="-2.011837652054888" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2010-10-02 03:44:34 +1000" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="1.5961262630566064" STUDY_ID="STD-Geelhoed-1995d" TOTAL_1="20" TOTAL_2="13" VAR="2.5476190476190474" WEIGHT="1.1026430772506584"/>
<DICH_DATA CI_END="1.333787724735291" CI_START="0.5976917186797733" EFFECT_SIZE="0.8928571428571429" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.12508671615336542" LOG_CI_START="-0.2235227614937286" LOG_EFFECT_SIZE="-0.04921802267018159" MODIFIED="2010-10-02 03:44:46 +1000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.20477493281464823" STUDY_ID="STD-Johnson-1996" TOTAL_1="28" TOTAL_2="25" VAR="0.0419327731092437" WEIGHT="19.50224910149823"/>
<DICH_DATA CI_END="0.5886015590566753" CI_START="0.1854782061668827" EFFECT_SIZE="0.3304130162703379" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="-0.23017859189863288" LOG_CI_START="-0.7317071129896877" LOG_EFFECT_SIZE="-0.48094285244416035" MODIFIED="2010-10-02 03:45:00 +1000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.294600335895104" STUDY_ID="STD-Johnson-1998a" TOTAL_1="47" TOTAL_2="24" VAR="0.08678935790950809" WEIGHT="15.01644574878813"/>
<DICH_DATA CI_END="0.8082788169704057" CI_START="0.3356111225676762" EFFECT_SIZE="0.5208333333333334" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="-0.0924388028585223" LOG_CI_START="-0.47416365454857684" LOG_EFFECT_SIZE="-0.28330122870354957" MODIFIED="2010-10-02 03:43:28 +1000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.2242270674512285" STUDY_ID="STD-Johnson-1998b" TOTAL_1="48" TOTAL_2="25" VAR="0.050277777777777775" WEIGHT="18.475488067480644"/>
<DICH_DATA CI_END="1.0836545067538899" CI_START="0.018832721257662836" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.03489084149502887" LOG_CI_START="-1.7250869215235427" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2010-10-02 03:43:43 +1000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="1.0338196500275416" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="27" VAR="1.0687830687830688" WEIGHT="2.4880420017919342"/>
<DICH_DATA CI_END="1.0329189383317927" CI_START="0.01750168255433071" EFFECT_SIZE="0.13445378151260504" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.014066240187036647" LOG_CI_START="-1.7569201976602487" LOG_EFFECT_SIZE="-0.871426978736606" MODIFIED="2010-10-02 03:43:57 +1000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="1.0402862001157474" STUDY_ID="STD-Roberts-1999" TOTAL_1="34" TOTAL_2="32" VAR="1.0821953781512605" WEIGHT="2.460009603967883"/>
<DICH_DATA CI_END="4.112322554851963" CI_START="0.009726863461331753" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6140871717212555" LOG_CI_START="-2.012027180393293" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-10-02 03:45:12 +1000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="1.5425925699077816" STUDY_ID="STD-Skowron-1966-A_x0026_B" TOTAL_1="97" TOTAL_2="97" VAR="2.379591836734694" WEIGHT="1.1771155631271748"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="22.052090702488016" CI_END="-4.915017651612815" CI_START="-18.540170224224436" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.727593937918625" ESTIMABLE="YES" I2="63.72226058775732" I2_Q="40.44178928779474" ID="CMP-001.13" MODIFIED="2010-11-07 22:46:39 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.004820284750175041" P_Q="0.1950535214375524" P_Z="7.408320811941525E-4" Q="1.6790296216791316" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="48.32958945705011" TOTALS="YES" TOTAL_1="427" TOTAL_2="398" UNITS="" WEIGHT="100.0" Z="3.374004308742205">
<NAME>Length of stay by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Favours Glucocort.</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="18.067649034766383" CI_END="-3.362681726970319" CI_START="-17.305678645702372" DF="7" EFFECT_SIZE="-10.334180186336345" ESTIMABLE="YES" I2="61.25671919722171" ID="CMP-001.13.01" NO="1" P_CHI2="0.011668499309401725" P_Z="0.0036684634646725416" STUDIES="8" TAU2="42.56239762994797" TOTAL_1="411" TOTAL_2="384" WEIGHT="88.31910418018775" Z="2.905346833686108">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="-1.0094713776029423" CI_START="-13.91052862239706" EFFECT_SIZE="-7.460000000000001" ESTIMABLE="YES" MEAN_1="12.54" MEAN_2="20.0" ORDER="28859" SD_1="14.66" SD_2="14.0" SE="3.291146507424629" STUDY_ID="STD-Geelhoed-1995-C_x0026_D" TOTAL_1="50" TOTAL_2="30" WEIGHT="20.42158023698045"/>
<CONT_DATA CI_END="-0.4804883166535774" CI_START="-37.51951168334642" EFFECT_SIZE="-19.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="55.0" ORDER="28860" SD_1="44.5" SD_2="44.5" SE="9.448904076516694" STUDY_ID="STD-Godden-1997" TOTAL_1="47" TOTAL_2="42" WEIGHT="8.779549506343033"/>
<CONT_DATA CI_END="-21.513643343093186" CI_START="-62.486356656906814" EFFECT_SIZE="-42.0" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="91.0" ORDER="28861" SD_1="23.0" SD_2="40.0" SE="10.452414849711822" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="21" WEIGHT="7.666875445428568"/>
<CONT_DATA CI_END="21.942683564223557" CI_START="-12.342683564223563" EFFECT_SIZE="4.799999999999997" ESTIMABLE="YES" MEAN_1="62.4" MEAN_2="57.6" ORDER="28862" SD_1="18.0" SD_2="18.0" SE="8.74642784226795" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" WEIGHT="9.678521802768135"/>
<CONT_DATA CI_END="3.616115038784784" CI_START="-36.81611503878479" EFFECT_SIZE="-16.6" ESTIMABLE="YES" MEAN_1="38.4" MEAN_2="55.0" ORDER="28863" SD_1="51.2" SD_2="51.2" SE="10.31453393952487" STUDY_ID="STD-Skowron-1966a" TOTAL_1="56" TOTAL_2="44" WEIGHT="7.808765197777952"/>
<CONT_DATA CI_END="7.341487131751901" CI_START="-33.341487131751904" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="61.0" ORDER="28864" SD_1="49.9" SD_2="49.9" SE="10.3785004684795" STUDY_ID="STD-Skowron-1966b" TOTAL_1="41" TOTAL_2="53" WEIGHT="7.742525945172613"/>
<CONT_DATA CI_END="62.55967854130849" CI_START="-33.75967854130848" EFFECT_SIZE="14.400000000000006" ESTIMABLE="YES" MEAN_1="86.4" MEAN_2="72.0" ORDER="28865" SD_1="84.0" SD_2="46.0" SE="24.571716072941076" STUDY_ID="STD-Super-1989" TOTAL_1="16" TOTAL_2="13" WEIGHT="1.8527343796932747"/>
<CONT_DATA CI_END="-3.1093010429878363" CI_START="-7.490698957012166" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="12.3" ORDER="28866" SD_1="6.63" SD_2="13.15" SE="1.1177240879384103" STUDY_ID="STD-von-Muhlendahl-1982" TOTAL_1="176" TOTAL_2="173" WEIGHT="24.368551666023727"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.451133177076404" CI_START="-35.5488668229236" DF="0" EFFECT_SIZE="-21.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="1.0" P_Z="0.004668869071199932" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="11.680895819812243" Z="2.829034327985565">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="-6.4511331770764055" CI_START="-35.54886682292359" EFFECT_SIZE="-21.0" ESTIMABLE="YES" MEAN_1="34.4" MEAN_2="55.4" ORDER="28867" SD_1="17.7" SD_2="22.3" SE="7.423027636060254" STUDY_ID="STD-Leipzig-1979" TOTAL_1="16" TOTAL_2="14" WEIGHT="11.680895819812243"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.773988226216841" CI_END="1.7675803149687304" CI_START="1.1432699158443285" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.421555977773085" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="84" I2="26.188238995620218" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.2473791563050211" LOG_CI_START="0.05814877555978953" LOG_EFFECT_SIZE="0.1527639659324053" METHOD="MH" MODIFIED="2010-11-07 22:38:02 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.2379990530164766" P_Q="0.5520998608040822" P_Z="0.001553378057342806" Q="0.35356914599519984" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.019082604692019917" TOTALS="YES" TOTAL_1="239" TOTAL_2="182" WEIGHT="100.00000000000001" Z="3.164522210269486">
<NAME>Improvement (at 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glucocort.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.158089418527639" CI_END="1.929250840838467" CI_START="0.9503423120748131" DF="3" EFFECT_SIZE="1.3540490037863129" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="51" I2="51.28359145006892" ID="CMP-001.14.01" LOG_CI_END="0.28538869820353946" LOG_CI_START="-0.02211993421890986" LOG_EFFECT_SIZE="0.13163438199231484" NO="1" P_CHI2="0.10416717048815194" P_Z="0.09334848903011715" STUDIES="4" TAU2="0.06543675112792212" TOTAL_1="117" TOTAL_2="107" WEIGHT="61.723364798109905" Z="1.6779928797425852">
<NAME>Inpatient</NAME>
<DICH_DATA CI_END="1.4627070635714547" CI_START="0.6836638893083112" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.165157358652405" LOG_CI_START="-0.165157358652405" LOG_EFFECT_SIZE="0.0" ORDER="28868" O_E="0.0" SE="0.19402850002906635" STUDY_ID="STD-Eden-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.0376470588235294" WEIGHT="21.779440700941144"/>
<DICH_DATA CI_END="1.9718090886128539" CI_START="0.5071484890575736" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.2948648640658332" LOG_CI_START="-0.2948648640658331" LOG_EFFECT_SIZE="0.0" ORDER="28869" O_E="0.0" SE="0.34641016151377546" STUDY_ID="STD-Eden-1967" TOTAL_1="25" TOTAL_2="25" VAR="0.12" WEIGHT="8.883500170687713"/>
<DICH_DATA CI_END="3.5437328647772333" CI_START="1.0651744986393905" EFFECT_SIZE="1.9428571428571428" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.5494609762720617" LOG_CI_START="0.02742076043985964" LOG_EFFECT_SIZE="0.28844086835596067" ORDER="28870" O_E="0.0" SE="0.30664900692058034" STUDY_ID="STD-Massicotte-1973" TOTAL_1="25" TOTAL_2="17" VAR="0.09403361344537813" WEIGHT="10.922751510490617"/>
<DICH_DATA CI_END="2.5985554025429116" CI_START="1.1606865880921564" EFFECT_SIZE="1.7366946778711485" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="17" LOG_CI_END="0.41473198064018346" LOG_CI_START="0.0647149661319379" LOG_EFFECT_SIZE="0.2397234733860607" ORDER="28871" O_E="0.0" SE="0.20560172693430842" STUDY_ID="STD-Roberts-1999" TOTAL_1="42" TOTAL_2="40" VAR="0.04227207011836993" WEIGHT="20.137672415990433"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.602118645147866E-4" CI_END="2.0311503150422285" CI_START="1.1827993875904361" DF="1" EFFECT_SIZE="1.5499817252910013" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="33" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.30774206450661434" LOG_CI_START="0.07291109099259617" LOG_EFFECT_SIZE="0.1903265777496052" NO="2" P_CHI2="0.9766019053436286" P_Z="0.0014878852479907189" STUDIES="2" TAU2="0.0" TOTAL_1="122" TOTAL_2="75" WEIGHT="38.27663520189011" Z="3.1770360792523014">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="2.0748497511419424" CI_START="1.153986706340123" EFFECT_SIZE="1.5473684210526315" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="25" LOG_CI_END="0.31698665304208323" LOG_CI_START="0.062200805876573416" LOG_EFFECT_SIZE="0.18959372945932831" ORDER="28872" O_E="0.0" SE="0.14966246783530443" STUDY_ID="STD-Johnson-1998-A_x0026_B" TOTAL_1="95" TOTAL_2="49" VAR="0.022398854278553534" WEIGHT="29.785363706655808"/>
<DICH_DATA CI_END="3.1413626113033852" CI_START="0.7794851176534358" EFFECT_SIZE="1.5648148148148149" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.4971180704318468" LOG_CI_START="-0.10819217217839906" LOG_EFFECT_SIZE="0.19446294912672385" ORDER="28873" O_E="0.0" SE="0.3555622328432836" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="26" VAR="0.12642450142450143" WEIGHT="8.491271495234303"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.319466022185765" CI_END="1.6053316087039686" CI_START="1.0819104786069134" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3178865994825644" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="99" I2="51.547880585579456" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.20556475696194618" LOG_CI_START="0.03419132707788047" LOG_EFFECT_SIZE="0.11987804201991335" METHOD="MH" MODIFIED="2010-11-07 22:38:10 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.06667319079407485" P_Q="1.0" P_Z="0.006105837395459889" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.029573605922872222" TOTALS="YES" TOTAL_1="178" TOTAL_2="162" WEIGHT="99.99999999999999" Z="2.7420428599130897">
<NAME>Improvement (at 12 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Glucocorticoids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glucocort.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.319466022185765" CI_END="1.6053316087039686" CI_START="1.0819104786069134" DF="5" EFFECT_SIZE="1.3178865994825644" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="99" I2="51.547880585579456" ID="CMP-001.15.01" LOG_CI_END="0.20556475696194618" LOG_CI_START="0.03419132707788047" LOG_EFFECT_SIZE="0.11987804201991335" NO="1" P_CHI2="0.06667319079407485" P_Z="0.006105837395459889" STUDIES="6" TAU2="0.029573605922872222" TOTAL_1="178" TOTAL_2="162" WEIGHT="99.99999999999999" Z="2.7420428599130897">
<NAME>Inpatient</NAME>
<DICH_DATA CI_END="1.2737218521439448" CI_START="0.7851007645953372" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.10507459968876369" LOG_CI_START="-0.10507459968876365" LOG_EFFECT_SIZE="0.0" ORDER="28874" O_E="0.0" SE="0.1234426799696735" STUDY_ID="STD-Eden-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.015238095238095231" WEIGHT="22.613654396955752"/>
<DICH_DATA CI_END="1.6409440107198088" CI_START="0.8434675625377149" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.2150937631065617" LOG_CI_START="-0.07393161453514713" LOG_EFFECT_SIZE="0.07058107428570728" ORDER="28875" O_E="0.0" SE="0.16977493752543307" STUDY_ID="STD-Eden-1967" TOTAL_1="25" TOTAL_2="25" VAR="0.0288235294117647" WEIGHT="17.352843032228844"/>
<DICH_DATA CI_END="2.388587086200282" CI_START="1.170703457558322" EFFECT_SIZE="1.6722222222222223" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="20" LOG_CI_END="0.37814107997849317" LOG_CI_START="0.06844690100258145" LOG_EFFECT_SIZE="0.2232939904905373" ORDER="28876" O_E="0.0" SE="0.18191589374136052" STUDY_ID="STD-James-1969" TOTAL_1="45" TOTAL_2="43" VAR="0.03309339239571797" WEIGHT="16.170494042845615"/>
<DICH_DATA CI_END="1.867480317300011" CI_START="0.9904254319928459" EFFECT_SIZE="1.36" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.2712560331738936" LOG_CI_START="-0.0041782164334584525" LOG_EFFECT_SIZE="0.13353890837021754" ORDER="28877" O_E="0.0" SE="0.1617914416408831" STUDY_ID="STD-Massicotte-1973" TOTAL_1="25" TOTAL_2="17" VAR="0.026176470588235287" WEIGHT="18.17677008554204"/>
<DICH_DATA CI_END="1.796408774372892" CI_START="1.0469868291459365" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="25" LOG_CI_END="0.2544051676623443" LOG_CI_START="0.019941218388278927" LOG_EFFECT_SIZE="0.13717319302531158" ORDER="28878" O_E="0.0" SE="0.13772528441885304" STUDY_ID="STD-Roberts-1999" TOTAL_1="42" TOTAL_2="40" VAR="0.01896825396825396" WEIGHT="20.87592698892504"/>
<DICH_DATA CI_END="5.612681287639063" CI_START="1.0585682574004147" EFFECT_SIZE="2.4375" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.7491703817975278" LOG_CI_START="0.02471886694362092" LOG_EFFECT_SIZE="0.3869446243705744" ORDER="28879" O_E="0.0" SE="0.42554640591801923" STUDY_ID="STD-Super-1989" TOTAL_1="16" TOTAL_2="12" VAR="0.1810897435897436" WEIGHT="4.8103114535027025"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.354402760070676" CI_END="1.4503132967383132" CI_START="1.06177478227323" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2409295245388807" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="70" I2="31.10421416434829" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.16146182868146947" LOG_CI_START="0.026032406398208092" LOG_EFFECT_SIZE="0.09374711753983873" METHOD="MH" MODIFIED="2010-11-07 22:38:17 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.22565094361516114" P_Q="1.0" P_Z="0.006658515847253884" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.007754123906070671" TOTALS="YES" TOTAL_1="108" TOTAL_2="97" WEIGHT="100.0" Z="2.7134572522685403">
<NAME>Improvement (at 24 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Glucocorticods</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glucocort.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.354402760070676" CI_END="1.4503132967383132" CI_START="1.06177478227323" DF="3" EFFECT_SIZE="1.2409295245388807" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="70" I2="31.10421416434829" ID="CMP-001.16.01" LOG_CI_END="0.16146182868146947" LOG_CI_START="0.026032406398208092" LOG_EFFECT_SIZE="0.09374711753983873" NO="1" P_CHI2="0.22565094361516114" P_Z="0.006658515847253884" STUDIES="4" TAU2="0.007754123906070671" TOTAL_1="108" TOTAL_2="97" WEIGHT="100.0" Z="2.7134572522685403">
<NAME>Inpatient</NAME>
<DICH_DATA CI_END="1.3804344217129263" CI_START="0.9461676907178801" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.14001578007004198" LOG_CI_START="-0.0240318861146685" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="28880" O_E="0.0" SE="0.09636241116594309" STUDY_ID="STD-Eden-1967" TOTAL_1="25" TOTAL_2="25" VAR="0.009285714285714272" WEIGHT="37.139477478612704"/>
<DICH_DATA CI_END="1.519410696919528" CI_START="1.035226374914145" EFFECT_SIZE="1.2541666666666667" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="32" LOG_CI_END="0.18167517958884752" LOG_CI_START="0.015035328175627131" LOG_EFFECT_SIZE="0.09835525388223733" ORDER="28881" O_E="0.0" SE="0.09788507360069364" STUDY_ID="STD-James-1969" TOTAL_1="45" TOTAL_2="43" VAR="0.00958148763381321" WEIGHT="36.5058184020222"/>
<DICH_DATA CI_END="1.6536715067323253" CI_START="0.953025148058912" EFFECT_SIZE="1.2553846153846153" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.21844924343770725" LOG_CI_START="-0.02089563921569616" LOG_EFFECT_SIZE="0.09877680211100555" ORDER="28882" O_E="0.0" SE="0.1405923688468861" STUDY_ID="STD-Massicotte-1973" TOTAL_1="25" TOTAL_2="17" VAR="0.019766214177978872" WEIGHT="22.995745358586063"/>
<DICH_DATA CI_END="5.8392754487303495" CI_START="1.10352509293762" EFFECT_SIZE="2.5384615384615383" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.7663589621569414" LOG_CI_START="0.042782212985160065" LOG_EFFECT_SIZE="0.4045705875710507" ORDER="28883" O_E="0.0" SE="0.4250325642261787" STUDY_ID="STD-Super-1989" TOTAL_1="13" TOTAL_2="12" VAR="0.1806526806526807" WEIGHT="3.3589587607790357"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="84.53662120083568" CI_END="0.007910154279447645" CI_START="-0.01491659629348217" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0035032210070172626" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="140" I2="71.60993702009614" I2_Q="22.836567353002067" ID="CMP-001.17" LOG_CI_END="-2.101815045951202" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-11-07 22:38:23 +1000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.1337886296480804E-8" P_Q="0.26895284587731827" P_Z="0.5474462405223559" Q="5.183802563966964" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.002655731377263903" TOTALS="SUB" TOTAL_1="1080" TOTAL_2="902" WEIGHT="500.0" Z="0.60159127613902">
<NAME>Additional treatments</NAME>
<GROUP_LABEL_1>Glucocorticoids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucocort.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.271226328289058" CI_END="0.010109222168096276" CI_START="-0.013174275345920411" DF="10" EFFECT_SIZE="-0.0015325265889120673" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="-1.9952822589588757" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.9342831003518901" P_Z="0.7963985717940978" STUDIES="11" TAU2="0.0" TOTAL_1="584" TOTAL_2="505" WEIGHT="99.99999999999999" Z="0.25801080080940975">
<NAME>Intubation/tracheostomy</NAME>
<DICH_DATA CI_END="0.0746548727053014" CI_START="-0.0746548727053014" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28884" O_E="0.0" SE="0.038089920679241815" STUDY_ID="STD-Eden-1967" TOTAL_1="25" TOTAL_2="25" VAR="0.0014508420573509332" WEIGHT="2.431756729218696"/>
<DICH_DATA CI_END="0.051938996722906555" CI_START="-0.051938996722906555" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28885" O_E="0.0" SE="0.026499975067192424" STUDY_ID="STD-Geelhoed-1995-C_x0026_D" TOTAL_1="50" TOTAL_2="30" VAR="7.022486785618201E-4" WEIGHT="5.023996546667827"/>
<DICH_DATA CI_END="0.030007402152662233" CI_START="-0.1325715047167648" EFFECT_SIZE="-0.05128205128205128" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28886" O_E="0.0" SE="0.04147497304844086" STUDY_ID="STD-Godden-1997" TOTAL_1="43" TOTAL_2="39" VAR="0.0017201733893688956" WEIGHT="2.0510112281710344"/>
<DICH_DATA CI_END="0.043343845210409016" CI_START="-0.043343845210409016" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28887" O_E="0.0" SE="0.022114613101209886" STUDY_ID="STD-James-1969" TOTAL_1="45" TOTAL_2="43" VAR="4.890561126162039E-4" WEIGHT="7.214090254639898"/>
<DICH_DATA CI_END="0.18474695595348345" CI_START="-0.041889813096340614" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28888" O_E="0.0" SE="0.05781656470157258" STUDY_ID="STD-Johnson-1996" TOTAL_1="28" TOTAL_2="27" VAR="0.0033427551538911283" WEIGHT="1.055445216168392"/>
<DICH_DATA CI_END="0.031111667333254957" CI_START="-0.031111667333254957" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28889" O_E="0.0" SE="0.01587359134078984" STUDY_ID="STD-Johnson-1998-A_x0026_B" TOTAL_1="95" TOTAL_2="49" VAR="2.5197090205439815E-4" WEIGHT="14.001993512865809"/>
<DICH_DATA CI_END="0.10032532593431856" CI_START="-0.2431824687914614" EFFECT_SIZE="-0.07142857142857142" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28890" O_E="0.0" SE="0.0876311497138023" STUDY_ID="STD-Leipzig-1979" TOTAL_1="16" TOTAL_2="14" VAR="0.007679218400162833" WEIGHT="0.45943411844124893"/>
<DICH_DATA CI_END="0.20159926948921522" CI_START="-0.20159926948921522" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28891" O_E="0.0" SE="0.1028586601995774" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" VAR="0.010579903978052127" WEIGHT="0.33347135695329716"/>
<DICH_DATA CI_END="0.039037919814456916" CI_START="-0.039037919814456916" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28892" O_E="0.0" SE="0.019917672019681507" STUDY_ID="STD-Skowron-1966a" TOTAL_1="56" TOTAL_2="44" VAR="3.9671365868360357E-4" WEIGHT="8.893303416130772"/>
<DICH_DATA CI_END="0.035877439842483025" CI_START="-0.0736132888990868" EFFECT_SIZE="-0.018867924528301886" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28893" O_E="0.0" SE="0.02793182160621795" STUDY_ID="STD-Skowron-1966b" TOTAL_1="41" TOTAL_2="53" VAR="7.801866582415838E-4" WEIGHT="4.522116468831179"/>
<DICH_DATA CI_END="0.015741922284623264" CI_START="-0.015938979562605395" EFFECT_SIZE="-9.85286389910663E-5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28894" O_E="0.0" SE="0.008082011224982593" STUDY_ID="STD-von-Muhlendahl-1982" TOTAL_1="176" TOTAL_2="173" VAR="6.531890544074465E-5" WEIGHT="54.01338115191184"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2535888593458292" CI_END="0.10352927565398592" CI_START="-0.10219022078758125" DF="1" EFFECT_SIZE="6.695274332023384E-4" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="-0.9849368245339815" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-3.174231623514841" NO="2" P_CHI2="0.6145593477890807" P_Z="0.989821136477093" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="100.0" Z="0.012757659613568647">
<NAME>Use of antibiotics</NAME>
<DICH_DATA CI_END="0.2145717567938602" CI_START="-0.1395717567938602" EFFECT_SIZE="0.037500000000000006" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28895" O_E="0.0" SE="0.09034439315751698" STUDY_ID="STD-Husby-1993" TOTAL_1="20" TOTAL_2="16" VAR="0.008162109375" WEIGHT="33.74367050156561"/>
<DICH_DATA CI_END="0.1082785904488334" CI_START="-0.14445430104314863" EFFECT_SIZE="-0.018087855297157618" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28896" O_E="0.0" SE="0.0644738611233438" STUDY_ID="STD-James-1969" TOTAL_1="45" TOTAL_2="43" VAR="0.0041568787681522225" WEIGHT="66.25632949843438"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.159726552506592" CI_END="0.0656338711557276" CI_START="-0.14720769745467305" DF="4" EFFECT_SIZE="-0.04078691314947272" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="38" I2="35.06205241574773" ID="CMP-001.17.03" LOG_CI_END="-1.18287197983587" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="0.18753329727181356" P_Z="0.452545946504179" STUDIES="5" TAU2="0.005071347813894948" TOTAL_1="115" TOTAL_2="106" WEIGHT="100.0" Z="0.7511773319041714">
<NAME>Use of supplemental glucocorticoids</NAME>
<DICH_DATA CI_END="0.15547961569661564" CI_START="-0.32322155118048657" EFFECT_SIZE="-0.08387096774193548" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28897" O_E="0.0" SE="0.12211988859311598" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" VAR="0.01491326718999506" WEIGHT="14.752340994654537"/>
<DICH_DATA CI_END="0.04168570646804677" CI_START="-0.1898338546161949" EFFECT_SIZE="-0.07407407407407407" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28898" O_E="0.0" SE="0.05906219780323476" STUDY_ID="STD-Johnson-1996" TOTAL_1="28" TOTAL_2="27" VAR="0.003488343209348429" WEIGHT="34.44281509504343"/>
<DICH_DATA CI_END="0.02215636964042092" CI_START="-0.4666008140848653" EFFECT_SIZE="-0.2222222222222222" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28899" O_E="0.0" SE="0.12468524615261825" STUDY_ID="STD-Klassen-1994" TOTAL_1="27" TOTAL_2="27" VAR="0.015546410608139005" WEIGHT="14.299316596376658"/>
<DICH_DATA CI_END="0.378270119988106" CI_START="-0.1560478977658838" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28900" O_E="0.0" SE="0.13630812146769586" STUDY_ID="STD-Roorda-1998" TOTAL_1="9" TOTAL_2="8" VAR="0.018579903978052127" WEIGHT="12.465296034971681"/>
<DICH_DATA CI_END="0.22871898978437255" CI_START="-0.10371898978437255" EFFECT_SIZE="0.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28901" O_E="0.0" SE="0.08480716538440845" STUDY_ID="STD-Super-1989" TOTAL_1="16" TOTAL_2="13" VAR="0.0071922553005384065" WEIGHT="24.040231278953698"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.971455678961757" CI_END="-0.008462470217467197" CI_START="-0.19644756778524192" DF="4" EFFECT_SIZE="-0.10245501900135455" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="45" I2="55.414147456804805" ID="CMP-001.17.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="0.061816990520517257" P_Z="0.03264468741624411" STUDIES="5" TAU2="0.006088807056106802" TOTAL_1="272" TOTAL_2="192" WEIGHT="100.0" Z="2.1364262367193656">
<NAME>Use of epinephrine</NAME>
<DICH_DATA CI_END="0.1355380918406633" CI_START="-0.2155380918406633" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28902" O_E="0.0" SE="0.08956189665998221" STUDY_ID="STD-Geelhoed-1995-C_x0026_D" TOTAL_1="50" TOTAL_2="30" VAR="0.008021333333333333" WEIGHT="16.29893906430012"/>
<DICH_DATA CI_END="0.08157488445919532" CI_START="-0.1443915004673007" EFFECT_SIZE="-0.031408308004052685" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28903" O_E="0.0" SE="0.05764554520105727" STUDY_ID="STD-Godden-1997" TOTAL_1="47" TOTAL_2="42" VAR="0.0033230088815271366" WEIGHT="24.435275819261303"/>
<DICH_DATA CI_END="-0.04628892346204849" CI_START="-0.34669353267830233" EFFECT_SIZE="-0.1964912280701754" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28904" O_E="0.0" SE="0.07663523707216231" STUDY_ID="STD-Johnson-1998-A_x0026_B" TOTAL_1="95" TOTAL_2="48" VAR="0.005872959561106521" WEIGHT="19.226283688335513"/>
<DICH_DATA CI_END="0.04255587275181369" CI_START="-0.14493682513276607" EFFECT_SIZE="-0.05119047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28905" O_E="0.0" SE="0.04783064876791059" STUDY_ID="STD-Roberts-1999" TOTAL_1="42" TOTAL_2="40" VAR="0.002287770961559227" WEIGHT="27.45516342248363"/>
<DICH_DATA CI_END="-0.07311003458082277" CI_START="-0.5058373338402299" EFFECT_SIZE="-0.2894736842105263" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28906" O_E="0.0" SE="0.11039164563040567" STUDY_ID="STD-Tibballs-1992" TOTAL_1="38" TOTAL_2="32" VAR="0.012186315424989064" WEIGHT="12.584338005619431"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.047979489491475" CI_END="0.4681739330332709" CI_START="-0.8733329771005949" DF="1" EFFECT_SIZE="-0.20257952203366197" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="95.24895014032455" ID="CMP-001.17.05" LOG_CI_END="-0.32959277059446146" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-10-10 08:35:08 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="4.479343023833238E-6" P_Z="0.5538880077383166" STUDIES="2" TAU2="0.22351131513328437" TOTAL_1="44" TOTAL_2="40" WEIGHT="100.0" Z="0.5919441252102016">
<NAME>Use of mist tent</NAME>
<DICH_DATA CI_END="0.06819566228736405" CI_START="-0.06819566228736405" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28907" O_E="0.0" SE="0.03479434460290226" STUDY_ID="STD-Johnson-1996" TOTAL_1="28" TOTAL_2="27" VAR="0.0012106464163455135" WEIGHT="52.11756751931626"/>
<DICH_DATA CI_END="-0.1384634699989818" CI_START="-0.7076903761548645" EFFECT_SIZE="-0.42307692307692313" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28908" O_E="0.0" SE="0.14521361378215922" STUDY_ID="STD-Super-1989" TOTAL_1="16" TOTAL_2="13" VAR="0.021086993627674102" WEIGHT="47.88243248068374"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-11-07 22:40:06 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Any glucocorticoid versus epinephrine</NAME>
<CONT_OUTCOME CHI2="1.7211109337230637" CI_END="0.5239669680487086" CI_START="-0.171126139557082" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.17642041424581328" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-11-07 22:38:56 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4229274248759879" P_Q="1.0" P_Z="0.3197798893787035" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.9949103343879873">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7211109337230637" CI_END="0.5239669680487086" CI_START="-0.171126139557082" DF="2" EFFECT_SIZE="0.17642041424581328" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.4229274248759879" P_Z="0.3197798893787035" STUDIES="3" TAU2="0.0" TOTAL_1="67" TOTAL_2="62" WEIGHT="100.0" Z="0.9949103343879873">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="0.7191454042928563" CI_START="-0.2511506914360373" EFFECT_SIZE="0.23399735642840955" ESTIMABLE="YES" MEAN_1="-3.16" MEAN_2="-3.62" ORDER="28909" SD_1="1.9" SD_2="1.99" SE="0.24752906262116686" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.318906818097524"/>
<CONT_DATA CI_END="0.49695032570292147" CI_START="-0.8928181537727355" EFFECT_SIZE="-0.19793391403490707" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.27" ORDER="28910" SD_1="1.65" SD_2="1.6" SE="0.35453929011909746" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="16" WEIGHT="25.01503122726795"/>
<CONT_DATA CI_END="1.1616737585126078" CI_START="-0.26715434458059495" EFFECT_SIZE="0.4472597069660065" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-1.1" ORDER="28911" SD_1="1.45" SD_2="1.6" SE="0.3645036629151394" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="15" WEIGHT="23.666061954634536"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.770939164030551" CI_END="0.4222302211249602" CI_START="-0.27023914813991334" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07599553649252347" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-11-07 22:39:06 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6801313630672332" P_Q="1.0" P_Z="0.6670536228232191" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="62" UNITS="" WEIGHT="99.99999999999999" Z="0.43019524363733036">
<NAME>Croup score (change baseline - 12 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.770939164030551" CI_END="0.4222302211249602" CI_START="-0.27023914813991334" DF="2" EFFECT_SIZE="0.07599553649252347" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.6801313630672332" P_Z="0.6670536228232191" STUDIES="3" TAU2="0.0" TOTAL_1="67" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.43019524363733036">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="0.46785479080300524" CI_START="-0.49895745103045325" EFFECT_SIZE="-0.015551330113724029" ESTIMABLE="YES" MEAN_1="-3.69" MEAN_2="-3.65" ORDER="28912" SD_1="2.08" SD_2="2.98" SE="0.24664030805146167" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.29993955961978"/>
<CONT_DATA CI_END="0.692951912174839" CI_START="-0.692951912174839" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.9" ORDER="28913" SD_1="1.64" SD_2="1.8" SE="0.3535533905932738" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.9651942010638"/>
<CONT_DATA CI_END="1.064482529979858" CI_START="-0.3568875631923023" EFFECT_SIZE="0.3537974833937778" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.7" ORDER="28914" SD_1="1.5" SD_2="1.8" SE="0.36260107440334266" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="15" WEIGHT="23.734866239316407"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6763299246193877" CI_END="0.49449010736156906" CI_START="-0.19855167451095282" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1479692164253081" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2010-11-07 22:39:18 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7130777219512658" P_Q="1.0" P_Z="0.4026309416900108" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.8369317481281721">
<NAME>Croup score (change baseline - 24 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6763299246193877" CI_END="0.49449010736156906" CI_START="-0.19855167451095282" DF="2" EFFECT_SIZE="0.1479692164253081" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="0.7130777219512658" P_Z="0.4026309416900108" STUDIES="3" TAU2="0.0" TOTAL_1="67" TOTAL_2="62" WEIGHT="100.0" Z="0.8369317481281721">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="0.6897304069337049" CI_START="-0.2797529703217895" EFFECT_SIZE="0.20498871830595775" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="-4.32" ORDER="28915" SD_1="2.53" SD_2="2.88" SE="0.2473217326702571" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.102024030988325"/>
<CONT_DATA CI_END="0.5953522091867852" CI_START="-0.7915014319025885" EFFECT_SIZE="-0.09807461135790159" ESTIMABLE="YES" MEAN_1="-2.11" MEAN_2="-1.95" ORDER="28916" SD_1="1.62" SD_2="1.56" SE="0.3537956952343763" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.972244239718574"/>
<CONT_DATA CI_END="0.9914190908238423" CI_START="-0.4254404650722529" EFFECT_SIZE="0.2829893128757947" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.3" ORDER="28917" SD_1="1.18" SD_2="1.56" SE="0.3614504059952383" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="15" WEIGHT="23.9257317292931"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.721110933723064" CI_END="0.5239669680487086" CI_START="-0.171126139557082" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.17642041424581328" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-11-07 22:39:28 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.4229274248759879" P_Q="0.7775080374970438" P_Z="0.3197798893787035" Q="0.07984466370063731" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.9949103343879873">
<NAME>Croup score (change baseline - 6 hours) by glucocorticoid</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7191454042928563" CI_START="-0.2511506914360373" DF="0" EFFECT_SIZE="0.23399735642840955" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="1.0" P_Z="0.34448897944300294" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.318906818097524" Z="0.9453328588996152">
<NAME>Budesonide</NAME>
<CONT_DATA CI_END="0.7191454042928563" CI_START="-0.2511506914360373" EFFECT_SIZE="0.23399735642840955" ESTIMABLE="YES" MEAN_1="-3.16" MEAN_2="-3.62" ORDER="28918" SD_1="1.9" SD_2="1.99" SE="0.24752906262116686" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.318906818097524"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6099673294476105" CI_END="0.7512949142990466" CI_START="-0.5130740235355864" DF="1" EFFECT_SIZE="0.11911044538173014" ESTIMABLE="YES" I2="37.886938342835435" ID="CMP-002.04.02" NO="2" P_CHI2="0.20449644901343877" P_Z="0.7119200903045765" STUDIES="2" TAU2="0.07885689003178165" TOTAL_1="32" TOTAL_2="31" WEIGHT="48.68109318190248" Z="0.36927858023865745">
<NAME>Dexamethasone</NAME>
<CONT_DATA CI_END="0.49695032570292147" CI_START="-0.8928181537727355" EFFECT_SIZE="-0.19793391403490707" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.27" ORDER="28919" SD_1="1.65" SD_2="1.6" SE="0.35453929011909746" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="16" WEIGHT="25.01503122726795"/>
<CONT_DATA CI_END="1.1616737585126078" CI_START="-0.26715434458059495" EFFECT_SIZE="0.4472597069660065" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-1.1" ORDER="28920" SD_1="1.45" SD_2="1.6" SE="0.3645036629151394" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="15" WEIGHT="23.666061954634536"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.770939164030551" CI_END="0.4222302211249602" CI_START="-0.27023914813991334" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07599553649252347" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2010-11-07 22:39:40 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6801313630672332" P_Q="0.5948083106042557" P_Z="0.6670536228232191" Q="0.2828976630730956" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="62" UNITS="" WEIGHT="99.99999999999999" Z="0.43019524363733036">
<NAME>Croup score (change baseline - 12 hours) by glucocorticoid</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4678547908030053" CI_START="-0.4989574510304533" DF="0" EFFECT_SIZE="-0.015551330113724029" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="1.0" P_Z="0.9497245626051605" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.29993955961978" Z="0.06305267065462483">
<NAME>Budesonide</NAME>
<CONT_DATA CI_END="0.46785479080300524" CI_START="-0.49895745103045325" EFFECT_SIZE="-0.015551330113724029" ESTIMABLE="YES" MEAN_1="-3.69" MEAN_2="-3.65" ORDER="28921" SD_1="2.08" SD_2="2.98" SE="0.24664030805146167" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.29993955961978"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.48804150095745524" CI_END="0.6685714865831794" CI_START="-0.3237121222118228" DF="1" EFFECT_SIZE="0.1724296821856783" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" NO="2" P_CHI2="0.4848022942366246" P_Z="0.49576513913826814" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="48.700060440380206" Z="0.6811680933841491">
<NAME>Dexamethasone</NAME>
<CONT_DATA CI_END="0.692951912174839" CI_START="-0.692951912174839" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.9" ORDER="28922" SD_1="1.64" SD_2="1.8" SE="0.3535533905932738" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.9651942010638"/>
<CONT_DATA CI_END="1.064482529979858" CI_START="-0.3568875631923023" EFFECT_SIZE="0.3537974833937778" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.7" ORDER="28923" SD_1="1.5" SD_2="1.8" SE="0.36260107440334266" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="15" WEIGHT="23.734866239316407"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6763299246193877" CI_END="0.494490107361569" CI_START="-0.19855167451095285" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.14796921642530808" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2010-11-07 22:39:50 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7130777219512658" P_Q="0.7416285553169915" P_Z="0.4026309416900108" Q="0.10870046313898578" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.836931748128172">
<NAME>Croup score (change baseline - 24 hours) by glucocorticoid</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6897304069337049" CI_START="-0.2797529703217895" DF="0" EFFECT_SIZE="0.20498871830595775" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" NO="1" P_CHI2="1.0" P_Z="0.4071982229283678" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.102024030988325" Z="0.8288342318030739">
<NAME>Budesonide</NAME>
<CONT_DATA CI_END="0.6897304069337049" CI_START="-0.2797529703217895" EFFECT_SIZE="0.20498871830595775" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="-4.32" ORDER="28924" SD_1="2.53" SD_2="2.88" SE="0.2473217326702571" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" WEIGHT="51.102024030988325"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5676294614804019" CI_END="0.5839256002894537" CI_START="-0.4071664135158747" DF="1" EFFECT_SIZE="0.08837959338678955" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" NO="2" P_CHI2="0.4512025622605964" P_Z="0.7266723314015568" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="48.897975969011675" Z="0.34955547536159676">
<NAME>Dexamethasone</NAME>
<CONT_DATA CI_END="0.5953522091867852" CI_START="-0.7915014319025885" EFFECT_SIZE="-0.09807461135790159" ESTIMABLE="YES" MEAN_1="-2.11" MEAN_2="-1.95" ORDER="28925" SD_1="1.62" SD_2="1.56" SE="0.3537956952343763" STUDY_ID="STD-Kuusela-1988" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.972244239718574"/>
<CONT_DATA CI_END="0.9914190908238423" CI_START="-0.4254404650722529" EFFECT_SIZE="0.2829893128757947" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-2.3" ORDER="28926" SD_1="1.18" SD_2="1.56" SE="0.3614504059952383" STUDY_ID="STD-Martinez-1993" TOTAL_1="16" TOTAL_2="15" WEIGHT="23.9257317292931"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-11-07 22:40:06 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="35" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Any Glucocorticoid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Budesonide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Epinephrine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Inpatients</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28927" O_E="0.0" SE="0.0" STUDY_ID="STD-Fitzgerald-1996" TOTAL_1="35" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-11-07 22:41:11 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Dexamethasone versus budesonide</NAME>
<CONT_OUTCOME CHI2="3.914798887780478" CI_END="0.2776074730812201" CI_START="-1.0665428605568337" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3944676937378068" ESTIMABLE="YES" I2="74.45590364497735" I2_Q="74.45590364497735" ID="CMP-003.01" MODIFIED="2010-11-07 22:40:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04786280288749423" P_Q="0.04786280288749423" P_Z="0.24998701992980532" Q="3.914798887780478" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.17812228135961838" TOTALS="YES" TOTAL_1="93" TOTAL_2="88" UNITS="" WEIGHT="100.00000000000001" Z="1.1503809558237488">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dexamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dexameth.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Budesonide</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1899452661983767" CI_START="-1.3809076821738124" DF="0" EFFECT_SIZE="-0.7854264741860946" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="0.009733694568405853" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="43.47944490386079" Z="2.585148920334653">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="-0.1899452661983767" CI_START="-1.3809076821738124" EFFECT_SIZE="-0.7854264741860946" ESTIMABLE="YES" MEAN_1="-3.67" MEAN_2="-2.93" ORDER="28928" SD_1="0.85" SD_2="1.0" SE="0.30382252566108237" STUDY_ID="STD-Vad-Pedersen-1998" TOTAL_1="24" TOTAL_2="23" WEIGHT="43.47944490386079"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24525686268908514" CI_START="-0.432688222992005" DF="0" EFFECT_SIZE="-0.09371568015145991" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="0.5879074450058839" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="65" WEIGHT="56.520555096139226" Z="0.5418709030068569">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.24525686268908514" CI_START="-0.432688222992005" EFFECT_SIZE="-0.09371568015145991" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-2.3" ORDER="28929" SD_1="1.14" SD_2="0.97" SE="0.17294835288521485" STUDY_ID="STD-Klassen-1998" TOTAL_1="69" TOTAL_2="65" WEIGHT="56.520555096139226"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.2007617551930574" CI_START="-1.6317350437191578" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.9162483994561076" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-11-07 22:40:59 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.012075869473706676" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="2.509919476800471">
<NAME>Croup score (change baseline - 12 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dexamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dexameth.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Budesonide</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.2007617551930574" CI_START="-1.6317350437191578" DF="0" EFFECT_SIZE="-0.9162483994561076" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="1.0" P_Z="0.012075869473706676" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="15" WEIGHT="100.0" Z="2.509919476800471">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="-0.2007617551930574" CI_START="-1.6317350437191578" EFFECT_SIZE="-0.9162483994561076" ESTIMABLE="YES" MEAN_1="-3.91" MEAN_2="-3.07" ORDER="28930" SD_1="0.85" SD_2="0.95" SE="0.36505091415287094" STUDY_ID="STD-Vad-Pedersen-1998" TOTAL_1="19" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.10445411843563396" CI_END="0.0478204626163161" CI_START="-0.024260827324128334" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.011779817646093883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-1.320386226824562" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.9288614324613242" METHOD="MH" MODIFIED="2010-11-07 22:41:11 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7465486406491153" P_Q="1.0" P_Z="0.5217757304008117" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.00000000000001" Z="0.6406105759169785">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dexamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dexameth</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Budesonide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Inpatients</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10445411843563396" CI_END="0.0478204626163161" CI_START="-0.024260827324128334" DF="1" EFFECT_SIZE="0.011779817646093883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-1.320386226824562" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.9288614324613242" NO="2" P_CHI2="0.7465486406491153" P_Z="0.5217757304008117" STUDIES="2" TAU2="0.0" TOTAL_1="99" TOTAL_2="84" WEIGHT="100.00000000000001" Z="0.6406105759169785">
<NAME>Outpatients</NAME>
<DICH_DATA CI_END="0.0807971673240739" CI_START="-0.0807971673240739" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28931" O_E="0.0" SE="0.04122380205013543" STUDY_ID="STD-Duman-2005" TOTAL_1="31" TOTAL_2="19" VAR="0.00169940185546875" WEIGHT="19.897240006561603"/>
<DICH_DATA CI_END="0.05497469406325893" CI_START="-0.025562929357376574" EFFECT_SIZE="0.014705882352941176" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28932" O_E="0.0" SE="0.020545689628969206" STUDY_ID="STD-Klassen-1998" TOTAL_1="68" TOTAL_2="65" VAR="4.2212536232993274E-4" WEIGHT="80.10275999343841"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-11-07 22:41:42 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Budesonide and dexamethasone versus budesonide</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1520191637719296" CI_START="-0.5399344161328654" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1939576261804679" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2010-11-07 22:41:27 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.27186710113643364" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="1.0987730185394937">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Bud and Dex</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Bud + Dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Budesonide</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Inpatients</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1520191637719296" CI_START="-0.5399344161328654" DF="0" EFFECT_SIZE="-0.1939576261804679" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" NO="2" P_CHI2="1.0" P_Z="0.27186710113643364" STUDIES="1" TAU2="0.0" TOTAL_1="64" TOTAL_2="65" WEIGHT="100.0" Z="1.0987730185394937">
<NAME>Outpatients</NAME>
<CONT_DATA CI_END="0.1520191637719296" CI_START="-0.5399344161328654" EFFECT_SIZE="-0.1939576261804679" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.3" ORDER="28933" SD_1="1.02" SD_2="1.03" SE="0.1765220140173076" STUDY_ID="STD-Klassen-1998" TOTAL_1="64" TOTAL_2="65" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-11-07 22:41:42 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="64" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Bud and Dex</GROUP_LABEL_1>
<GROUP_LABEL_2>Budesonide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Bud and Dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Budesonide</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Inpatients</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="64" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Outpatients</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="28934" O_E="0.0" SE="0.0" STUDY_ID="STD-Klassen-1998" TOTAL_1="64" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-11-07 22:42:12 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Budesonide and dexamethasone versus dexamethasone</NAME>
<CONT_OUTCOME CHI2="9.053634067052254" CI_END="0.47932693758254385" CI_START="-0.6375545544863309" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.07911380845189353" ESTIMABLE="YES" I2="77.90942305390554" I2_Q="79.71288359980379" ID="CMP-005.01" MODIFIED="2010-11-07 22:41:56 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010815060982311109" P_Q="0.026406122221734996" P_Z="0.7812684783571158" Q="4.929236764227015" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1879796269151194" TOTALS="YES" TOTAL_1="124" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="0.2776663707772315">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Bud and Dex</GROUP_LABEL_1>
<GROUP_LABEL_2>Dexamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Bud + Dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dexameth.</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.313371464970825E-32" CI_END="0.9418195262044642" CI_START="-0.0021831625681007494" DF="0" EFFECT_SIZE="0.46981818181818175" ESTIMABLE="YES" I2="100.0" ID="CMP-005.01.01" NO="1" P_CHI2="0.0" P_Z="0.05106912091139951" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="36" WEIGHT="33.00409030808182" Z="1.950898501874031">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="0.9418195262044642" CI_START="-0.0021831625681008604" EFFECT_SIZE="0.4698181818181817" ESTIMABLE="YES" MEAN_1="-2.72" MEAN_2="-3.1" ORDER="28935" SD_1="0.8" SD_2="0.8" SE="0.24082143759240932" STUDY_ID="STD-Geelhoed-2005" TOTAL_1="35" TOTAL_2="36" WEIGHT="33.00409030808182"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5862582762262356" CI_END="0.19508301461923916" CI_START="-0.854661103175678" DF="1" EFFECT_SIZE="-0.3297890442782194" ESTIMABLE="YES" I2="61.334101501294754" ID="CMP-005.01.02" NO="2" P_CHI2="0.1077951020627782" P_Z="0.21813970812548034" STUDIES="2" TAU2="0.09103508225472798" TOTAL_1="89" TOTAL_2="94" WEIGHT="66.99590969191817" Z="1.231489918969899">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="-0.08204719411992922" CI_START="-1.2223167997274726" EFFECT_SIZE="-0.6521819969237009" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.1" ORDER="28936" SD_1="1.2" SD_2="1.5" SE="0.2908904486515682" STUDY_ID="STD-Klassen-1996" TOTAL_1="25" TOTAL_2="25" WEIGHT="29.780853095772446"/>
<CONT_DATA CI_END="0.23305054714346546" CI_START="-0.4477360357377191" EFFECT_SIZE="-0.1073427442971268" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.4" ORDER="28937" SD_1="1.02" SD_2="0.83" SE="0.17367323793986578" STUDY_ID="STD-Klassen-1998" TOTAL_1="64" TOTAL_2="69" WEIGHT="37.21505659614572"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.5300575190900185" CI_END="1.8457008473380654" CI_START="0.41225852591416706" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8722992093325087" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="0.0" I2_Q="27.655633267217215" ID="CMP-005.02" LOG_CI_END="0.26616131159858614" LOG_CI_START="-0.38483035395103043" LOG_EFFECT_SIZE="-0.059334521176222184" METHOD="MH" MODIFIED="2010-11-07 22:42:12 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.46532067293791635" P_Q="0.23971376024466662" P_Z="0.7208813429062485" Q="1.3822776328856174" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="128" WEIGHT="100.0" Z="0.3572811472083619">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Bud and Dex</GROUP_LABEL_1>
<GROUP_LABEL_2>Dexamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Bud and Dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dexamethasone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.285112885394374" CI_START="0.4629789584731531" DF="0" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.3589076592386504" LOG_CI_START="-0.3344387464046273" LOG_EFFECT_SIZE="0.012234456417011586" NO="1" P_CHI2="1.0" P_Z="0.9448549717056097" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="36" WEIGHT="88.1556840989325" Z="0.06916915917526154">
<NAME>Inpatient</NAME>
<DICH_DATA CI_END="2.285112885394374" CI_START="0.4629789584731531" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3589076592386504" LOG_CI_START="-0.3344387464046273" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="28938" O_E="0.0" SE="0.4072751107949218" STUDY_ID="STD-Geelhoed-2005" TOTAL_1="35" TOTAL_2="36" VAR="0.16587301587301584" WEIGHT="88.1556840989325"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07528285404436522" CI_END="2.258227478189814" CI_START="0.028987202995699554" DF="1" EFFECT_SIZE="0.25585092988057484" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.35376768760958033" LOG_CI_START="-1.5377936881336747" LOG_EFFECT_SIZE="-0.5920130002620472" NO="2" P_CHI2="0.7837947612699918" P_Z="0.21988173109612863" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="92" WEIGHT="11.844315901067507" Z="1.2268427276774836">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="3.8101144995410996" CI_START="0.009706335209916737" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5809380270592663" LOG_CI_START="-2.0129447143288646" LOG_EFFECT_SIZE="-0.7160033436347991" ORDER="28939" O_E="0.0" SE="1.5236595622180376" STUDY_ID="STD-Klassen-1996" TOTAL_1="25" TOTAL_2="24" VAR="2.3215384615384616" WEIGHT="6.298689179652234"/>
<DICH_DATA CI_END="8.531237261480072" CI_START="0.014676312093328658" EFFECT_SIZE="0.35384615384615387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9310120202492846" LOG_CI_START="-1.83338306149981" LOG_EFFECT_SIZE="-0.4511855206252627" ORDER="28940" O_E="0.0" SE="1.6238193549957651" STUDY_ID="STD-Klassen-1998" TOTAL_1="64" TOTAL_2="68" VAR="2.6367892976588627" WEIGHT="5.545626721415274"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-11-07 22:42:46 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Oral versus intramuscular dexamethasone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2010-11-07 22:42:35 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="138" TOTAL_2="139" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Croup score (change baseline-discharge) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="139" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.38" MEAN_2="0.42" ORDER="28941" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Rittichier-2000" TOTAL_1="138" TOTAL_2="139" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.08801241549671032" CI_END="1.1215804368170799" CI_START="0.5759371006305215" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8037162340679345" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.04983042550089332" LOG_CI_START="-0.23962494425160094" LOG_EFFECT_SIZE="-0.0948972593753538" METHOD="MH" MODIFIED="2010-11-07 22:42:46 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7667193440121245" P_Q="1.0" P_Z="0.19874367085071584" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="184" TOTAL_2="188" WEIGHT="99.99999999999999" Z="1.285139127087462">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08801241549671032" CI_END="1.1215804368170799" CI_START="0.5759371006305215" DF="1" EFFECT_SIZE="0.8037162340679345" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="57" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.04983042550089332" LOG_CI_START="-0.23962494425160094" LOG_EFFECT_SIZE="-0.0948972593753538" MODIFIED="2010-05-25 09:12:28 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7667193440121245" P_Z="0.19874367085071584" STUDIES="2" TAU2="0.0" TOTAL_1="184" TOTAL_2="188" WEIGHT="99.99999999999999" Z="1.285139127087462">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="1.8539315313377307" CI_START="0.4250307130928257" EFFECT_SIZE="0.8876811594202898" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.26809369091349927" LOG_CI_START="-0.37157968631486976" LOG_EFFECT_SIZE="-0.051742997700685266" MODIFIED="2009-09-02 09:58:54 +1000" MODIFIED_BY="[Empty name]" ORDER="28942" O_E="0.0" SE="0.3757473082182288" STUDY_ID="STD-Donaldson-2003" TOTAL_1="46" TOTAL_2="49" VAR="0.14118603963324464" WEIGHT="20.476073001988542"/>
<DICH_DATA CI_END="1.1383749611644165" CI_START="0.5391345375336033" EFFECT_SIZE="0.78341384863124" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="45" LOG_CI_END="0.05628533476797337" LOG_CI_START="-0.26830284591239234" LOG_EFFECT_SIZE="-0.10600875557220946" MODIFIED="2009-09-02 09:58:55 +1000" MODIFIED_BY="[Empty name]" ORDER="28943" O_E="0.0" SE="0.19066470406905428" STUDY_ID="STD-Rittichier-2000" TOTAL_1="138" TOTAL_2="139" VAR="0.03635302937774004" WEIGHT="79.52392699801145"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-11-07 22:43:18 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Dexamethasone 0.30 mg/kg versus 0.15 mg/kg</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6729729289284344" CI_START="-0.34156710847151917" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.16570291022845762" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2010-11-07 22:43:03 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5220201996603435" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.6402344396650336">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dex 0.30mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>Dex 0.15mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Dex 0.30 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Dex 0.15 mg/kg</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6729729289284344" CI_START="-0.34156710847151917" DF="0" EFFECT_SIZE="0.16570291022845762" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" MODIFIED="2010-05-25 09:12:08 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5220201996603435" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.6402344396650336">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.6729729289284344" CI_START="-0.34156710847151917" EFFECT_SIZE="0.16570291022845762" ESTIMABLE="YES" MEAN_1="-2.84" MEAN_2="-3.07" ORDER="28944" SD_1="1.37" SD_2="1.37" SE="0.258815989835149" STUDY_ID="STD-Geelhoed-1995a" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="66.3993085345109" CI_START="0.11913009976434784" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="1.8221635567594336" LOG_CI_START="-0.9239784945205962" LOG_EFFECT_SIZE="0.4490925311194189" METHOD="MH" MODIFIED="2010-11-07 22:43:18 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5214911455142895" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.64104854758676">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dex 0.30 mk/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>Dex 0.15 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Dex 0.30 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Dex 0.15 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="66.3993085345109" CI_START="0.11913009976434784" DF="0" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="1.8221635567594336" LOG_CI_START="-0.9239784945205962" LOG_EFFECT_SIZE="0.4490925311194189" MODIFIED="2010-05-25 09:12:13 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5214911455142895" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.64104854758676">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="66.3993085345109" CI_START="0.11913009976434784" EFFECT_SIZE="2.8125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8221635567594336" LOG_CI_START="-0.9239784945205962" LOG_EFFECT_SIZE="0.4490925311194189" ORDER="28945" O_E="0.0" SE="1.6130974345442786" STUDY_ID="STD-Geelhoed-1995a" TOTAL_1="31" TOTAL_2="29" VAR="2.6020833333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-11-07 22:43:55 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Dexamethasone 0.60 mg/kg versus 0.30 mg/kg</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7167463745073634" CI_START="-0.2988868617573397" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.20892975637501188" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2010-11-07 22:43:43 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4200219287475693" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.8063832162480059">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dex 0.60 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>Dex 0.30 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Dex 0.60 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Dex 0.30 mg/kg</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7167463745073634" CI_START="-0.2988868617573397" DF="0" EFFECT_SIZE="0.20892975637501188" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" MODIFIED="2010-05-25 09:11:42 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4200219287475693" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.8063832162480059">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.7167463745073634" CI_START="-0.2988868617573397" EFFECT_SIZE="0.20892975637501188" ESTIMABLE="YES" MEAN_1="-2.23" MEAN_2="-2.52" ORDER="28946" SD_1="1.37" SD_2="1.37" SE="0.25909487222109395" STUDY_ID="STD-Geelhoed-1995a" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.54855216614242" CI_START="0.17906800777941861" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8709677419354838" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="1.2911145975610654" LOG_CI_START="-0.7469819981037364" LOG_EFFECT_SIZE="0.2720662997286646" METHOD="MH" MODIFIED="2010-11-07 22:43:55 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6007845018833395" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.5232726947383235">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dex 0.60 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>Dex 0.30 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Dex 0.60 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Dex 0.30 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.54855216614242" CI_START="0.17906800777941861" DF="0" EFFECT_SIZE="1.8709677419354838" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="1.2911145975610654" LOG_CI_START="-0.7469819981037364" LOG_EFFECT_SIZE="0.2720662997286646" MODIFIED="2010-05-25 09:11:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6007845018833395" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.5232726947383235">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="19.54855216614242" CI_START="0.17906800777941861" EFFECT_SIZE="1.8709677419354838" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2911145975610654" LOG_CI_START="-0.7469819981037364" LOG_EFFECT_SIZE="0.2720662997286646" ORDER="28947" O_E="0.0" SE="1.1971880290343624" STUDY_ID="STD-Geelhoed-1995a" TOTAL_1="31" TOTAL_2="29" VAR="1.4332591768631813" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-11-07 22:44:31 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Dexamethasone 0.60 mg/kg versus 0.15 mg/kg</NAME>
<CONT_OUTCOME CHI2="0.4630122426361556" CI_END="0.3237301444066103" CI_START="-0.367584136928917" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.021926996261153377" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2010-11-07 22:44:15 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49621958462194393" P_Q="1.0" P_Z="0.9010526879111462" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="66" UNITS="" WEIGHT="99.99999999999999" Z="0.12433165094747034">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dex 0.6 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>Dex 0.15 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Dex 0.60 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Dex 0.15 mg/kg</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4630122426361556" CI_END="0.3237301444066103" CI_START="-0.367584136928917" DF="1" EFFECT_SIZE="-0.021926996261153377" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.01" MODIFIED="2010-05-25 09:11:22 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49621958462194393" P_Z="0.9010526879111462" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="99.99999999999999" Z="0.12433165094747034">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.5891096897905178" CI_START="-0.3915091972908745" EFFECT_SIZE="0.09880024624982167" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-3.1" MODIFIED="2009-07-23 05:26:20 +1000" MODIFIED_BY="[Empty name]" ORDER="179" SD_1="2.26" SD_2="1.7" SE="0.250162476151702" STUDY_ID="STD-Alshehri--2005" TOTAL_1="32" TOTAL_2="32" WEIGHT="49.6993318451257"/>
<CONT_DATA CI_END="0.3461588824674715" CI_START="-0.6285808108997306" EFFECT_SIZE="-0.14121096421612955" ESTIMABLE="YES" MEAN_1="-2.23" MEAN_2="-2.09" MODIFIED="2010-03-31 12:28:07 +1000" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="0.99" SD_2="0.97" SE="0.24866265427727866" STUDY_ID="STD-Fifoot--2007" TOTAL_1="31" TOTAL_2="34" WEIGHT="50.30066815487429"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.08203127793773132" CI_END="1.7532095738000197" CI_START="0.6163560634972423" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0395197696018377" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.24383383355228833" LOG_CI_START="-0.2101683272229028" LOG_EFFECT_SIZE="0.0168327531646927" METHOD="MH" MODIFIED="2010-11-07 22:44:31 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7745633384965825" P_Q="1.0" P_Z="0.8844450328517165" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="67" WEIGHT="100.0" Z="0.14533670900208273">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dex 0.6 mg/kg</GROUP_LABEL_1>
<GROUP_LABEL_2>Dex 0.15 mg/kg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Dex 0.60 mg/kg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Dex 0.15 mg/kg</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.08203127793773132" CI_END="1.7532095738000197" CI_START="0.6163560634972423" DF="1" EFFECT_SIZE="1.0395197696018377" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="0.24383383355228833" LOG_CI_START="-0.2101683272229028" LOG_EFFECT_SIZE="0.0168327531646927" MODIFIED="2010-05-25 09:11:07 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7745633384965825" P_Z="0.8844450328517165" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="67" WEIGHT="100.0" Z="0.14533670900208273">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="1.8815295588053689" CI_START="0.6101201962526371" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.27451104547024746" LOG_CI_START="-0.21458459871536104" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="28948" O_E="0.0" SE="0.28729720245711154" STUDY_ID="STD-Alshehri--2005" TOTAL_1="36" TOTAL_2="36" VAR="0.08253968253968255" WEIGHT="86.16447566052041"/>
<DICH_DATA CI_END="3.510270332055557" CI_START="0.21124080926405317" EFFECT_SIZE="0.8611111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5453405635311122" LOG_CI_START="-0.6752221773971412" LOG_EFFECT_SIZE="-0.06494080693301456" MODIFIED="2010-03-31 12:15:03 +1000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.7169645959042659" STUDY_ID="STD-Fifoot--2007" TOTAL_1="27" TOTAL_2="31" VAR="0.5140382317801673" WEIGHT="13.835524339479598"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2011-07-18 14:49:01 +1000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Dexamethasone versus betamethasone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.612185412150042" CI_START="-2.407814587849958" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.51" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2011-07-18 14:49:01 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="9.79365066398521E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="3.2963884266381274">
<NAME>Croup score (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dexamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dexamethasone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Betamethasone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.612185412150042" CI_START="-2.407814587849958" DF="0" EFFECT_SIZE="-1.51" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.02" MODIFIED="2011-07-18 14:49:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.79365066398521E-4" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="3.2963884266381274">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="-0.612185412150042" CI_START="-2.407814587849958" EFFECT_SIZE="-1.51" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-1.89" MODIFIED="2011-07-18 14:49:01 +1000" MODIFIED_BY="[Empty name]" ORDER="28949" SD_1="2.26" SD_2="0.59" SE="0.45807708454431045" STUDY_ID="STD-Amir--2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3397548585812895" CI_START="0.6699038405862964" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="0.12702534067457305" LOG_CI_START="-0.17398753237361886" LOG_EFFECT_SIZE="-0.023481095849522914" METHOD="MH" MODIFIED="2010-11-07 22:45:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.759770923131032" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.30578162134102327">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dexamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour Dexamethasone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Betamethasone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3397548585812895" CI_START="0.6699038405862964" DF="0" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="0.12702534067457305" LOG_CI_START="-0.17398753237361886" LOG_EFFECT_SIZE="-0.023481095849522914" NO="2" P_CHI2="1.0" P_Z="0.759770923131032" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.30578162134102327">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="1.3397548585812895" CI_START="0.6699038405862964" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.12702534067457305" LOG_CI_START="-0.17398753237361886" LOG_EFFECT_SIZE="-0.023481095849522914" ORDER="28950" O_E="0.0" SE="0.17681645166626053" STUDY_ID="STD-Amir--2006" TOTAL_1="26" TOTAL_2="26" VAR="0.03126405757984704" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2010-11-07 22:47:35 +1000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Dexamethasone versus prednisolone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5501880769053992" CI_START="-0.17018807690539928" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.01" MODIFIED="2010-11-07 22:45:16 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3011898037598594" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="1.0338852975425297">
<NAME>Croup (change baseline - 6 hours) by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dexamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Prednisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dexamethasone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Prednisolone</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.01" MODIFIED="2010-05-25 09:12:02 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5501880769053992" CI_START="-0.17018807690539928" DF="0" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.02" MODIFIED="2010-05-25 09:12:02 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3011898037598594" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="34" WEIGHT="100.0" Z="1.0338852975425297">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.5501880769053992" CI_START="-0.17018807690539928" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" MEAN_1="-2.16" MEAN_2="-2.35" MODIFIED="2010-03-31 13:13:18 +1000" MODIFIED_BY="[Empty name]" ORDER="200" SD_1="0.97" SD_2="0.81" SE="0.18377280386094683" STUDY_ID="STD-Fifoot--2007" TOTAL_1="65" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.4988690032047538" CI_END="0.603581722464015" CI_START="0.1685822215079416" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31898769197975885" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-0.2192639199123619" LOG_CI_START="-0.7731882275055383" LOG_EFFECT_SIZE="-0.4962260737089501" METHOD="MH" MODIFIED="2010-11-07 22:45:28 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4799975461215953" P_Q="1.0" P_Z="4.453880030412415E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="125" TOTAL_2="94" WEIGHT="100.0" Z="3.5116178124956563">
<NAME>Return visits and/or (re)admissions by inpatient/outpatient</NAME>
<GROUP_LABEL_1>Dexamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Predisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Dexamethasone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Prednisolone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4988690032047538" CI_END="0.603581722464015" CI_START="0.1685822215079416" DF="1" EFFECT_SIZE="0.31898769197975885" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="0.0" ID="CMP-011.02.02" LOG_CI_END="-0.2192639199123619" LOG_CI_START="-0.7731882275055383" LOG_EFFECT_SIZE="-0.4962260737089501" MODIFIED="2010-04-28 04:59:35 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4799975461215953" P_Z="4.453880030412415E-4" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="94" WEIGHT="100.0" Z="3.5116178124956563">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="0.954752739557315" CI_START="0.16400852861257204" EFFECT_SIZE="0.39571150097465885" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="-0.020109086792908196" LOG_CI_START="-0.7851335676042985" LOG_EFFECT_SIZE="-0.4026213271986034" MODIFIED="2010-04-28 04:59:35 +1000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.44937916696086555" STUDY_ID="STD-Fifoot--2007" TOTAL_1="57" TOTAL_2="29" VAR="0.20194163569844148" WEIGHT="52.42641745951493"/>
<DICH_DATA CI_END="0.6341162416583922" CI_START="0.09978673611674663" EFFECT_SIZE="0.2515479876160991" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.197831123059241" LOG_CI_START="-1.000927182301141" LOG_EFFECT_SIZE="-0.5993791526801908" ORDER="28951" O_E="0.0" SE="0.4717426005882995" STUDY_ID="STD-Sparrow--2006" TOTAL_1="68" TOTAL_2="65" VAR="0.22254108120981186" WEIGHT="47.57358254048507"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-11-10 13:43:20 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-11-10 13:43:20 +1000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-11-10 13:43:20 +1000" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWAAAAZCCAIAAACFwK6oAABTSUlEQVR42u3dv24kRb/G8ZGQEIEDB74CrsERsogg4p5wOAEShHsXiEtALITLRmQIsBHrgGAWMlhWfcb46OAz7j/VPV099av+PBq92ncYPx53VX3rT1fXs9kQEfWoISJ6IoAgIoAgIoAgIoAgIoAgIoAgIoAgIoAgIoAgIoAgmrWq2bwLEKSxPf22KW8SQNC6Glv/F1P3AII0NgIIojS6qXIAQRpb5xc23gEI0tgAAiBIYwMIgCCNba6qhg4AQRobAQQRAQTRnFXNbmuAII3t6Rd+/A9VDiBIY+v8zhgBEKSxAQRAkMY2/murcgBBGhsBBBEBBNExgx2JsABBGhsBBBEBBFGWqmbIAxCksbVOjvrfIYCglTY2gAAI0thSv7YqBxCksbXMhixDAARpbAQQRAQQRAQQREQAQUQAQYVWNQurAEEa29MvrNQAgjQ2gAAI0tgwAiBIY8s3J1LrAII0NgIIIgIIohkHPi4IQJDG9t8XHnyHAIJW2tiyfmdjE4AggOisvilvEkAARNG98ezO/SZqNUBYg5iz+PTGBBBUYW8sqRQgKDZ68m3uCpp1DhAUr7FF7I0BAiAofGPLt7AKEABBgRvbAidxP3ZTmQFi9aUVcD6vjgEEnWwEMXuF0KoJIOhkXMu6BUt9BgjFFizncrF1E5UZIJTZclut3cVQ2QACIJbojRfYuAEQAEEaW9/XVpkBgpZoaXpjAgharjd+PN5R5QCClphiRJwFzDU2WeDJFHJBTQR8ZwIIgDhpbwwQAEF646RpUfmH2RFAVLIGofgcqA8QFB49C2zuAgiAoHi98TLnQaADQNBy50Es0M+XfzUIIEhvTABBZUwE7KQECFq0PTcr3klJAEGVNDZ7NwCCNLZ6vrMgQoAAiEp649nXTcQCA0QlaxCKT+0FCDoZegJNXnIP1qxBEDqE3M6UqQK78wIQNSxDlN/SnppnPYbbI+oAgQ65Km7u3jjQ2gFAAARALN0bBwJEI4gQIABi6armwBiAID3b8riMNTYBCIpcIeL0xhGDCAGCFmoM8zaM0EuJs39nscAAEXty0f/meobrgggBghZtEubzAAEQtAR6Qh8MZ6s1QNAJFgtmnBA5kxIgqCo6mLwABIVswHWcly0WGCAobFWzugEQtHBjW/MTE2ovQFD2JqE3XmbUAxAUuM/MfR5EjpMjPYEKEBR+XB2xjgEEQFSyAFF+EG7cUc+a6QAQtFyfGYgRVmQAghYFRNaVAs0YIKivVYRwJoCg8BMBV4MAQpM4/ahnltucVgoAghYFxOM2lu/wlShZHgQQ1iA6m3GT7fi2puyHtfpHKABBax+bhADEwqF+6zxXCiBoCUA0AeMCu8YmAEFFN+DcfabVPoAACKquEi+FS4CgkD2baVHjpgZAKK0cU4y4ewocTg8QZLxwGkDYggUQdIKWPPvzIzmctQuAqGeuMbtzk3MnZeO0S4CgZQbVq91JmTvKGCMAwqw7tnPuKGNrEAABEAtNBPJtJbC5CyCosyVrbAQQREvz1xQDIGIPH0JWNcMTgKC4jMi9pyDQhmhb2gEicpnlzJKKtfy5zBU2xSDoCXx/ZIHoPVMMAoiMzTjW5EW7AIjws4wmz56CQC1kGaiFqxUAoZ/3gHP2aVGgNYh8oaoAoUlkfK5hmWPyckxegtaKg0tx5AUBCIBoelqX6hEUEEYQ1iBkc7Y3jNUe4ZvjSwIERYVa7t0KNkoBBIXv55fPxQAICtYbRzydyXdepmIcWT0AoobeONzXzrpusvIYoXnjAgECIPL2mYutFMjFaDKkgQEERizRjBe4FLaNAQR1NubVTl6WfAwsYvUwxSDEXCgXw10M0tic+wQQAFFLM2484LwUI4JOMTyLseoR9bx1N2tNmB1qC9wfCbdwa6s1hTwBYbHv7DYnQABEvBMQlhz1YARAYETUZy5jASLfyV2LLUBYg6C1Q22Bc2hWOzYBCIrdZ0Yc9QAELT2MnDft3rblJmCWhykGtUyzc5xM6V5D7mmREQQtQYeD3qNYQLjXABAUHhBN/gW/QIAIGophikEzP7EXfbieNUaojuknQNDax1MrD87JNFIDCBpoFasFRE3TT4Cg0kfUgTZx58sZCzeVAwhaouoviZ4ZPVPeXMWIUtugrC057knc9kEAROCK24Q6Ql7BLQ81axDr7eQDHRiTO91bV5+pBAECIGJ38movQNBCgIjY3tTerBcEIGqYZ658IqAC5ytBgKATjHpCLKwGjRozxSDTooWGD5keqwcIWm6eGeUI+XCAyPrUrCkGNQtX3ECDiBDPXEYExOxXBiAAooox8CILqxGvthGEVhFjJyUBBFVSmWJt4qZ8F1lRUScgmmipn2seT+VbiAEIHUVgQORbkYm41mCrNS105z/6vYa1AaLJs7MLIACiklFPjuvjyRSAwIgaRj3hnkwJhnVNLvpIcnbzlXfFBBDUtwBhuE4AQQsBIveoZ14MZQrCBQhaepaRqZMPtK3YxvMeBLuLoZ+ffyIQ60yXJW9zGkHQ2gGxZFdfLNRyP/wOEAQQy61BhCPawpcaINY+4czUKoIOTJzx3cy38xogKOqse4GJQNwNaXONLgGCFgJExOVPWecAUcMkM2IzVusWYIQpBlkpcK8hf2/kQmBEHasbWQ+MAQhaOyDCTV7yXY3op4c37mJYgyh/wW/52rVmQMz+nQGClgDEkvcawk2LAILWzoigS4kR1yCcaq0N59ogtED0HoWsbC5E3H5+5U9qNe41AARFnxs3AU+1joWeTIfcAARALNEklpy8OA/CCAIjrNsDxBLfGSCohsmLh98dOUeVTF6CcmedCZ0AEXuK0QR5+iDoMXkEEIH7+YhnTwPE8qMegAAIgAg2Uosy4wAIgOisUit/dLqOUY8RhJHk2s99EiMEEHSayrTmyUsd8QKmGBRgbNLEvD/iKQ+ACL8M4UzKCiYCAEEBBtVBJy8RQzHyIX7eFRmAAIgTMCLQ4SuxSlAuBtWTzTnXKlq+yUvuJ1ABgjK2t5VPueNmcAME1dPqso7Sc/uvEPFuc1K8KXfrREDFC9NhuBDUhD05MvoTEwBBGBFvPh9rKtdagqYYlLfWrvw50WWe8ij5aRqAqKQlG/IEehZjAWeAMAugvKsbQR8DcxdDexBCU8Pk5fEFLx2+Wh1GNIvvSgy3AXS9ozNNzhpEk/+Rqp7OeUboGPg4k9LwYSHn3Ogpf3Sd4wov9pSHNQiAiDGojgiIgwuyznUTgMCIU87nZ/lDlplfrHNXCEDUMMm0DyIfPTNd4QXiAt3mpDBz44iAyPfnBzocGCDoZAOfHO1t5Sd0AgRlHKAueRcj64TryMuywHhqsYAiaxBm3fPdzcp/+03ZxbrOAAEQCzXjuA+SB/oTAIKiVtysw/UsTyjFvFuUZcKi1VmDyNTYwvWZ0adF1iAoe2MLdHyb2muKQacBRDPfqdOL3RHI197CfWGAWPvMIlCgS6BBdU9jWyEjACL8SLLkjbqVrUGEyOyyBoEOke5ihN5h4YEXgACIekY9ZA2C8vZsiy3LlT9cX6YEC8clQNBCzTjoqGeBXIyScQkQtFAzjrslMdax96YY1Cy2bXnNEy6AAIhK+nlXI+u0qPx4m3ydB0AAROxRj2lRD9QcOYcRwYbrsdZN4lYMh9ZagIjUG9vOtPB4CiAoWG8cqJpF3/35+K8wxaAAgHBUf2xWahvRZxkrH66Ha3vBpkKaXMT+J9CxLnGnRfPupFzgMDu3OQEi0qkNi8XV5pgWBbrOmb4hQADEQj3bYhOu8kEc6G4RQIRnhOID4nyMAAhatHs3Nsk0Vcl0nQGCamvG6rMRhJa8yd0jhZsIxMUxQND8jeHx3YGslWNeqEV5yuPxlwx02yXXs6HaXkRAZG0bOdpDlJiJfN+5y2Fe5/l3VWh7QUcQmbiwQM59yZu4AQIgAKKvggYCxJLXGSDICGIDEFm/c6Y1CICghW5GLpD1NOeTyHmuxoFV+U/E2QdBp+GR66AOqAREBBBEBBBEBBBEBBBEBBDU9N6sIsongAgDCM6cy3EGCIDgzBkgAIIzZ4AACM6cAQIgOHMGCIDgzBkgKL0S7N7stjfbq5dX59+eb77enD0/u3xxef3z9e9//8555c5v3+5ev97e3V3d3p7/8svm5ubs1avL3e767dvfAWIVgHj227OL7y72terpa1/bvvj1C86rdf7zz2e3txd7Ljx97Xnxxx9fAETlgNh3Mq0V6/Fr/xnOK3TeDxNa0fD4tf8MQFQLiH3PM1i3Hl5dvRDnWp33Y4dBOjy8usYRUQEx6qDE9L9i8JODv6g1mWLsm62/pfXN/ay1a1zaOlK9++uO80qc377dPZ5ZfPPN5sMPN++9d//65JPN998fzjX++eeuEkA8PRxxMUAk/mxrZGP/m9P+iu3NNrFu9QxTOVfp/Pr19jEC3n//vjl/9dXmyy/v//HBB0kTjQoB8bQT7gqSSfzk41+XeEEmAGLa4OXq5VVLNXpQW/W6fHHJeSXOd3dXrbOJH3+893733cP3X726rB8QXW/2xzEPfnJsiPM0QPQ/P9f6/sP9sPTqdfb8jPNKnB/uaB68fvhh89FH996ff374n25uzmoARH+TG5y9H9m3p1yQwRnEtN/S/mZrxXqsJzWM80qcW4cPH398b/npp+1LlZUA4mlnmzLF6OmxSwDEcE3SZ3I+egTxzjv3xj/91EKHVYwgpo3zj2zPibdXcgDCrJvz2DWIrlcNaxBd0UNzTRyOBER/MlKOKYZ1e86JdzEeXg9K3y5VGyDSpxijJiMjrleb5zGbI/p/tTv/nJu0fRD9gKhqH8Q6Ze8gZzspaTQgGk8fcPYsBg0+C9i+Hv7vuPSz2884r9b536c5z7uf5pzoDBCRANF0nybQOmvlvCrnrvMgWtcdAKJOQHDmvKQzQAAEZ84AARCcOQMEQHDmDBAAwZkzQAAEZ84AQYflQSTdm/RsnI0gSMXlDBCkenEGCAIIzgBBAMGZM0AABGfOAFENIGJlQ8dtbBHTvd/sdjfb7curq2/Pz7/ebJ6fnb24vPz5+vrv36V7rwMQ4bKhgwIiYrr3b8+efXdx0XoMzZ4Xv34h3bt2QEQ8jygiICKeKLUfJgyeZbf/DEBUC4igJxqGA0TEMyn3Y4fE47K7xhFrBMTYP2pU9u8s6d7pXyNuNnQsQEQ81frNbtc1s2ida/x151TrkRm8kytWjvSNyrKhYwEiYi7GzXY7xrh9ogEQLYneXWEZ6XCpIN07dzZ0LEBETNZ6eXU1ChAvLi8BojNop/XfT/+RNd27/1dUlg0dCxARszkf7mimv56fna0dEKPG9onR4Ym/JQUQ6bmh/70ZNhs6FiAipns/RcDFgPEGIFITvU8CiAlrEHGzoY0gjCDWOIKYnO49DRBxs6GtQViDKJcO/QuWkwFRU7p37mxodzHcxVgXICpL986dDR0LEPZBrOUuRk2Ae5CdlNGvs52UlLdJeBYj+nX2LAblbRLhsqEjAqKJme69H0d03dHYv3/7mXTvFQCiiZYNHRQQTcx0767zIFrXHQCiTkBw5rykM0AABGfOAAEQnDkDBEBw5gwQAMGZM0AABGfOAEGH5UEk3Zv0bJyNIEjF5QwQpHpxBggCCM4AQQDBmTNAAARnzgABECdMndbYlnGW7g0QuZzzpU5rxss4S/cGiFzO+U460oyXcXaiFEDkcs53VqJmvIzzus6k7Dk2urRvOO3N/j+nmnOcNeNlnFd3qnVPJk1pX29yBMbYY+/zVa98eQ2a8TLOq8vF6AJEfwjF4/CLroDcxE5+MF+3JkDkS3zSjJdxXl2y1iAgUkJx039q0Gp2QDwN8jlh9cqXGakZL+O8umzOwTWII6M3p80XEn82HCDypU5rxss4ry7de/IIIqXp9ix8LgOIwbGJEQRnI4jTAOL4tYPBL5k4f5lwd8MaBGdrEBkBkTWAe4KPuxgAMYvzGu9iDO6DSJwsDP7UKKvBr2cfhGbc2AdRyMiiVtlJyXmss3TvZj2bwT2LwXmCs2cxGoDI6pwvdVozXsZZujdA5HXOlzqtGS/jLN0bIDhzXtQZIACCM2eAAAjOnAECIDhzBgiA4MwZIACCM2eAoMPyIJLuTXo2zkYQpOJyBghSvTgDBAEEZ4AggODMGSAAgjNngACIQee3b3evX2/v7q5ub89/+WVzc3P26tXlbnf99q107/WWIEAAxL3+/PPZ7e3FvlY9fe1r2x9/SPdeaQkCBEA0+06mtWI9fu0/oxmvsAQBYu2A2Pc8g3Xr4dXVC2nGFZdgQYAY3PX59O9JjMZb4HsGPdV6P2t9PC795pvNhx9u3nvv/vXJJ5vvvz8cqf7zj1Oty3LOXYKlACIxz2pUGeT4uypL9379evu4Ar3//v0X++qrzZdf3v/jgw+ShqmaccUlWAQgBqNonmbzHiRctkZy92dbpX9m1EAmFiDu7q5ax6I//nj/Dd999/D9V68ka5XlnLsECwVEYo+dmOjd02hT3pkXEEWF9z7cDzt4/fDD5qOP7q/n558f/qebG9mcZTnnLsF6ANH1scGm2POx6tO9Wzufjz++rxKfftq+0KUZF+WcuwQDAOLpU+vpgOhZOOwBROJz8scsTJQ8gnjnnfs//KefWuqWEUSIEcSMJVj6GkRiPPeMA41VpXt3zWC7XtYgoqxBzFWCpd/FOL7lD65Z9DfmCUuqKaAp8y7Gw+tB6ZttNOOKSzDAPoiuKO1py4RPf7bpvstQfbr3wV30/uplH0SBzrlL0E7KvIVafsW1k1IJAkQMOjSexeBcWAkCxFpolfAs4Hn3s4DSvVdaggABEP/NZltPE2idtWrGKylBgAAIzpwBAiA4cwYIgODMGSAAgjNngAAIzpwBglRczgBBSUVFJN2b9GycjSBIxeUMEKR6cQYIAgjOAEEAwZkzQAAEZ84AARBJztK9lSBAAES7pHsrQYAAiHY5UUoJAgRAOJOyTmdnUh57WWf/G1OO3m6Sk3tOWL2ke0d3Xku69wLXdK4/s7XNP/13StLHyauXdO/ozqtI917sgramabUGZ3b18615GROi9wqpXtK9ozuvIt17+aJqTfrsb/k970+L3iuhekn3ju68inTvkwAiZfw/FhBdCcPpwZ/SvTkXVYIAMWWxoGuRsmlLCR/FAunenIsqwVWvQUxeLBjFjpIBId271jWI2tK9F7imo+K8RwFi2iJlCYCQ7h3deUXp3vkua/+NyadzgcHTuGbZB1FC9ZLuHd1Zuve6ZCcl56JKECDWDojGsxhKECAAQrp33c7SvQEir7N0byUIEADBmTNAAARnzgABEJw5AwRAcOYMEKTicgYIUnE5AwRNLCoi6d6kZ+NsBEEqLmeAINWLM0AQQHAGCAIIzpwBAiA4cwYIgEhy3r3ZbW+2Vy+vzr8933y9OXt+dvni8vrn69//lu4dw1m6N0Dkcn7227OL7y72XHj62vPii1+le5fuLN0bIHI574cJrWh4/Np/RjMu1tmJUgCRy3k/dhikw8OraxyhGZ/WuaozKRM3eM51+XL8aUceYF3Uqda7N7uumUXrXOPuL6dal+VcW7p3YrZdsYA4MgKjtFyM7c02kQ49Ew3N+ITOtaV796Rdtfauj4Mq+vvhwcy7xP686zf2/C0zsmDh6nX18qoFBA9qA8TlC8laZTnXlu49Ng6vKw6358fTU3PnyteKC4iHO5rpgDh7LpuzLOfa0r0nACKxRaX7TJgvJP5sok85axDtaHisJ4zQjItyri3dey5APF3pTP+RkwPCCAIgso4gAqd7zwKIxClG+qBjLCAmh/dagwCIZdYgoqZ7pzStUSzIsQYxtg27i6EZn8q5tnTv/n0QibOApu0+xbx3MXpY0Pr97YPQjE/iLN17XbKTkvNYZ+neAJHX2bMY0Z09iwEQeZ3344j2Oxr/ziw+u5XuXbqzdG+AyOvcdR5E67qDZlygs3RvgODMeVFngAAIzpwBAiA4cwYIgODMGSAAgjNngAAIzpwBgg7Lg0i6N+nZOBtBkIrLGSBI9eIMEAQQnAGCAIIzZ4AACM6cAaIaQOTL4M6RDZ37O3N+rDe73c12+/Lq6tvz8683m+dnZy8uL3++vv77d+ne6wBEvgzuTNnQWb8z58f67dmz7y4uWo/72fPi1y+ke9cOiHznPuU7jyjfd+b8WPthwuCZgfvPAES1gMh3cmS+Ew3zfWfOB2OHxGPJu8YRlQAiXzL4tK9x5Jvpx97nO3s6XzZ0vu/M+WDdoWtm0TrX+OvurmZALLOom/gdJmeCjR1B5EuvyJcNne87c36sm+12jHH7RKNOQCQ20YP4nNOme6d7Pla+/Kt82dD5vjPnx3p5dTUKEC8uLwGiPVkrPeY3X7r34BRp4QTNfNnQ+b4z58d6uKOZ/np+dgYQUwb5y4T3TgzszJbBnS8bOt935vxYTxFwMWC8AYgRgOhJCW+KSfdeeAQxSza0ft4IIjwgoqR7L78GcXw2tJUCaxAF3cVIT/RuJuWAJ3Iq0xRjsbsYM2ZDu9fgLsYJADGYDD5tipHehk+S7r3YPogZs6HtVljG2T6IdclOSs52UtJoQDSexeDsWQw6VQZ3pmzorN+Z88E4ouuOxv7928+ke68AEE3ODO4c2dC5vzPng/WI1vMgWtcdAKJOQHDmvKQzQAAEZ84AARCcOQMEQHDmDBAAwZkzQAAEZ84AQYflQSTdm/RsnI0gSMXlDBCkenEGCAIIzgBBAMGZM0AABGfOAAEQJ0z31tjiliBAAMS98qV7a8ahSxAgACLjiVKacfQSBIi1AyLfmZSacQUlWBsgUvaQHv/39px2Pfhm/3dYuHrlS/fWjOsowQoBkbsIW0Hw9N89x+ePPfY+35XJl+6tGddRgisCxNMIjGZ8uvdTh2Z8kHc5gMiX7q0Z11GCawFEeohWSrp3OiC6hhuFACJfurdmXEcJrmUNYplszoPf2ONZCCDypXtrxnWU4OpGEE/b84R078nBf2PHJifpf2ZJ99aM6yjBtQMi8ZOjLuhYJBU4gz0+3VszrqMErUHMOcVoxoQAl1C98qV7a8Z1lOCK9kGMuosxbYoRfR/EjOnemnEdJWgnZYwRUD5nOymVIEAAhGcxanb2LAZA5HXOl+6tGYcuQYAAiP9ms5nSvTXjuCUIEADBmTNAAARnzgABEJw5AwRAcOYMEADBmTNAkIrLGSAoqaiIpHuTno2zEQSpuJwBglQvzgBBAMEZIAggOHMGCIDgzBkgACLJefdmt73ZXr28Ov/2fPP15uz52eWLy+ufr3//W7p3DGfp3gCRy/nZb88uvrvYc+Hpa8+LL36V7l26s3RvgMjlvB8mtKLh8Wv/Gc24WGcnSgFELuf92GGQDg+vrnGEZnxaZ2dSjruIJad7l5aLsXuz65pZtM417v5yqnVZztK95y+ek6d7j30z35XZ3mwT6dAz0dCMT+gs3Xu24ikn3bspJhfj6uVVCwge1AaIyxeStcpylu49T/GUk+7dpCX3LXNlHu5opgPi7LlszrKcpXvPswZRTrp3UYBoR8NjPWGEZlyUs3TvmUcQzUnTvY0gAGKBEYR079kAkfjJCXOEsXmf1iA4z7gGId074xrE5ClGOEC4ixHdWbr3PGsQTTHp3kUBwj6I6M7SvdclOyk5j3W2kxIg8jp7FiO6s2cxACKv834c0X5H49+ZxWe30r1Ld5buDRB5nbvOg2hdd9CMC3SW7g0QnDkv6gwQAMGZM0AABGfOAAEQnDkDBEBw5gwQAMGZM0DQYXkQSfcmPRtnIwhScTkDBKlenAGCAIIzQBBAcOYMEADBmTNAVAOIfBncnKM7v9ntbrbbl1dX356ff73ZPD87e3F5+fP19d+/S/deByDyZXBzju7827Nn311ctB73s+fFr19I964dEPnOfeIc3Xk/TBg8M3D/GYCoFhD5To7kHN15P3ZIPJa8axxROSBS8m9G/Y2DB0+nH2A9S7p3vrOnOUd3frPbdc0sWucaf93drREQ8679JiZfHZmvkf5mvvQKztGdb7bbMcbtE401AuJxdu7TrL2efn7w8ZVZADEqsytf/hXn6M4vr65GAeLF5SVAtDfUaZ1/DkCMzebMl6DJObrzwx3N9Nfzs7M1AqInICsTIAbDuGYERL4Mbs7RnZ8i4GLAeLNGQCw/glgSEPpMzkYQkQCxcHivWTdnaxBhANG/4pgDENbtObuLkR0QzcjdCoPrHROcpwHCnX/OjX0Q1Ng7yNlOSpoAiMbTB5w9i0GnyuDmHN15P47ouqOxf//2M+neKwBEkzODm3N0567zIFrXHQCiTkBw5rykM0AABGfOAAEQnDkDBEBw5gwQAMGZM0AABGfOAEGH5UEk3Zv0bJyNIEjF5QwQpHpxBggCCM4AQQDBmTNAAARnzgABECfJhtbYlnTOkRsOEABxr0zZ0JrxYs6ZcsMBAiAynkekGS/jnO+sKoBYOyCynmioGS/gnO+0y4IA0Z/QvcA33IxJHGo9+X5y5PcJq1fuM5E149zO+c7LLg4QJ7noEwDRf5J9jsjvfH9g7lQFzTi3c77EjQCAOEjo7hpl/N/Henrpg8/0ZHl2ebb6HAOIEqpX7lwmzTi3c77MrjCA6GmQTzHR0zITm27rj/R/27GAKGeKkTvZUTPO7Zwv9bPcNYgJgJjcdScm9CUComsBZZBTp6peubOhNePsnWi23PCoI4iUWO2e9c4uHh0DiP6ZTslrEEYQRhBVAWLs2H4UVo4BxJGkswYBENYgMgIifYkhZUaQew2iHEC4ixHd2V2MllnD5LsY6YP/rrsY/VMM+yA0Y/sgCpW/YpqznZTRnVexk3LyJRs8dRMgBp09ixHd2bMYa9EJn+bMkQ2tGS/mnCk3HCAA4r/1iNmzoTXjJZ1z5IYDBEBw5gwQAMGZM0AABGfOAAEQnDkDBEBw5gwQpOJyBghKKioi6d6kZ+NsBEEqLmeAINWLM0AQQHAGCAIIzpwBAiA4cwYIgEhyfvt29/r19u7u6vb2/JdfNjc3Z69eXe5212/fSvdebwkCBEDc688/n93eXuxr1dPXvrb98Yd075WWIEAARLPvZFor1uPX/jOa8QpLECDWDoh9zzNYtx5eXb2QZlxxCU4BxJHHQObI7M56/HSPedd/7XcbG6uR7xLtZ62Px6XffLP58MPNe+/dvz75ZPP994cj1X/+cap1Wc65S3B0U0/JlSkEEMfEcDdjAsdHJQOOJVrWS/T69fZxBXr//fsr9tVXmy+/vP/HBx8kDVM144pLcBwgutKuR3XOg0m2Yzv5ZvEY7sHrkIKbEoJz7u6uWseiP/54f2Hffffw/VevJGuV5Zy7BI8FxDFtLz0aM92n/wuPDd3qmUEMXqXBIUMJgHi4H3bw+uGHzUcf3f/hn39++J9ubmRzluWcuwSnA6InHTe9YU/ozxeL4R7btnumNsUCorXz+fjj++//6aftC12acVHOuUtwtilGTy7eqBztaYHds8dwT2jbXROocCOId965vxo//dRSt4wgQowgZizBOQGRvnY4y4pA1hjusYCYsORZ8hpE18saRJQ1iLlKcLa7GCecYpw8hrvn34O55KetXgdr4A+vB6VvttGMKy7BOfdBTLuLMbi6Mfhmc4oY7vTr8PhmTeH7IPqrl30QBTrnLkE7KcuSnZSciypBgFg7IBrPYihBgACIhGcBz7ufBZTuvdISBAiA+G8223qaQOusVTNeSQkCBEBw5gwQAMGZM0AABGfOAAEQnDkDBEBw5gwQpOJyBghKKioi6d6kZ+NsBEEqLmeAINWLM0AQQHAGCAIIzpwBAiA4cwYIgEhylu6tBAECINol3VsJAgRAtMuJUkoQIADCmZR1Old4JqV88EKql3Tv6M7FpXvP+3euOR+8hOol3Tu6c1np3jn+yLXlg/ePKaR7cy6qBE8PiGPaXrh88FGBXQtceene0Z3LSveefX6x2nzwRro3QEQowYKmGCvJB+9fuZTuzbmoEiwLEGO72XD54KVNMaR717oGcbJ079lnGUeuQcxCjcXywQd/o3RvzkWVYFn7INaQD54+GVmgekn3ju4s3XtdspOSc1ElCBBrB0TjWQwlCBAAId27bmfp3gCR11m6txIECIDgzBkgAIIzZ4AACM6cAQIgOHMGCFJxOQMEqbicAYImFhWRdG/Ss3E2giAVlzNAkOrFGSAIIDgDBAEEZ84AARCcOQMEQCQ5S/dWggABEO2S7q0EAQIg2uVEKSUIEADhTMo6nes8k1LAdwnVS7p3dOcK070bAd/FVC/p3tGda0v3bgR8j8npyV29pHtHd64t3bsR8D0+ajDfZZfuHd25tnTvZvUB3/1XW7o356JKsKwpxhoCvosChHTvKkcQgdO9GwHfJQFCunetaxCB070bAd/FrEFI947uXGe6dyPgu4y7GNK9oztL916X7KTkXFQJAsTaAdF4FkMJAgRASPeu21m6N0DkdZburQQBAiA4cwYIgODMGSAAgjNngAAIzpwBglRczgBBKi5ngKCJRUUk3Zv0bJyNIEjF5QwQpHpxBggCCM4AQQDBmTNAAARnzgABEEnO0r2VIEAARLukeytBgACIdjlRSgkCBEA4k7JO5wrPpBTt3ZRx7L107+jOFaZ7i/YuBxDSvaM715buLdo7MaFvmeol3Tu6c23p3qK9+3+jdG/ORZXgKQGx8mjvEgAh3Tu6c23p3qK9iwKEdO8qRxCB071FexcFCOneta5BBE73Fu1dzhqEdO/oznWme4v2borcByHdO5yzdO91yU5KzkWVIECsHRCNZzGUIEAAhHTvup2lewNEXmfp3koQIACCM2eAAAjOnAECIDhzBgiA4MwZIEjF5QwQpOJyBgiaWFRE0r1Jz8bZCIJUXM4AQaoXZ4AggOAMEAQQnDkDBEBw5gwQAJHkLN07uvOb3e5mu315dfXt+fnXm83zs7MXl5c/X1///bt0b4A4zlm6d3Tn3549++7iYs+Fp689L379Qro3QEx1dqJUdOf9MKEVDY9f+88ABECMdnYmZXTn/dhhkA4Pr65xhHTv6Vd/9lOti6pe0r2jO7/Z7bpmFq1zjb/upHvPd/WPSfee9mdK9+Y8yvlmu02kQ89EQ7r3wJvN4uneE4K8clQv6d7RnV9eXY0CxItL6d4lJWt1oa0pOJtTuncg54c7mumv52fSvYtJ9z4mdnSZ6iXdO7rzUwRc/P/nuJ9+IOoUo7J078FYQOneAGEEMQ4QY7vZktO9p41ZpHtzXvUaRCPdu/c3SvfmPMq5trsYrasP/e9L985XvaR7R3eucB8EFVVx7aSM7lzhTkoqquJ6FiO6s2cxACKvs3Tv6M77cUTXHY39+7efSfcGiOOcpXtHd+46D6J13QEgAIIz52OdAQIgOHMGCIDgzBkgAIIzZ4AACM6cAQIgOHMGCDosDyLp3qRn42wEQSouZ4Ag1YszQBBAcAYIAgjOnAECIDhzBgiAkO5dvXOOEgQIgLiXdG8lCBAA0S4nSilBgAAIZ1LW6Zy1BAsCRJTI71lOtS7k2Hvp3tGdc5dgKYCIEvl9fK5f/9eT7s25qBIsAhCBIr8HkTQt8vtU1Uu6d3Tn3CVYKCCO6bEXiPw+xrx/JiXdm3NRJVgcIEJEfjdHhwY20r0BIkIJlj7FKDPyezIgUlZAT97/SPeOPoKYsQQDAGJs01o+8jsuIKR717oGMVcJln4Xo8DI7xy3Nk5VvaR7R3fOXYIB9kEUFfnddVDXkZsjTlW9pHtHd85dgnZSliU7KTkXVYIAsXZANJ7FUIIAARDSvet2zlSCAAEQ/81mpXsrQYAACM6cAQIgOHMGCIDgzBkgAIIzZ4AACBWXM0CQissZIGhKURFJ9yY9G2cjCFJxOQMEqV6cAYIAgjNAEEBw5gwQAMGZM0AARJKzdG8lCBAA0S7p3koQIACiXU6UUoIAARDOpKzT2ZmUj77oyK+a6Wj5Y47elu4NEIFKMAYgJmd/52iErSB4+u8QwTnSvaM7ryLde0J3ndJ1t35y8Me7wsEP/uuRgCgkF0O6d3TnVaR7T77i02K+UwI7RzXjsYBI/IsWuIzSvaM7ryLde9T84sjs72aOdO+uBj+IpNIAId07uvMq0r0nTzGOZ8G0dO+uRcqUSU35Iwjp3tFHELWle58QEInTlmmznlGeRc1gpXtHX4OoLd171Cwj9xrE5ClGk5YhXE71ku4d3XlF6d6DV2ds9ndzxF2MaVOMxHTvcqqXdO/oztK91yU7KTkXVYIAsXZANJ7FUIIAARDSvet2lu4NEHmdpXsrQYAACM6cAQIgOHMGCIDgzBkgAIIzZ4AgFZczQJCKyxkgaGJREUn3Jj0bZyMIUnE5AwSpXpwBggCCM0AQQHDmDBAAwZkzQABEkrN0byUIEADRLuneShAgAKJdTpRSggABEM6krNPZmZQjLtmEv2WWHxl1qnXPNZfuzbmoEgSI0T9yTLr3tMjvfNVLund0Z+neEwHRE3UxGOc9mLt7fLp3IYCQ7h3dWbr3nIBIjPMe27bjAkK6d3Rn6d7Do/30DN704MzWkcIgINLTvQtZg5DuHd1ZuvdCU4xjANGMTPcufAQh3Tv6CGJd6d7zAmLUZCRHuneINQjp3tHXINaV7n0MIFLmHaOivY9Zgyj8LoZ073DO0r0nAqIZGec9Koa71n0Q0r3DOUv3Log+oX+pnZS1OttJuRY6NJ7F4FxYCQLEWsAk3btuZ+neAJHXWbq3EgQIgODMGSAAgjNngAAIzpwBAiA4cwYIUnE5AwSpuJwBgiYWFZF0b9KzcTaCIBWXM0CQ6sUZIAggOAMEAQRnzgABEJw5AwRAJDlL947uvHuz295sr15enX97vvl6c/b87PLF5fXP17//Ld0bII5zlu4d3fnZb88uvrvYc+Hpa8+LL36V7g0QU52dKBXdeT9MaEXD49f+MwABEKOdnUkZ3Xk/dhikw8OraxyxolOtT/V7pXtrxidx3r3Zdc0sWucad3/dAUT2XyrdWzMuxHl7s02kQ89EYxWASIztPrKTn5bu3f/JE1Yv6d7Rna9eXrWA4EFtgLh8scpkrZTIrNbQrQmd/ChApOSAnrB6SfeO7vxwRzMdEGfP153N2aTl947t+RMBkY6k/hHKYtdKund053Y0PNYTRqx9ijEKEK2PxKc8JN+1MJEYL95I9wYII4gFoDBhspA+WDgm3XvabEK6N2drEBkBMXYEkXsNYhZq5Kte0r2jO7uL0f2l2249jBpBNJO2KjTSvTXjYpztg1iX7KTkPNbZTkqAyOvsWYzozp7FAIi8ztK9ozvvxxHtdzT+nVl8divdGyCOc5buHd256zyI1nUHgAAIzpyPdQYIgODMGSAAgjNngAAIzpwBAiA4cwYIgODMGSDosDyIpHuTno2zEQSpuJwBglQvzgBBAMEZIAggOHMGCIDgzBkgAOIk2dAa25LOOfLZAQIg7pUpG1ozXsw5Uz47QABExvOINONlnPOdCQYQawdE1hMNNeMFnLOeKlo6IPq/m3TvI69k7jORNePczrnz2QFiyleqJhcjd6qCZpzbOXc+eyRApOR3d72Z3p93/fjBfz0eECVUr9y5TJpxbufc+exhAJGS393/5jGe/Rd0LCDKmWLkTnbUjHM7585nDw+IY7ru2aP3UoCV/pUWqF65s6E149zOufPZ1wKIntnE8YBoOjK709MAjSAAYsYRxIz57CUCYsbBQn8jnBEQx/xGaxAAMfsaxFz57GsBhHRvdzGqdM6dz17oFGPUHYfJU4x0z8Qphn0QmnFl+ex2Uha65rKYs52U0Z1XvZMSIBZw9ixGdGfPYgBEXudM2dCa8WLOmfLZAQIg/luPmD0bWjNe0jlHPjtAAARnzgABEJw5AwRAcOYMEADBmTNAAARnzgBBKi5ngKCkoiKS7k16Ns5GEKTicgYIUr04AwQBBGeAIIDgzBkgAIIzZ4AAiCTnHNnQGlv0EgQIgLhXpmxozTh6CQIEQGQ8j0gzjl6CALF2QGQ90VAzjl6C8wNibXncTfcB9l0+5ZxqnTsbWjOOXoKrAMQCedw9YXxdP15CLkbubGjNOHoJ5gVEZXnc9QEidza0Zhy9BDMCoqY87mmA6CdCCYDInQ2tGUcvwRMAYsKbExp2IiAGgdW/BtGf4tW16lHOGkTubGjNOHoJlguIJkIed2ubP/hHF/KKHUHMmA2tGUcvwXkAsdo87rG8i7IGMVc2tGYcvQTLBUT5edxdvOiaa5R/F2P2bGjNOHoJzjbFWGEed887rZOO8vdBzJ4NrRlHL0E7KcuSnZSciypBgFg7IBrPYihBgACIk2RDa8bRSxAgAOK/2ezs2dCacfQSBAiA4MwZIACCM2eAAAjOnAECIDhzBgiA4MwZIEjF5QwQlFRURNK9Sc/G2QiCVFzOAEGqF2eAIIDgDBAEEJw5AwRAcOYMEACR5Lx7s9vebK9eXp1/e775enP2/OzyxeX1z9e//y3de70lCBAAca9nvz27+O5iX6uevva17YtfpXuvtAQBAiCafSfTWrEev/af0YxXWIIAsXZA7Huewbr18OrqhTTjikuwIECsMBb85NVrP2vtGpe2jlTv/nKq9bpKECAGvlK+UM8Sqtf2ZptYt3qGqZpxxSVYKCAqjgUvKhfj6uVVSzV6UFv1unwhWass59wlWCIgKo4FTw8ZXKZ6PdwPS69eZ89lc5blnLsEIwFiwpsTGnYiII6MBS8EEO0V67Ge1DDNuCjn3CVYISCasmPB+x/CN4LgbARxghF7IbHgpU0xrEFYg1gdIEqOBe+ajJyqermLEd25/rsYa4sFb52hnKp62QcR3XlF+yCosZOSc2ElCBBrB0TjWQwlCBAAMfgsYPt6+L/j0s9upXuvtAQBAiD+m822nibQOmvVjFdSggABEJw5AwRAcOYMEADBmTNAAARnzgABEJw5AwSpuJwBgpKKiki6N+nZOBtBkIrLGSBI9eIMEAQQnAGCAIIzZ4AACM6cAQIgkpyleytBgACIdkn3VoIAARDtcqKUEgQIgHAmZZ3O0r3zXvex3+qYU60H/wqnWnMuqgQBYuAr5cvmLKF6ycWI7izd+//91+jp3v2/sZGsxbmwEpTuvXS6d3rI8ALVSzZndGfp3lWle5eWzSndO7qzdO+q0r1LA4QRhBFEI927ke5tDcIahHTv2flS/RqEuxjRnaV7T5kjFJvuXdpdDPsgojtL916X7KTkXFQJAsTaAdF4FkMJAgRASPeu21m6N0DkdZburQQBAiA4cwYIgODMGSAAgjNngAAIzpwBglRczgBBKi5ngKCJRUUk3Zv0bJyNIEjF5QwQpHpxBggCCM4AQQDBmTNAAARnzgABEEnO0r2jO799u3v9ent3d3V7e/7LL5ubm7NXry53u+u3b6V7A8RxztK9ozv/+eez29uLPReevva8+OMP6d4AMdXZiVLRnffDhFY0PH7tPwMQADHa2ZmU0Z33Y4dBOjy8usYRUQHReqJ0c7qk7/4vlnjUdX+RONWa8yjnt293j2cW33yz+fDDzXvv3b8++WTz/feHc41//rmrFhDpGdm5v9XksIwuh1NVL7kY0Z1fv94+RsD7799Xra++2nz55f0/PvggaaJRAyCOjMBoyoj8Lg0QkrWiO9/dXbXOJn788b4M33338P1Xry4rBETKUGLGN/NFfg/OkmRzch7l/HBH8+D1ww+bjz66L8PPPz/8Tzc3Z7UBomslIpEmiW8uGfldDiCke0d3bh0+fPzxfdF9+mn7UmVVgEgZ0rdOExJnE09/fJnIbyMIgMg3gnjnnfsC/OmnFjpUOII4prc/cqyRI/K7/5QOaxCcZ1mD6HrVuQbR1bAHFw5Ki/w+Bj05qpe7GNGdD+5iPLwelL5dquZ9ED1j+2PuYkybYtgHoRmfdh9EPyBq2wexQtlJyXms83p3UgLEMs6exYju7FkMgMjrLN07uvO/T3Oedz/NKd0bII5zlu4d3bnrPIjWdQeAAAjOnI91BgiA4MwZIACCM2eAAAjOnAECIDhzBgiA4MwZIOiwPIike5OejbMRBKm4nAGCVC/OAEEAwRkgCCA4cwYIgODMGSAAQrp39c5vdrub7fbl1dW35+dfbzbPz85eXF7+fH399+/SvQHiOGfp3tGdf3v27LuLi9bjfva8+PUL6d4AMdXZiVLRnffDhMEzA/efAQiAGO3sTMrozvuxQ+Kx5F3jCOneS3yxYyJCT1W9nGod3fnNbtc1s2ida/x1J907/7eanIsxLeknX/WSixHd+Wa7HVOA7RMN6d4j3sya7j14qSVrcR7l/PLqahQgXlxK9y443bufPo1sTs4jnR/uaKa/np9J9y443XuQPtK9OY9yfoqAi4EClO4dId27EEAYQRhBNNK9J481cqR7FwUIaxDWIBrp3k0x6d7uYgDEvM7uYgysSoRL97YPAiBmdF71PogVyk5KzmOd17uTEiCWcfYsRnRnz2IARF5n6d7RnffjiK47Gvv3bz+T7g0QxzlL947u3HUeROu6A0AABGfOxzoDBEBw5gwQAMGZM0AABGfOAAEQnDkDBEBw5gwQdFgeRNK9Sc/G2QiCVFzOAEGqF2eAIIDgDBAEEJw5AwRAcOYMEAAh3bt6Z+neAJHLWbp3dGfp3gCRy9mJUtGdnSgFELmcnUkZ3Vm69+E70r3nql5OtY7uLN275f9K956resnFiO4sF2P430HTvSVrAcTxzpK1UocSgdK9ywGEbM7ozrI5q0r3Lm0NQrp3dGfp3tK9jSA4G0FMWoOQ7m0NwhqENYjOZibd+8jq5S5GdGd3MQZWJaR7H1O97IOI7izde12yk5LzWGfp3gCR19mzGNGdPYsBEHmdpXtHd5buDRB5naV7R3eW7g0QnDkv6gwQAMGZM0AABGfOAAEQnDkDBEBw5gwQAMGZM0DQYXkQSfcmPRtnIwhScTkDBKlenAGCAIIzQBBAcOYMEADBmTNAAMSg89u3u9evt3d3V7e357/8srm5OXv16nK3u377Vrr3eksQIADiXn/++ez29mJfq56+9rXtjz+ke6+0BAECIJp9J9NasR6/9p/RjFdYggCxdkDse57BuvXw6uqFNOOKS7AGQCRGb+X+jRFPtd7PWh+PS7/5ZvPhh5v33rt/ffLJ5vvvD0eq//zjVOuynHOXYIWAWIAO1eRivH69fVyB3n///k/76qvNl1/e/+ODD5KGqZpxxSVYGyDSw7sHP5Aj3XuwVBauXnd3V61j0R9/vP/z33338P1XryRrleWcuwSrAkRiuz1hundpgHi4H3bw+uGHzUcf3V+Ezz8//E83N7I5y3LOXYL1AKJ/JWKw3c6e7t2z3FDOGkRr5/Pxx/df79NP2xe6NOOinHOXYCWAmDzyz5fuHXcE8c4793/LTz+11C0jiBAjiBlLsOY1iONH/seke4deg+h6WYOIsgYxVwnWfBdj+SlGE/wuxsPrQembbTTjikuw8n0Q/eHdzerTvQ/uovdXL/sgCnTOXYJ2UpYOu9zOdlIqQYAACM9i1OzsWQyAyOv877OA593PAkr3XmkJAgRA/DebbT1NoHXWqhmvpAQBAiA4cwYIgODMGSAAgjNngAAIzpwBAiA4cwYIUnE5AwQlFRWRdG/Ss3E2giAVlzNAkOrFGSAIIDgDBAEEZ84AARCcOQMEQCQ5797stjfbq5dX59+eb77enD0/u3xxef3z9e9/S/eO4SzdGyByOT/77dnFdxd7Ljx97Xnxxa/SvUt3lu4NELmc98OEVjQ8fu0/oxkX6+xEKYDI5bwfOwzS4eHVNY7QjE/rvN4zKZeM7R7lXM2p1rs3u66ZRetc4+4vp1qX5bzqdO8lY7vTzWtK997ebBPp0DPR0IxP6LzqdO9ZIrMSu/GUTM3m6HTv0gBx9fKqBQQPagPE5QvJWmU5rzrde2xs9yxvripZ6+GOZjogzp7L5izLedXp3sfHdqenb45qrsekexe1BtGOhsd6wgjNuCjnVad7HxPb3T+bGAz1HtuME9O9jSAAYoERxFrSvTPFdqf/19nTva1BAMQyaxCrSPcejO1uHQL0jAtGrUGkjyDcxdCMT+W86nTvwdju1qlBM9NdjGYF6d72QUR3lu69LtlJyXmss3RvgMjr7FmM6M6exQCIvM77cUT7HY1/Zxaf3Ur3Lt1ZujdA5HXuOg+idd1BMy7QWbo3QHDmvKgzQAAEZ84AARCcOQMEQHDmDBAAwZkzQAAEZ84AQYflQSTdm/RsnI0gSMXlDBCkenEGCAIIzgBBAMGZM0AABGfOAAEQJ8mG1tiilyBAAMS9MmVDa8bRSxAgACLjeUSacfQSBIi1AyLriYaacfQSjAeIUSm7mco15VTrrq2sRZ1qnTsbWjOOXoI1AyLfF0jJxWj9QGm5GLmzoTXj6CVYDyB6oi7+L+TiIFbj8Y8k5mKkRwEO/tcSAJE7G1ozjl6ClQBiMCxrMCh89mStsZ88SfXKnQ2tGUcvwbUAYrDFHpPN2cOU9E+epHrlzobWjKOXYD2A6AnsnjcEuElL9x77yXL6nxmzoTXj6CVY4Qgisc0PDiWa49K9B+tKyWsQc2VDa8bRS3C9axCjosOnrUGkL1ieqnrlzobWjKOXYEhAdE0oFriL0T9xGJxfNGXvg5g9G1ozjl6Cq9hJOfkPXP7K2EnJuagSBIi+EUoglh3j7FkMJbhqQKxhsHOkc6ZsaM04egkCBED8N5udPRtaM45eggABEJw5AwRAcOYMEADBmTNAAARnzgABEJw5AwSpuJwBgpKKiki6N+nZOBtBkIrLGSBI9eIMEAQQnAGCAIIzZ4AACM6cAQIgkpx3b3bbm+3Vy6vzb883X2/Onp9dvri8/vn697+le8dwfrPb3Wy3L6+uvj0//3qzeX529uLy8ufr679/l+4NEMc5P/vt2cV3F3suPH3tefHFr9K9S3f+7dmz7y4u2gpws+fFr19I9waIqc77YUIrGh6/9p/RjIt13g8Thgpws/8MQADEaOf92GGQDg+vrnGEZnxa5/3YIa0AN13jiHUBYtqfMyo0vPUA68Q3m+RYjQUuy+7Nrmtm0TrXuPvLqdZlOb/Z7bpmFq1zjb/u7gBis4x5ejBP65n6JVSv7c02kQ49Ew3N+ITON9vtmAJsn2gARNOfl9HahgcvywRA9MdtLF+9rl5etVSiB7XVr8sXkrXKcn55dTUKEC8uLwFiBCCmhfceM4IoChAPdzTTAXH2XDZnWc4PdzTTX8/PzgBidDZfMz4I75gQ4HIA0Y6Gx3pSxTTjopyfIuBioAA3AHEsIBKfk68AEEYQRhAAMWWZoP/CpYT3hgCENQhrEAAxvO7QjEn3TszsDgEIdzGiO7uLMeU69sR/N2PuRPakeD9NErcPQjNu7IOg5Yc/WZ3tpIzubCclQOR19ixGdGfPYgBEXuf9OKL9jsa/M4vPbqV7l+68H0d03dHYv3/7mXRvgDjOues8iNZ1B824QOeu8yBa1x0AAiA4cz7WGSAAgjNngAAIzpwBAiA4cwYIgODMGSAAgjNngKDD8iCS7k16Ns5GEKTicgYIUr04AwQBBGeAIIDgzBkgAIIzZ4AACOne1Tu/fbt7/Xp7d3d1e3v+yy+bm5uzV68ud7vrt2+lewPEcc7SvaM7//nns9vbiz0Xnr72vPjjD+neADHV2YlS0Z33w4RWNDx+7T8DEAAx2tmZlNGd92OHQTo8vLrGEYEBMepI6K5Pzv4H9px2Pe3NU1Uvp1pHd377dvd4ZvHNN5sPP9y8997965NPNt9/fzjX+Oefu9oAkR6NvUxRtbb5firNEvaXo3rJxYju/Pr19jEC3n//vnJ+9dXmyy/v//HBB0kTjWoB0ZpP0TzJznsart3fq/c8x9KalzEjCyRrcR7lfHd31Tqb+PHH+zJ8993D91+9uqwNEK3/20wK7B4b550peq8cQMjmjO78cEfz4PXDD5uPProvw88/P/xPNzdnawHE4HJDIgtmBEQXgFoHLCVUL+ne0Z1bhw8ff3xfdJ9+2r5UuSJAtObrTQBEV5re2EXKJjnCzwgCIPKNIN55574Af/qphQ4rGkFMWBoc/JHEYh4brmkNAiAWXoPoetW5BjH4j9mnGKMA4S6GZnwq54O7GA+vB6Vvl6oTEE1CYPeoOO+Uuxj9Uwz7IDTj0+6D6AdEhfsg1iY7KTmPdV71TkqAWMDZsxjRnT2LARB5naV7R3f+92nO8+6nOaV7A8RxztK9ozt3nQfRuu4AEADBmfOxzgABEJw5AwRAcOYMEADBmTNAAARnzgABEJw5AwQdlgeRdG/Ss3E2giAVlzNAkOrFGSAIIDgDBAEEZ84AARCcOQMEQEj3rt5ZujdA5HKW7h3dWbo3QORydqJUdGcnSgFELmdnUkZ3rvBMymMyu+ctnmkJ4CmnWvfk8TjVGiDmcq4z3fuYzO5MF31UaHhKLsbgb5GLARDHO9eZ7j02szv9zX7u9OdfPH2/61KOAsSowYJkLc6jnOtM9543UK9JDuAa9fnmuHTvlEt/8uolmzO6c53p3sdkdk8YzC8GiP7ZR8qUSro351HOdaZ7j83snjDFOAYQg8/JJ6Z7G0FoxicZQYRP9x47xZgwcJhlBDGhEqQMQKxBAETuNYjY6d7zZnYXuwaRCKkTVi93MaI715nuPTazu8lzF+Pgd6XcxeifYqQvQNgHARCzOEv3XpfspOQ81lm6N0DkdfYsRnRnz2IARF5n6d7RnaV7A0ReZ+ne0Z2lewMEZ86LOgMEQHDmDBAAwZkzQAAEZ84AARCcOQMEQHDmDBB0WB5E0r1Jz8bZCIJUXM4AQaoXZ4AggOAMEAQQnDkDBEBw5gwQACHdu3pn6d4AkctZund0Z+neAJHL2YlS0Z2dKAUQuZydSRndeY1nUvZsBZ0WaTHjGfPHRIc2TrUGiFmd60z3nnAtet45Mupm8hebK0/0hNVLLkZ05zrTvY8BxOMYi4MhRn9ieNebXR17T2hoNYCQrBXduc507+MBMeEfE0K3ErPz4gJCNmd05zrTvXOvQUwO5kyfuQzG7YUAhHTv6M51pntPm+pnBcRTGK0BEEYQVY4gwqd7j70WS44gEq/ajCuX1iAAYvY1iNjp3osBYmy0d8oUYyx9GncxACKbc53p3nMtUh7cmxi8i9HfXHt+pGtxpOfHG/sgNOP8ztK91yU7KTmPdZbuDRB5nT2LEd3ZsxgAkddZund0Z+neAJHXWbp3dGfp3gDBmfOizgABEJw5AwRAcOYMEADBmTNAAARnzgABEJw5AwQdlgeRdG/Ss3E2giAVlzNAkOrFGSAIIDgDBAEEZ84AARCcOQMEQEj3rt45RwkCBEDcS7q3EgQIgGiXE6WUIEAAhDMp63TOWoIBAJG+LfSYEhr1U62HbjvVWjOurwRjAGJUGeQGRGubf/pvuRiacQUlGB4QPancg13306DwwU6+NfJbspZmXGsJxgbEYCr3XJ/s/0qyOTXjWksw9hrEkS1zQqh3PyC6iNP/5gmrl3Tv6M65SzDYCOKYrrs/v3swRy9lkbLpiP8bfNMIAiCMIOa5LsePIFLQM2qKMYz54960BsHZGsScgJiQ373ONQh3MaI7u4uR/S5GK1amTTHsg9CM7YOgRWmY29lOSiUIEADhWYyanT2LARB5naV7K0GAAIg+SfdWggABEJw5AwRAcOYMEADBmTNAAARnzgBBKi5ngCAVlzNA0MSiIpLuTXo2zkYQpOJyBghSvTgDBAEEZ4AggODMGSAAgjNngACIJOe3b3evX2/v7q5ub89/+WVzc3P26tXlbnf99q107/WWIEAAxL3+/PPZ7e3FvlY9fe1r2x9/SPdeaQkCBEA0+06mtWI9fu0/oxmvsAQBYu2A2Pc8g3Xr4dXVC2nGFZdgJECMjfnOV67VnGq9n7U+Hpd+883mww837713//rkk8333x+OVP/5x6nWZTnnLsFggMhXGOtM9379evu4Ar3//v2f9tVXmy+/vP/HBx8kDVM144pLsB5AJHbXB7F3Pel4a0j3vru7ah2L/vjj/Z//7ruH7796JVmrLOfcJVgJIMaGdKa82awgWevhftjB64cfNh99dH9BPv/88D/d3MjmLMs5dwlWsgZxfBM9JptzVJB3UWsQrZ3Pxx/ff71PP21f6NKMi3LOXYJRRxCz9+GtbTi9GScGeYcYQbzzzv3X/umnlrplBBFiBDFjCQaeYmQaQUyYYgz+p3BrEF0vaxBR1iDmKkGASJ0aVLkGcbAG/vB6UPpmG8244hJc6V2MsVODxClG9H0Q/dXLPogCnXOXoJ2UpUMwt7OdlEoQIADCsxg1O3sWAyDyOv/7LOB597OA0r1XWoIAARD/zWZbTxNonbVqxispQYAACM6cAQIgOHMGCIDgzBkgAIIzZ4AACM6cAYJUXM4AQUlFRSTdm/RsnI0gSMXlDBCkenEGCAIIzgBBAMGZM0AABGfOAAEQSc7SvZUgQABEu6R7K0GAAIh2OVFKCQIEQDiTsk7nMGdSDmZeFdXw5jqHuuk+wL7LR7o3QEQpwdkA0ZNGVwIdcidZpPz5Pd/hVNVLund05zDp3qNayEEv2h+B05rH3fqxGfO408s7NCCke0d3DpPuPThm7mkzg4CYkIuVyK+nX2wUffoB0U8E6d4AUX4JLrQGkRiT1zVkmDA1SB/gpAfwDUZ79UxqylyDkO4d3TlquvfgjOC0gGiSo7f7zVvbfOsfFWgEId07+giixHTvwUl4SjtcEhCzLFJOCxAvfw1Cunf0NYji0r2PBMQx/z5minEMILp40TXXKP8uhnTvcM6R0r0H90H0zDtGdbwpvyJxinHMPoied1onHeXvg5DuHc5Zuve6ZCcl56JKECDWDojGsxhKECAAQrp33c7SvQEir7N0byUIEADBmTNAAARnzgABEJw5AwRAcOYMEKTicgYIUnE5AwRNLCoi6d6kZ+NsBEEqLmeAINWLM0AQQHAGCAIIzpwBAiA4cwYIgEhylu6tBAECINol3VsJAgRAtMuJUkoQIADCmZR1Otd/JuVqY8FPXr2ke0d3DpPuPdefvZ5Y8BKql3Tv6M5h0r2zAqKmWPCicjGke0d3DpPuPfsFrTIWfHBYId2bc1ElWPoaRK2x4IUAQrp3dOeo6d7HX4VaY8H7H8KX7s25qBIMsAZRUyx4aVMM6d61rkEUl+59KkA0oWLBWycgJ6xe0r2jO0dK986xBjE472iixYI/naGcsHpJ947uLN17XbKTknNRJQgQawdE41kMJQgQACHdu25n6d4AkddZurcSBAiA4MwZIACCM2eAAAjOnAECIDhzBghScTkDBKm4nAGCJhYVkXRv0rNxNoIgFZczQJDqxRkgCCA4AwQBBGfOAAEQnDkDBEAkOUv3VoIAARDtku6tBAECINrlRCklCBAA4UzKOp2le5fVYo851Xrwj5LuzbmoEpTuPUyurm97ZHBOCdVLund0Z+neh2+GTvfu/42NdG/OhZWgdO+l070nYCXfdZbuHd1ZundV6d6lZXNK947uLN27qnTv0gAh3bvKEYR0b+neeWew0r2jr0FI946a7l3UGoR07+jO0r0H5h1NqHTv0u5iSPeO7izde12yk5JzUSUIEGsHRONZDCUIEAAh3btuZ+neAJHXWbq3EgQIgODMGSAAgjNngAAIzpwBAiA4cwYIUnE5AwSpuJwBgiYWFZF0b9KzcTaCIBWXM0CQ6sUZIAggOAMEAQRnzgABEJw5A0RVgNi92W1vtlcvr86/Pd98vTl7fnb54vL65+vf//6d88qdpXuvHRDPfnt28d3FvlY9fe1r2xe/fsF5tc7SvdcOiH0n01qxHr/2n+G8QmcnSq0dEPueZ7BuPby6eiHOtTqv8UzKlE2gJ/9uM77ZX1T7WWvXuLR1pHr31x3nlTjXn+49+HXLDP5qFgzO2d5sE+tWzzCVc5XO9ad7pwOiK1SiP9ezP+N7bExGzxcb+2b6COLq5VVLNXpQW/W6fHHJeSXO9ad7p3/d9DjcwWTdJjkcOAcgxk4xHu6HpVevs+dnnFfivIp078Q1iPTx+YQAvtbhxti5RpMneq+9Yj3WkxrGeSXOq0v3ntbsJ0wcTgWICWsQ+kzOzWrTvceuQRzTDucCxLyJvmbdnGdfg6gn3XsUIPqzv2fPAU9cJnAXg3MhdzHqTPcetQbRdRcjsR2Oygfv/2Kt05yU32UfBOdM+yBWne69hh2f9g5ytpMSIKb8jZ4+4Nz1nzyLsRYNPgvYvh7+77j0s9vPOK/WWbo3QPzvbLb1NIHWWSvnVTlL9wYIzpwXdQYIgODMGSAAgjNngAAIzpwBAiA4cwYIgODMGSDosDyIpHuTno2zEQSpuJwBglQvzgBBAMEZIAggOHMGCIDgzBkgAOKEqdMa2zLO0r0BIpdzvtRpzXgZZ+neAJHLOd9JR5rxMs5OlAKIXM75zkrUjJdxdiZl0rVbMg289eT7fKda56te+U5b1oyXcV5juveRFy73n5N4av6MuRj5qle+vAbNeBnnNaZ7zwWIUfG5/RHhKW9GBES+xCfNeBnnNaZ7z1Uk6fG5g59MH7PEAkS+zEjNeBnnlaZ7z7IGcWS77b9qXWOW/ritQfosXL3ypU5rxss4S/eefh1HsaA/InzwgqbH/z39pBEEQMw7gqg83XuBNYiUwcIoQMw1m7AGwXmWNYia071nB8TBuCB9DWLsb2zcxdCMT3oXYy3p3rOsQfSM/NPvYoyaYtgHoRmfdh/EqtO9Cy+/oBXXTsroznZSAkReZ89iRHf2LAZ+5XXOlzqtGS/jLN0bIPI650ud1oyXcZbuDRCcOS/qDBAAwZkzQAAEZ84AARCcOQMEQHDmDBAAwZkzQNBheRBJ9yY9G2cjCFJxOQMEqV6cAYIAgjNAEEBw5gwQAMGZM0AAhHTv6p2lewNELmfp3tGdpXsDRC5nJ0pFd3aiFEDkcnYmZXTnVZ9J2bUtdHKkRdcnR10Ep1prxoU4S/ce+BuWB4R0b824HGfp3u1/Q3/OxYTwi/5MzafO0wAxI9pmqV6StaI7S/ceBsRglFZKM05v2DUBQjZndGfp3kkjiMmNsx8Qs9Nq2owpX/WS7h3dWbr3nIDoifBOnGL0L1I2yUHehQDCCKLKEcQa073njfBOHDhMaMYpPtNyw61BcE5fg1hduveMaxCD/zXrGkT/1XYXg/MoZ+neSSOIUXcxUrgwbYqRctOk/5wv+yA4j3KW7r0u2UnJeayzdG+AyOvsWYzozp7FAIi8ztK9oztL9waIvM7SvaM7S/cGCM6cF3UGCIDgzBkgAIIzZ4AACM6cAQIgOHMGCIDgzBkg6LA8iKR7k56NsxEEqbicAYJUL84AQQDBGSAIIDhzBgiA4MwZIADiJNnQGlv0EgQIgLhXpmxozTh6CQIEQGQ8j0gzjl6CALF2QGQ90VAzjl6C0wGRHgaT8oMpuz6XLIzJf8K0N09VvXJnQ2vG0UuwFEBMu8QnAURN6d65s6E14+gleNQUYzDhrrVdjQJEulVXcvdBXk5i3nemdO/SAJE7G1ozjl6C8wNiMOEuHRDpVl2fnBbGNxjkWw0gcmdDa8bRSzDLCGJsw+hag5grdzOlNc4SvZeS7l3UGkTubGjNOHoJHnsXo2vI3RWi3YyMuk60GvxkkxyENwEQTXK6d4gRxIzZ0Jpx9BKcHxATuuVR3emgf7ptuv+oCzp5JNVUlw2tGUcvwRn2QRwz3k5vh9PWIHIsE9S0BpE7G1ozjl6C8wMifbw94vsdcRcjxWoQJYl/cvR9ELNnQ2vG0UvQTsqyZCcl56JKECDWDojGsxhKECAA4iTZ0Jpx9BIECID4bzY7eza0Zhy9BAECIDhzBgiA4MwZIACCM2eAAAjOnAECIDhzBghScTkDBCUVFZF0b9KzcTaCIBWXM0CQ6sUZIAggOAMEAQRnzgABEJw5AwRAJDlL91aCAAEQ7ZLurQQBAiDa5UQpJQgQAOFMyjqdaziTcmzSb44j4Wf8jdK9NeNCnMtN9x77t7UegR8RENK9NeNynE+f7t0fdXfwn3pCsbsA0dOQ+hMrEr/A2CjwlBCwyYDIDcGx1Uu6d3Tn06d7t7aiLmSktKuUuMquVK5jfuSYH++/oHEBId07unMR6d6JTTqx453sljXgOz3ys0lLG+xfbpDuDRAhSjAqINJTv/tnKLMAohkf5F0IIKR7VzmCWDrdu+QRxFwrhUcCYtQFGRsOvvwMVrp39DWIpdO9pyVlpzTyCWndkwcdk3/jjGsQE26mLLYGLt07nHMp6d5HhmIPNvIJw4rEL5AYNT7LFCPlKvWf8yXdm3NRJWgnZVmyk5JzUSUIEGsHRONZDCUIEAAh3btuZ+neAJHXWbq3EgQIgODMGSAAgjNngAAIzpwBAiA4cwYIUnE5AwSpuJwBgiYWFZF0byKK02O5EEQEEEQEEEQEEEQEEEQEEEQEEEQUDBBERK36H8XHYUbZh+TwAAAAAElFTkSuQmCC</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-12-01 06:54:46 +1000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-12-01 06:54:46 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Taste of oral steroids may be a problem</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2010-11-07 22:52:13 +1000" MODIFIED_BY="[Empty name]">
<P>A recent letter in the Lancet has questioned the results of a study on oral prednisolone for wheeze in young children on the basis that (amongst other things) oral prednisolone tastes very bitter and may not have been taken well by the children in the study.(1)</P>
<P>Whilst the authors have replied that they overcame the problem by asking parents to mix the powder with the child's favourite juice, I have had comments from parents in the past that their children did not like the taste of soluble prednisolone tablets, and I gather that dexamethasone solution is also very bitter.</P>
<P>For this reason I have abandoned the use of prednisolone and dexamethasone in children with croup or acute asthma, and use soluble betamethasone tablets instead. Betamethasone and dexamethasone are of equal potency and both are more potent than oral prednisolone; the British National Formulary states that the equivalent dose is that 5mg of prednisolone is equivalent to 750 micrograms of betamethasone (which equates to one and a half 500 microgram tablets). It should also be noted that dexamethasone oral solution costs about ten times as much as betamethasone tablets!</P>
<P>My extrapolation of the results of this review to the use of betamethasone in primary care is based on two assumptions. Firstly that betamethasone is equivalent to dexamethasone, and secondly that the outpatient trials in secondary care contain patients that are similar to those presenting in primary care. I wonder if the authors agree that this is reasonable?</P>
<P>Reference</P>
<P>1. Weinberger M, Ahrens R. Oral prednisolone for viral wheeze in young children. Lancet 2004;363(9405):330</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2011-12-01 06:54:46 +1000" MODIFIED_BY="[Empty name]">
<P>In response to Dr. Cates' comment regarding the use of betamethasone for the treatment of croup, we are unable to conclude that betamethasone is efficacious for the treatment of croup.</P>
<P>Among the included studies, only Klassen et al (1998) reported the results of the blinding methodology. Children were randomized to identically tasting and appearing budesonide, dexamethasone or both treatments. Research assistants and parents were asked to identify which study medication the child received. The responses were similar and this indicates that blinding was successful. In addition, Klassen has conducted RCTs using intravenous dexamethasone with a 70% sucrose solution. This has been very well-tolerated with a very low incidence of vomiting. Paediatric croup and asthma trials have shown that when compared to prednisone/prednisolone, oral dexamethasone combined with flavoured syrup is both well-tolerated and an inexpensive treatment.</P>
<P>To date, we are not aware of any RCTs in children with croup that compared betamethasone to placebo or an active treatment, such as dexamethasone. Although betamethasone is theoretically as potent as dexamethasone, there is no actual empirical data to prove this. Therefore, we cannot judge the equivalency, or the tolerability, of betamethasone versus dexamethasone. Perhaps a randomized controlled trial should be conducted that directly compares betamethasone to dexamethasone so the palatability and equivalency can be assessed.</P>
<P>In response to the second stated assumption, there are guidelines for generalising results of trials to clinical practice and physicians need to carefully consider the comparability of participants in any one study to their own patients.<SUP>1</SUP>
</P>
<P>
<SUP>1</SUP>Guyatt G, Haynes B, Jaeschke R, Cook D, Greenhalgh T, Meade M, Green L, Naylor C, Wilson M, McAlister F, Richardson M. Introduction: the philosophy of evidence-based medicine. In: Guyatt G, Rennie D, editors. Users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago: AMA Press; 2002. p. 3-12.</P>
<P>
<BR/>Kelly Russell<BR/>Terry Klassen<BR/>David Johnson</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Chris Cates</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2010-11-07 22:53:58 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-07 22:53:45 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-12-10 17:17:20 +1000" MODIFIED_BY="[Empty name]">Original Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-07 22:53:45 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>MEDLINE</B>
<BR/>1 exp glucocorticoids/<BR/>2 hydrocortisone.tw,rn.<BR/>3 hydroxypregnenolone.tw,rn.<BR/>4 pregnenolone.tw,rn.<BR/>5 tetrahydrocortisol.tw,rn.<BR/>6 hydrocortisone.tw,rn.<BR/>7 cortodoxone.tw,rn.<BR/>8 cortisone.tw,rn.<BR/>9 corticosterone.tw,rn.<BR/>10 hydroxycorticosteroids.tw,rn.<BR/>11 glucocorticoids.tw,rn.<BR/>12 exp glucocorticoids, synthetic/<BR/>13 triamcinolone.tw,rn.<BR/>14 prednisone.tw,rn.<BR/>15 prednisolone.tw,rn.<BR/>16 paramethasone.tw,rn.<BR/>17 methylprednisolone.tw,rn.<BR/>18 methylprednisolone hemisuccinate.tw,rn.<BR/>19 dexamethasone.tw,rn.<BR/>20 clobetasol.tw,rn.<BR/>21 beclomethasone.tw,rn.<BR/>22 betamethasone.tw,rn.<BR/>23 glucocorticoids, synthetic.rn.<BR/>24 glucocorticoid$.tw.<BR/>25 exp glucocorticoids, topical/<BR/>26 pregnenediones/<BR/>27 budesonide.tw,rn.<BR/>28 corticosteroid$.tw.<BR/>29 or/1-28<BR/>30 croup/ or croup.tw.<BR/>31 laryngotracheitis.tw.<BR/>32 or/30-31<BR/>33 29 and 32<BR/>34 exp laryngitis/<BR/>35 29 and 34<BR/>36 33 or 35</P>
<P>
<B>EMBASE</B>
</P>
<P>1 exp glucocorticoid/<BR/>2 hydrocortisone.tw,hw,tn,rn.<BR/>3 hydroxypregnenolone.tw,hw,tn,rn.<BR/>4 pregnenolone.tw,hw,tn,rn.<BR/>5 tetrahydrocortisol.tw,hw,tn,rn.<BR/>6 hydrocortisone.tw,hw,tn,rn.<BR/>7 cortodoxone.tw,hw,tn,rn.<BR/>8 cortisone.tw,hw,tn,rn.<BR/>9 corticosterone.tw,hw,tn,rn.<BR/>10 hydroxycorticosteroids.tw,hw,tn,rn.<BR/>11 glucocorticoid$.tw,hw,tn,rn.<BR/>12 triamcinolone.tw,hw,tn,rn.<BR/>13 prednisone.tw,hw,tn,rn.<BR/>14 prednisolone.tw,hw,tn,rn.<BR/>15 paramethasone.tw,hw,tn,rn.<BR/>16 methylprednisolone.tw,hw,tn,rn.<BR/>17 dexamethasone.tw,hw,tn,rn.<BR/>18 clobetasol.tw,hw,tn,rn.<BR/>19 beclomethasone.tw,hw,tn,rn.<BR/>20 betamethasone.tw,hw,tn,rn.<BR/>21 pregnenedione$.tw,hw,tn,rn.<BR/>22 budesonide.tw,hw,tn,rn.<BR/>23 corticosteroid$.tw.,hw,tn,rn.<BR/>24 or/1-23<BR/>25 exp laryngitis/<BR/>26 laryngitis.tw,hw.<BR/>27 croup.tw,hw.<BR/>28 laryngothracheitis.tw,hw.<BR/>29 pseudocroup.tw,hw.<BR/>30 or/25-29<BR/>31 24 and 30</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-12-10 17:36:22 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-12-10 17:30:48 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-10 17:36:22 +1000" MODIFIED_BY="[Empty name]">
<P>25. #21 AND #24<BR/>24. #22 OR #23<BR/>23. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross-over':ab,ti OR 'cross over':ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti <BR/>22. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp<BR/>21. #9 AND #20 <BR/>20. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19<BR/>19. hydrocortisone:ab,ti OR hydroxypregnenolone:ab,ti OR pregnenolone:ab,ti OR tetrahydrocortisol:ab,ti<BR/>OR hydrocortisol:ab,ti OR cortisone:ab,ti OR hydroxycorticosteroid:ab,ti OR triamcinolone:ab,ti OR prednisone:ab,ti OR paramethasone:ab,ti OR cortodoxone:ab,ti OR corticosterone:ab,ti OR methylprednisolone:ab,ti OR dexamethsone:ab,ti OR clobetasol:ab,ti OR beclamethasone:ab,ti OR beclametasone:ab,ti OR pregnenedione*:ab,ti OR budesonide:ab,ti <BR/>18. 'pregnane derivative'/de <BR/>17. 'hydroxycorticosteroid'/de <BR/>16. 'corticosterone'/de<BR/>15. 'cortodoxone'/de <BR/>14. corticoid*:ab,ti <BR/>13. corticosteroid*:ab,ti <BR/>12. 'corticosteroid'/de <BR/>11. glucocorticoid*:ab,ti <BR/>10. 'glucocorticoid'/exp <BR/>9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 <BR/>8. laryngotracheobronchit*:ab,ti OR laryngotracit*:ab,ti <BR/>7. 'laryngotracheobronchitis'/de <BR/>6. pseudocroup:ab,ti OR 'pseudo-croup':ab,ti <BR/>5. 'pseudocroup'/de <BR/>4. croup:ab,ti<BR/>3. 'croup'/de <BR/>2. laryngit*:ab,ti <BR/>1. 'laryngitis'/de </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-11-07 22:53:58 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-11-07 22:53:58 +1000" MODIFIED_BY="[Empty name]">MEDLINE in-process &amp; other non-indexed citations search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-10 17:38:35 +1000" MODIFIED_BY="[Empty name]">
<P>1 laryngit*.tw. <BR/>2 croup.tw. <BR/>3 laryngotracheobronchit*.tw.<BR/>4 (pseudocroup* or pseudo-croup*).tw. <BR/>5 laryngotracheit*.tw. <BR/>6 or/1-5 <BR/>7 glucocorticoid*.tw. <BR/>8 corticosteroid*.tw. <BR/>9 corticoid*.tw. <BR/>10 hydrocortisone.tw. <BR/>11 hydroxypregnenolone.tw. <BR/>12 pregnenolone.tw. <BR/>13 tetrahydrocortisol.tw. <BR/>14 hydrocortisone.tw. <BR/>15 cortodoxone.tw. <BR/>16 cortisone.tw. <BR/>17 corticosterone.tw. <BR/>18 hydroxycorticosteroid*.tw. <BR/>19 triamcinolone.tw. <BR/>20 prednisone.tw. <BR/>21 prednisolone.tw. <BR/>22 paramethasone.tw. <BR/>23 methylprednisolone.tw. <BR/>24 dexamethasone.tw. <BR/>25 clobetasol.tw. <BR/>26 beclomethasone.tw. <BR/>27 betamethasone.tw. <BR/>28 pregnenedione*.tw.<BR/>29 budesonide*.tw. <BR/>30 or/7-29 <BR/>31 6 and 30 </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>